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Abstract 
 
In the last 20 years laparoscopic liver resection has been increasingly practised. However its 
role in the treatment of liver cancer remains under scrutiny. I performed a pilot study at a 
specialist HPB unit assessing the results of the laparoscopic resections of one surgeon and 
comparing them to the results of matched cases on whom he had performed open 
resection. The resection technique was radiofrequency assisted resection pioneered in this 
unit. I also analysed the resected tissue to investigate any differential effect on cell 
characteristics of the 2 operative techniques. Operative time was significantly longer in 
laparoscopic cases and time to recurrence of R0 resections significantly shorter. Resected 
tissue demonstrated significantly higher levels of the hypoxia inducible factor-2 and CD10, a 
recognised poor prognostic marker in primary colorectal tumours. 
 
I hypothesised that livers resected laparoscopically are under a relative hypoxia because of 
the increased intraabdominal pressure associated with the pneumoperitoneum and tumours 
cells therefore have a positive selection advantage. In the setting of longer resection times 
this may compromise the oncological result of the surgery causing earlier recurrence. Using 
a established model of HIF activation, I showed that poor prognostic marker CD10 may be a 
function of hypoxia inducible regulation. Certainly I was able to replicate data from cervical 
squamous epithelia demonstrating that both in benign, dysplastic and malignant tissue, HIF 
expression corresponded to a reduced cell E-cadherin expression that may allow a more 
malignant potential.  
 
I also analysed the effect of RF ablation on circulating tumour cells in palliative irresectable 
cancers and in the context of both open and laparoscopic liver resection. This showed only a 
transient rise in both resectional techniques, (open and lap) that would unlikely count for 
the differential oncological outcome previously demonstrated in the pilot study.  
 
In keeping with current international opinion, further work is required to verify the role of 
laparoscopic liver resection in liver cancer. 
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1.1 Liver surgery: a brief history 
 
Liver surgery has grown over 2000 years from the mystic hepatoscopy of the Babylonians to 
the ultimate of orthotropic transplantation by Starzl in 1968 (Starzl, Groth et al. 1968). The 
first successful liver resection was for trauma by Hildanus in the 17th century. The first 
successful planned resection was by Langenbuch in 1888 and the first hemihepatectomy by 
Wendel in 1911 (Foster 1991). The principles of liver regeneration and liver haemostasis 
were determined in the period 1880-1900; Ponfick, Mayer, Kousnetzoff, Pensky and Pringle 
making significant contributions. Couinaud, Healey and Schroy popularized segmental 
anatomy and Lortat-Jacob and Robert performed the first inflow ligation resection starting 
the modern era (Foster 1991; Ellis 2009). Starzl brought liver transplantation to its current 
status and Bismuth introduced hepatobiliary units as a means of optimizing treatment of 
liver disease (Gugenheim, Castaing et al. 1987). 
 
1.2 The current role of liver surgery in cancer  
 
1.2.1 Hepatocellular carcinoma (HCC) 
 
Primary liver cancer or hepatocellular carcinoma (HCC) ranks fifth in frequency in the world 
with an estimated number of 437,000 new cases in 1990 (Bosch, Ribes et al. 1999). The 
incidence of HCC is rising (El-Serag and Mason 1999) owing to a large pool of people 
infected with hepatitis C virus, hepatitis B virus or both (Nagasue, Yukaya et al. 1984; 
Schafer and Sorrell 1999; Okuda 2000). HCC is the most common primary cancer of the 
liver and accounts for 90% of all primary liver malignancy (Kaczynski, Hansson et al. 1996). 
Within this population more than 80% of patients have cirrhosis (Nagasue, Yukaya et al. 
1984; Schafer and Sorrell 1999; Okuda 2000). The prognosis of untreated patients with 
HCC is poor (Nagasue, Yukaya et al. 1984; Okuda, Ohtsuki et al. 1985) although early 
detection through the wide use of ultrasonography (US) and improved management of 
patients with liver function impairment have improved the outcome (Llovet, Bustamante et 
al. 1999). 
 
Different methods of non-surgical local treatment for these tumours have been devised. 
These are particularly important in cases of multiple tumours involving both lobes of the 
liver, poor hepatic reserve in cirrhosis, in tumours within the liver which are not easily 
accessible and patients unfit to withstand surgery (Hargreaves, Adam et al. 2000). 
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When there is no evidence of extrahepatic disease, partial or total liver resection (the latter 
followed by orthotropic liver transplantation (OLT)) is the only potentially curative treatment 
for HCC. It appears from different reports that OLT may lead to a better outcome than liver 
resection in carefully selected cirrhotic patients with HCC. For example, those with small 
tumours, uninodular or binodular tumours and the absence of portal vein tumoural 
thrombosis (Bismuth, Chiche et al. 1993; Mazzaferro, Regalia et al. 1996; Bismuth, Majno 
et al. 1999; Yamamoto, Iwatsuki et al. 1999; Figueras, Jaurrieta et al. 2000). 
 
In patients with early stage HCC in whom liver transplantation is contraindicated and in 
those with good liver function, partial hepatectomy is associated with excellent survival. 
Tumour spread and the frequent coexistence of underlying cirrhosis may limit the cases 
amenable to surgical resection. Resectability rates in large series of HCC range from 17 to 
54% (Lai, Fan et al. 1995; Cance, Stewart et al. 2000; Takano, Oishi et al. 2000). However, 
progress in imaging, surgical procedures and perioperative care have turned hepatectomy 
for HCC into a safe operation with low mortality (Fan, Lo et al. 1999; Torzilli, Makuuchi et 
al. 1999). 
 
1.2.2 Colorectal carcinoma  
Colorectal cancer is the commonest gastrointestinal malignancy and the second commonest 
cause of cancer death, comprising 11% of new cancer diagnoses and 10% of all cancer 
deaths in the UK. Approximately 32 000 cases are diagnosed each year and 17000 deaths 
are attributed to the disease (Weiss, Grundmann et al. 1986). Surgery is the treatment of 
choice for patients with localised disease but over half of all patients will develop 
metastases. 
The liver is often the first site of metastatic disease and may be the only site of spread in as 
many as 30–40% of patients with advanced disease. Of new cases, 20–25% of patients will 
have clinically detectable colorectal liver metastases (CLMs) at the time of the initial 
diagnosis and a further 40–50% of patients will eventually develop liver metastases after 
resection of the primary, most commonly within the first three years of follow up (Scheele, 
Stangl et al. 1990; Sugarbaker 1990; Stangl, Altendorf-Hofmann et al. 1994; Scheele, 
Stang et al. 1995). It has been postulated that the principal mode of tumour dissemination 
is via the portal system and therefore that surgical resection of isolated hepatic metastases 
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from colorectal cancer may be curative in a number of cases (Weiss, Grundmann et al. 
1986). 
The natural history of metastatic colorectal cancer is variable. Median survival without 
treatment is less than eight months from presentation (Lahr, Soong et al. 1983; Seymour, 
Stenning et al. 1997; Simmonds 2000). Patients with isolated hepatic metastases have a 
better prognosis than those with more extensive metastatic disease (Goslin, Steele et al. 
1982; Lahr, Soong et al. 1983; Stangl, Altendorf-Hofmann et al. 1994; Rougier, Milan et al. 
1995) suggesting biological differences in the two settings. However, few patients with 
limited liver-only metastases survive greater than 5 years (Goslin, Steele et al. 1982; 
Stangl, Altendorf-Hofmann et al. 1994). 
Approximately 20–30% of patients with metastatic colorectal cancer have disease that is 
confined to the liver and is potentially resectable (Stangl, Altendorf-Hofmann et al. 1994). 
Several large series on resection for colorectal liver metastases (CLM) have reported five 
year survival ranging from 25% to 44%, with operative mortality of 0–6.6% (Cady and 
Stone 1991; Scheele, Stang et al. 1995; Choti and Bulkley 1999; Fong, Fortner et al. 
1999).Given that approximately 18 000 patients will develop hepatic metastases annually in 
the UK, approximately 3600 patients maybe suitable for hepatic resection although many 
more patients may benefit from hepatic resection with less restrictive criteria of resectability 
being employed in many centres (Fong, Fortner et al. 1999). It seems unlikely that a 
randomised study assessing outcome following resection compared with other treatment 
modalities will be undertaken in patients with resectable liver metastases. However, a 
variety of therapeutic approaches have been used in the treatment of metastatic colorectal 
cancer including radiofrequency ablation, cryotherapy, new chemotherapy regimens or 
some combination of these that allow safe ablation of liver metastases (Bismuth, Adam et 
al. 1996; Giacchetti, Perpoint et al. 2000; Adam, Avisar et al. 2001; Primrose 2002; 
Tournigand, Andre et al. 2004). 
It has been postulated that because haematogenous spread usually occurs in a stepwise 
fashion, initially to the liver, with subsequent intrahepatic spread via the portal vein and 
further spread to the systemic circulation, surgical resection of isolated hepatic metastases 
from colorectal cancer may be curative. 
The selection criteria for surgery are usually controlled primary tumour, no extra hepatic 
metastases and a resection that is technically feasible with tumour-free margins (Hugh, 
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Kinsella et al. 1997). Rarely, a small proportion of patients with completely resectable 
extrahepatic disease may become long-term survivors (Scheele, Stang et al. 1995). 
Chemotherapy used alone is palliative but may prolong the survival of patients with 
unresectable disease (de Gramont, Figer et al. 2000; Douillard, Cunningham et al. 2000; 
Saltz, Cox et al. 2000; Simmonds 2000). Used in combination with surgery it may prolong 
the time to recurrence after resection of hepatic metastases (Kemeny, Adak et al. 2002) or 
downsize to resectability patients previously judged inoperable (Giacchetti, Itzhaki et al. 
1999). The role of other treatments is poorly defined (Armstrong, Anderson et al. 1994; 
Adam, Akpinar et al. 1997; De Baere, Elias et al. 1999; Primrose 2002). 
1.2.3 Feasibility of hepatic surgery 
Operative morbidity and mortality following liver resection are related to the development of 
hepatic failure. The risk of this occurring is a function of the extent of resection (Wigmore, 
Redhead et al. 2001; Shoup, Gonen et al. 2003; Stewart, O'Suilleabhain et al. 2004) and 
the presence of coexisting liver disease (Kooby, Fong et al. 2003). Techniques for 
determination of the hepatic functional reserve in patients with chronic liver disease such as 
the plasma retention rate of indocyanine green at 15 min (ICG15) (Caesar, Shaldon et al. 
1961; Matsumata, Kanematsu et al. 1987) and preoperative portal pressure assessment 
(Bruix, Castells et al. 1996) are usually all considered together when deciding whether to 
proceed to surgery. Other complications that may contribute to or be related to 
postoperative liver failure include haemorrhage, bile leak, intra-abdominal sepsis, and 
cardiopulmonary dysfunction (Scheele, Stangl et al. 1990; Rees, Plant et al. 1996; Fong, 
Cohen et al. 1997; Kooby, Fong et al. 2003).  Laparoscopic liver resection may have some 
advantage in the short term over open surgery but there are no data to indicate the impact 
of this procedure on long term outcome (Vibert, Perniceni et al. 2006). Duration of survival 
is shortened by the presence of inadequate or involved resection margins (Pawlik, Scoggins 
et al. 2005). Previous data from the Registry of Hepatic Metastases, a multi-institutional 
database of liver resections, suggested that a margin >1cm was associated with 45% five 
year survival, but only 23%survived five years if the margin was less (Hughes, Simon et al. 
1986). A number of other studies have supported the view that poorer overall survival and 
disease free 5 year survival is associated with resection margins <1 cm although others 
have produced evidence to suggest that a lesser margin may be acceptable as long as the 
tumour pseudocapsule is resected during dissection (Yamamoto, Sugihara et al. 1995; 
Rees, Plant et al. 1996; Rees, Plant et al. 1997). 
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Studies have shown that long term survival is achieved in patients whose primary colorectal 
cancer has been managed by radical resection and appropriate local adjuvant treatment. 
Long term survival may be affected adversely by the presence of more than three 
metastases but multivariate analysis has provided inconsistent results as to whether the 
number of resected metastases has a significant effect on long term survival (Hughes, 
Simon et al. 1986; Scheele, Stang et al. 1995; Fong, Cohen et al. 1997; Fong, Fortner et al. 
1999; Schindl, Wigmore et al. 2005). 
Resectability of liver tumours requires assessment by a radiologist in conjunction with a 
liver surgeon experienced in the management of colorectal metastases as there is a need to 
define the acceptable residual functioning volume. It is accepted that prediction of liver 
dysfunction following liver resection is difficult to quantify for the individual patient. Previous 
studies have suggested that that liver volume can be readily calculated by CT volumetry 
(Wigmore, Redhead et al. 2001; Shoup, Gonen et al. 2003). Based on liver transplant and 
liver resectional experience, acceptable residual functioning volume is thought to consist of 
approximately one third of the standard liver volume or the equivalent of two liver 
segments. Such decisions are again best made by the hepatobiliary team. 
As for most surgical procedures, the operating surgeon and the anaesthetist are best able to 
assess the patient’s fitness for intervention. Increasing ASA and POSSUM grade have been 
shown to be of value for several operative procedures (Pol, Campan et al. 1999). Experience 
of the managing team is likely to have an effect on outcome and it has been demonstrated 
that patients who undergo liver resection at low volume hospitals are at a higher risk of 
postoperative complications and death than those who have the same operation at high 
volume hospitals (Dimick, Cowan et al. 2003). 
For those patients not considered fit for operative intervention, radiofrequency ablation has 
been shown to be a safe and effective treatment (Oshowo, Gillams et al. 2003; Oshowo, 
Gillams et al. 2003). However, its precise role in the management of hepatic colorectal 
metastases has yet to be defined and no study has addressed its potential superiority over 
other treatment modalities in the setting of a randomised controlled trial. The NCRN/EORTC 
CLOCC trial (EORTC 40044-Chemotherapy and local ablation versus chemotherapy (5-FU 
and oxaliplatin) alone) trial aims to address this issue in part. 
Surgical resection for HCC is technically demanding but may be considered after careful 
selection of patients with normal or subnormal preoperative liver function. Two different 
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populations of patients are involved:
these cases good preoperative liver function, classified a
10% have non-cirrhotic livers. The former have a higher operative mortality, lower 
regeneration capacity (Yamanaka, Okamoto et al. 1993)
rate.  
In summary, careful patient selection for
requirements and the objectives of these resections are contradictory: 
balance need to conserve functional liver parenchyma 
failure with the need to ensure a sufficient surgical margin so as to avoid local recurrence.
1.3 Liver resection techniques
 
1.3.1 Classical liver resection 
 
Liver resections as performed today are the result of the practical application of segmental 
surgery to the liver as described by Bismuth
precise knowledge of the segmental anatomy as described by the French anatomist and 
surgeon Couinaud (Couinaud 1957)
imaging techniques. Intraoperative ultrasound (IOUS) ‘has become the eyes of the surgeon’ 
to operate upon a segmental organ with no external landmarks
1987). 
 
Figure 1: Couinaud’s segmental anatomy of the liver.
 
 in 90% the tumour arises in a cirrhotic liver (and in 
s Child grade A, is necessary) whilst 
 and higher intrahepatic recurrence 
 resectional surgery is paramount as very often the 
it is important to 
so as to prevent postoperative 
 
technique 
 (Bismuth 1982). This approach is based on 
 and on the other hand on the development of advanced 
 (Bismuth, 
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1.3.2 Surgical aids and resection tools 
 
Technological innovations such as an ultrasonic dissector that skeletonises portal and 
hepatic vein ramifications free from hepatocytes (particularly useful in fine 
intraparenchymatous dissections) have facilitated the task of liver surgery (Andrus and 
Kaminski 1986).  
 
Haemostasis of the exposed raw surface of the liver at the end of the operation can be 
improved with the argon beam coagulator and biological glues. However, use of the argon 
beam coagulator (a modified, powerful means of diathermy based on the concentration of 
current through argon gas) instead of conventional contact coagulation and/or biological 
glues (fibrin tissue adhesive: tissucol, biocol) can help and enhance haemostasis that 
depends mainly on selective surgical ligation and coagulation of vessels.  
 
Together with these technological advances, evolving surgical techniques have contributed 
to better safety and improved results after surgical resection. Methods of vascular control to 
stop blood inflow to the liver during parenchymal transection have contributed to lowering 
perioperative blood loss and the need for blood transfusion. The Pringle manoeuvre, initially 
developed for liver trauma, which consists of intermittent clamping and unclamping of the 
whole hepatic pedicle is still used today (Pringle 1908).  
 
More selective ways of limiting vascular inflow to the liver permit perfusion of the liver that 
is to remain, either by using suprahilar vascular control (Takasaki, Kobayashi et al. 1990) or 
a more precisely demarcated exclusion area by means of balloon occlusion of segmental 
portal branches (Castaing, Garden et al. 1989) which can be helpful when a limited 
segmentectomy is necessary (Bismuth, Houssin et al. 1982). 
1.3.3 Indications for surgical resection 
As previously mentioned, HCC usually occurs in association with chronic liver disease and 
cirrhosis. When HCC arises in non-cirrhotic liver it is often diagnosed when the tumour 
becomes large and symptomatic. In the absence of diffuse disease involving both lobes or 
metastases, aggressive surgical management of HCC is indicated in a non-cirrhotic liver. In 
these patients resection of the tumour may be considered no matter its size, since they are 
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usually in good general condition and surgical resection usually involves the tumour mass 
rather than the functional parenchyma (Bismuth, Chiche et al. 1995). 
 
Since most HCCs occur in patients with cirrhosis or chronic liver disease, important changes 
in portal haemodynamics and a reduction in the functional liver parenchyma must be 
anticipated. The Pugh–Child Classification (Child and Turcotte 1964; Pugh, Murray-Lyon et 
al. 1973) is useful and decisive for evaluating cirrhotic patients with impaired liver function.  
 
Liver resection for HCC in a cirrhotic liver is contraindicated in the presence of severe 
hepatic impairment (such as ascites, jaundice, Child–Pugh B and C, liver atrophy). In these 
settings, there is an increased risk of decompensation of the liver disease or liver failure in 
the postoperative period. However, although cirrhotic patients presenting with jaundice due 
to hepatic insufficiency have a dismal prognosis, a few cases of obstructive jaundice due to 
the tumour itself may benefit from surgical resection (Lau, Leung et al. 1997). 
 
Other situations that preclude resection are the presence of portal vein thrombosis reflecting 
extensive disease, lymph node metastases, extrahepatic localisations and intrahepatic 
multiple, diffuse disease. All these situations, in the absence of currently effective adjuvant 
treatments, render any treatment palliative. Recently a reduction of up to 60% in the 
number of laparotomies done for HCC is evident in patients in whom laparoscopic US is 
employed first (Lo, Lai et al. 1998). 
1.3.4 Strategies to increase resectability 
HCC is mainly fed by branches of the hepatic artery, and this is used to selectively deliver a 
combination of lipidiol (iodised poppy seed oil) and a chemotherapeutic agent (adriamycin 
or cisplatin) followed by embolisation with absorbable gelatin particles. The so-called 
chemoembolisation is effective in producing tumour necrosis and reducing the size of the 
tumour, improving surgical access and resectability (Majno, Adam et al. 1997).  
 
Although no survival benefit has been obtained in randomised trials many HPB teams favour 
(Figueras, Jaurrieta et al. 2000) the use of preoperative transarterial chemoembolisation 
(TACE) not only to downstage the tumour but for accurate staging of the intrahepatic 
disease. Lipidiol fixation to tumoural tissue increases the possibility of detection of small 
sized lesions on CT scan and US (Novell, Dusheiko et al. 1991).  
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The remnant liver appears to be an important predictor for postoperative liver failure, 
particularly after major hepatectomies (Shirabe, Shimada et al. 1999). It is possible to 
accurately determine the volume of the potential remnant liver by means of CT. In some 
cases when a large hepatectomy is planned, compensatory hypertrophy of the future 
remnant liver can be induced by preoperative portal vein embolisation of the liver to be 
resected (Azoulay, Raccuia et al. 1995) using Histoacryl™ (enbucrilate, Braun Melsungen 
Lab, Germany) or ethanol to overcome potential postoperative liver failure. This was first 
reported to be feasible by Makuuchi (Makuuchi, Thai et al. 1990) who reported that fatal 
liver failure did not occur after major liver resection for cancer when the portal vein of the 
resected liver was obstructed. The same technique has been shown to offer satisfactory 
results even when used in chronic liver disease (Lee, Kinoshita et al. 1993; Azoulay, 
Castaing et al. 2000). 
 
1.3.5 Results of surgical resection 
 
1.3.5.1 Hepatocellular carcinoma (HCC) 
 
Aside from the underlying functional liver parenchyma, other aspects of the general 
condition of the patient are directly linked to the outcome of surgical resection for HCC. The 
importance of the nutritional balance of the patient undergoing surgical resection for HCC 
has been well established (Fan, Lo et al. 1994). Diabetes mellitus (Shirabe, Shimada et al. 
1999) and pre-existing cardiovascular disease (Miyagawa, Makuuchi et al. 1995) have also 
been shown to intervene as morbidity co-factors. Although old age has long been regarded 
as an adverse factor for major surgery including liver resections, several groups report on 
the feasibility and good results obtained after hepatic resection for HCC in elderly patients 
(Ezaki, Yukaya et al. 1987), even in those with underlying cirrhosis (Lui, Chau et al. 1999). 
Improvements in perioperative technique including reduction in blood loss and blood 
transfusion (Fan, Lo et al. 1999; Torzilli, Makuuchi et al. 1999) intermittent warm ischemia 
(Miyagawa, Makuuchi et al. 1995; Torzilli, Makuuchi et al. 1999) and shortening the 
operation time have made considerable contributions to safer procedures and improved 
outcomes (Miyagawa, Makuuchi et al. 1995).  
Through application of all the above-mentioned patient selection criteria, surgical principles 
and techniques and postoperative care, overall mortality has been much improved after 
surgical resection for HCC from 58% to less than 10% reported in recent series (Belli, 
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Limongelli et al. 2009). Moreover, it has been found that the results of liver resection for 
HCC are related to the hospital volume (Begg, Cramer et al. 1998). 
The long-term prognosis after surgical resection of HCC is limited by the high rate of 
postoperative recurrence. At the present time, tumour recurrence is the major cause of 
death following resection of HCC both in cirrhotic (Nagasue, Kohno et al. 1993) and non-
cirrhotic livers (Bismuth, Chiche et al. 1995). Without some form of treatment most patients 
with recurrent HCC will die within 1 year, (Hu, Lee et al. 1996). The frequency of tumour 
recurrence depends on the duration of the time of follow-up. In different series between 
43% and 65% of the patients had recurrences within 2 years of removal of the first 
tumour(Lee, Lin et al. 1995; Hu, Lee et al. 1996) and up to 85% within 5 years (Lai, Fan et 
al. 1995). The disease is confined to the liver in 30–91% (Matsuda, Ito et al. 1993; 
Bismuth, Chiche et al. 1995). However, up to 50% of the intrahepatic recurrences are of 
multiple or diffuse pattern (Nagasue, Kohno et al. 1993). 
Intrahepatic recurrence after resection of HCC may arise through two different mechanisms; 
firstly, growth of residual satellite tumours, not identified at the time of the initial surgery, 
from intrahepatic metastasis through the portal vein (Shirabe, Takenaka et al. 1996), and 
secondly, multicentric occurrence from synchronous and metachronous multicentric 
carcinogenesis. It is difficult to establish the role of each type of process and this is very 
much a matter of controversy for hepatologists. Further studies based on clonal analysis of 
both recurrent and primary tumours may help to clarify this issue (Yamamoto, Kajino et al. 
1999). Intrahepatic spread would appear, however, to be more frequent (Shimada, 
Takenaka et al. 1998). This differentiation may have prognostic and even therapeutic 
implications. Patients whose relapse is due to a solitary recurrence and good liver function, 
classified as Child grade A, would appear to be good candidates for re-resection, as opposed 
to patients with intrahepatic metastases, which are often multifocal (Poon, Fan et al. 1999). 
Several reports have studied the risk factors for development of postoperative intrahepatic 
recurrence (Nagasue, Uchida et al. 1993). Factors involved in recurrence are related to the 
tumour characteristics such as: the size of the tumour, with tumours larger than 5 cm 
associated with a higher risk of recurrence (Bismuth, Chiche et al. 1995); multiple nodules 
whether due to intrahepatic metastasis or to multicentric carcinogenesis (Ikeda, Saitoh et 
al. 1993; Bismuth, Chiche et al. 1995; Hu, Lee et al. 1996); the presence of satellite 
nodules associated with tumour invasiveness (Nagasue, Uchida et al. 1993; Fuster, Garcia-
Valdecasas et al. 1996); vascular involvement (Nagasue, Uchida et al. 1993; Bismuth, 
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Chiche et al. 1995; Vauthey, Klimstra et al. 1995; Fuster, Garcia-Valdecasas et al. 1996; 
Yamamoto, Ikai et al. 1999), evidence of the importance of intrahepatic metastasis through 
the portal vein circulation (Yamamoto, Kosuge et al. 1996); the absence of capsule 
formation (Nagasue, Uchida et al. 1993; Bismuth, Chiche et al. 1995); preoperative AFP 
(Chen, Hwang et al. 1994); and DNA aneuploid content (Okada, Shimada et al. 1994), 
nuclear DNA content possibly reflecting the malignant potential of some tumours. 
Other risk factors for recurrence are related to the patient and the underlying liver status 
(Kakazu, Makuuchi et al. 1993). A higher intrahepatic recurrence rate has been found in 
cirrhotic patients (Sasaki, Imaoka et al. 1992). It is likely that this is due to the presence of 
more cases of multicentric tumours and more cases of positive surgical margins as a result 
of limited resections due to poorer residual liver function (Nagasue, Kohno et al. 1993). 
Active hepatitis with increased inflammatory activity, as reflected by high levels of 
transaminase (Shirabe, Takenaka et al. 1996) and alcohol abuse (Okada, Shimada et al. 
1994) has also been linked to an increased recurrence rate. 
Another group of risk factors is related to surgery and include distance from the tumour to 
the resection margin of less than 1cm. However, this is controversial as some authors found 
it to be an unfavourable prognostic factor (Chen, Hwang et al. 1994) whereas others have 
found no correlation (Fuster, Garcia-Valdecasas et al. 1996; Poon, Fan et al. 2000). A wide 
resection margin during hepatectomy for HCC has been reported not to be an effective 
means of reducing postoperative recurrence (Poon, Fan et al. 2000). Although, 1cm of clear 
margin from the edge of the tumour appears desirable to ensure tumour clearance and 
avoid local recurrence (Poon, Fan et al. 2000), particularly for tumours larger than 4cm. 
Perioperative transfusion, another example of risk factors related to surgery, has been 
shown to be associated with increased intrahepatic recurrence (Matsumata, Ikeda et al. 
1993). 
While the precise role played by each of these risk factors is difficult to determine, it 
appears from most studies that factors related to tumour invasiveness and vascular 
involvement are the key risk factors for recurrence of HCC. 
Although no effective adjuvant treatment is yet available, the recurrence rate may be 
reduced by careful attention to some of the following technical aspects: avoiding 
manipulation, especially of large tumours, using an anterior approach to minimise the risk of 
tumour cell dissemination (Lai, Fan et al. 1996) and minimising intraoperative blood loss so 
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as to avoid blood transfusion (using portal clamping and lowering central venous pressure 
(Cunningham, Fong et al. 1994). The treatment modalities in use and available today for 
primary HCC, namely surgical resection (partial or total and followed by liver 
transplantation), TACE and percutaneous treatments (Hargreaves, Adam et al. 2000) have 
also been used in postoperative recurrent HCC. The use of multiple therapies may improve 
survival rates (Ikeda, Saitoh et al. 1993). 
While the use of systemic chemotherapy after curative resection for HCC has been 
associated with a worse outcome (Lai, Lo et al. 1998), postoperative regional chemotherapy 
or lipidiolisation may be an effective therapy to reduce recurrence and improve survival 
(Lau, Leung et al. 1999). However, adjuvant therapies still need to be developed to prevent 
recurrence. The use of polyprenoic acid, a synthetic retinoid or percutaneous alcohol 
injection (Muto, Moriwaki et al. 1996) would appear to reduce the incidence of a second 
primary HCC after resection. More recently the use of interferon beta has been reported to 
be effective in preventing recurrence of HCC after complete resection or ethanol ablation in 
patients with HCV-related chronic liver disease (Ikeda, Arase et al. 2000). Other promising 
lines of investigation may arise from investigation into the role of angiogenesis on 
recurrence of HCC (El-Assal, Yamanoi et al. 1998) and the potential use of antiangiogenic 
drugs. 
Embolisation or chemoembolisation, performed in most cases for non-operable patients (Lai, 
Fan et al. 1995; Lee, Lin et al. 1995), may be used to confirm the diagnosis of recurrence 
and in some cases these techniques may reduce the size of the tumour making it resectable 
(Majno, Adam et al. 1997). This treatment appears to be the most frequently used for 
intrahepatic recurrent HCC when unresectable because of multinodularity or inadequate 
functional liver reserve. 
Although randomised studies are not available, repeat hepatectomy appears to be the best 
treatment for recurrent HCC. This is possible with solitary, anatomically resectable 
recurrences and no extra-hepatic disease in patients with sufficient functional liver 
parenchyma to withstand a re-resection. The resectability rate of recurrent intrahepatic HCC 
is variable, ranging from 10 to 77% according to the different series (Table 1). This 
procedure has proved to be safe in selected patients, with mortality ranging from 0% to 
8%. 
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Table 1: Summary of the most recent series of documented repeat resections for recurrent 
HCC and their respective outcomes 
Authors Year Number 
of first 
resections 
Number of 
Intrahepatic 
recurrences 
Number of 
repeat 
resections 
Resectability 
rate of 
recurrence 
(%) 
5 year 
survival 
after 
second 
resection 
(%) 
Shimada 1998 312  41  43 
Farges 1998 251 89 15 17 60 
Poon 1999 244 105 11 10 69 
Adam 2000 236 102 22  59 
Long term survival rates after repeat resection range from 37 to 86% after 5 years. A 
longer interval from hepatectomy to recurrence predicts improved survival (Lee, Lin et al. 
1995). Patients treated by repeat hepatectomy have been reported to have better survival 
rates than those treated by other palliative methods (Matsuda, Ito et al. 1993; Lee, Lin et 
al. 1995; Hu, Lee et al. 1996). 
1.3.5.2 Colorectal liver metastases (CLM) 
Surgical resection of hepatic metastases from colorectal cancer can be undertaken safely in 
the majority of patients. The median postoperative (30 day) mortality reported by 24 
studies was only 2.8% (0–6.6%) (Simmonds, Primrose et al. 2006). The most frequent 
causes are hepatic failure, postoperative haemorrhage, and sepsis. It is likely that current 
surgical and anaesthetic practice is associated with perioperative mortalities nearer to 1% 
as demonstrated in a large multicentre trial (Nordlinger 2005). 
Operative morbidity is more difficult to quantify as many studies report only fatal morbidity 
or a very limited range of postoperative complications. Some studies present information on 
outcomes that may be surrogate markers for operative morbidity. The limited reported 
results suggest that most patients require only a short period of intensive care following 
hepatic resection for colorectal metastases. The median or mean length of hospital stay 
reported by 17 studies ranged from 7–21 days indicating that while most patients made a 
rapid recovery following surgery, some experienced a more prolonged hospital stay 
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(Simmonds, Primrose et al. 2006)
surgery. Few studies include information on recovery of patients' functional status or quality 
of life following discharge from hospital 
Studies including only patients who underwent resection reported a survival of around 30% 
at 5 years for patients undergoing potentially 'curative' resection of isolated hepatic 
metastases and the majority are
undergoing R0 resections were substantially better (32% at 5 years) than for patients 
undergoing R1 resections (7.2% at 5 years) and those who did not undergo resection (0% 
at 5 years) (Simmonds, Primrose et al. 2006)
Patients undergoing surgery have a better prognosis than other patients with metastatic 
colorectal cancer as their disease is both confined to the liver and circumscribed within it.
The patients are also more likely to be of good performance status and have little or no 
comorbidity. Identifying a comparable control group in the absence of randomised trials is 
difficult. The survival of the patients not treated surgically or who have 
poor. A small number of retrospective studies have attempted to determine the natural 
history of patients with isolated liver metastases. In a review of 484 untreated patients with 
liver metastases from colorectal cancer, those with t
involvement, primary tumour grade 1/2, no extra hepatic tumour and no mesenteric nodal 
involvement) had a median survival of 21.3 months, compared with 30 months in patients 
undergoing hepatic resection in the same institution
1994).  
In one group of 125 patients with
the median survival was 12.5 months and all patients died within 5 years
correlated with the extent of liver disease. 
175 untreated patients with liver metastases from colorectal cancer. Patients with 1
metastases lived longer than those with >5 metastases 
consistent with a study of 113 patients with hepatic metastases from colon cancer
mean survival in patients with widespread liver disease 
1976).  
Disease recurrence is common after resection of colorectal hepatic metastases indicating 
that in the majority of cases the extent of the metastatic disease is underestimated by pre 
and intraoperative staging investigations. Around one
. This may be as a result of complications from their 
(Simmonds, Primrose et al. 2006). 
 disease free at this time. The median survival of patients 
. 
palliative surgery is 
he best prognosis (
 (Stangl, Altendorf-
 liver-only metastases, most of whom had had no therapy, 
(Garden, Rees et al. 2006). Lahr
(Lahr, Soong et al. 1983)
was 3 months (Wood, Gillis et al. 
-third of patients experience disease 
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25% liver 
Hofmann et al. 
. Survival 
 et al. studied 
–4 liver 
. This is 
 where a 
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recurrence in the liver alone and may be candidates for repeat resection. The remainder 
experience recurrence concurrently in the liver and extrahepatic sites or in extrahepatic 
sites only. It may be that biological features within the tumour may be important however, 
this requires further study. 
Identification of prognostic factors that predict the outcome following surgical resection of 
colorectal hepatic metastases would assist in the identification of those patients most likely 
to benefit from this intervention, or more importantly assist in the identification of patients 
who are unlikely to benefit (Poston, Adam et al. 2005).  
Modern chemotherapy using cytotoxic agents alone offers extension of median survival to 2 
years in patients with nonresectable disease (Cals, Rixe et al. 2004; Goldberg, Sargent et 
al. 2004). When monoclonal biological agents are added to cytotoxic chemotherapy, the 
prospect of median survival now extends beyond 2 years and 20% of patients will still be 
alive 4 years after detection of unresectable liver disease (Cunningham, Humblet et al. 
2004; Hurwitz, Fehrenbacher et al. 2004). It is therefore inevitable that the combination of 
surgical resection and chemotherapy, which is becoming commonplace, will impact on the 
postoperative survival (Nordlinger 2005). Secondly, novel surgical strategies such as 
preoperative portal vein embolisation to increase residual acceptably safe volume, or two-
stage hepatectomy to allow compensatory hepatic hyperplasia before completion of R0 
resection (Abdalla, Barnett et al. 2002; Poston, Adam et al. 2005) have also increased the 
number of resectable patients including those with extensive liver-only disease. The 
changes in the definition of resectability mean that >20% of patients with liver metastases 
can now be considered for surgery with curative intent at the outset. It is unclear what the 
long-term outcome of these strategies will be but the results appear encouraging (Abdalla, 
Barnett et al. 2002; Pawlik, Scoggins et al. 2005; Poston, Adam et al. 2005).  
1.3.6 Non-surgical treatment techniques 
Surgical resection, hepatectomy or repeat hepatectomy are not always possible for example 
where there is multicentricity, advanced or decompensated liver cirrhosis or patients unfit to 
withstand surgery or anaesthesia. Several in-situ methods for destruction of liver tumours 
have been developed. All these local non-surgical techniques are performed under 
ultrasound or CT guidance that enables either precise intratumoural delivery of chemical 
agents (such as ethanol or acetic acid) or accurate delivery of means of thermal ablation 
(cryotherapy, percutaneous microwave coagulation, hot saline, radiofrequency (RF) or 
interstitial laser photocoagulation) (Hargreaves, Adam et al. 2000). 
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Percutaneous ethanol injection (PEI) was first described in 1983 by Sugiura et al. (Sugiura 
1983). The technique involves the intralesional injection of absolute alcohol using a fine 
needle and leads to coagulation and tumour cell destruction. The number of injections for 
effect needed is variable and the rare side effects and complications include pain and fever. 
Comparative case series studies have shown good local control of the disease for single 
tumours of <3cm (Castells, Bruix et al. 1993). However no prospective randomized control 
trials have been performed. 
Hepatic cryotherapy causes the in situ destruction of liver tumours by using subzero 
temperatures. Once the probe is placed into a lesion under US, CT or MR guidance, an 
iceball including the tumour is created through multiple freeze–thaw cycles. Technological 
advances in the design of cryoprobes and delivery systems have made it possible for 
cryotherapy to be more effective and less invasive, thus extending its use from laparotomy 
to laparoscopic and percutaneous approaches. Complications related to the technique 
include hypothermia, haemorrhage as a result of the frozen liver cracking during the 
thawing phase and ‘cryoshock’ (a syndrome of multiorgan failure, severe coagulopathy, and 
disseminated intravascular coagulation after treatment). To date, cryosurgery is limited to 
irresectable lesions, and is used alone or combined with surgical resection (Adam, Akpinar 
et al. 1997). Although few long term results are available, 5-year survival rates of 27% 
have been reported following cryoablation in patients with HCC (Zhou, Tang et al. 2002). 
However, some authors have abandoned its use in favour of RF owing to a higher local 
tumour recurrence rate with cryoablation compared with RF and a much higher complication 
rate after cryoablation (Pearson, Izzo et al. 1999). 
RF is becoming a widely used ablative method for liver malignancies that can be delivered 
through an open, percutaneous or laparoscopic approach. The non-insulated tip of a needle 
electrode probe is positioned within the lesion under US, CT or MR guidance. The probe is 
attached to a generator delivering high frequency (460–500 kHz) alternating current, which 
is turned into heat through ionic agitation within the tumour. Advances in probe technology 
from monopolar to multiple, expanding or cooled-tip electrodes have increased the extent of 
the thermal lesion (coagulative necrosis) from 1.6 to 3 cm (Buscarini and Rossi 1997). 
Severe complications or death after RF are rare. 
For small HCC nodules (smaller than 3 cm in diameter) RF causes a more complete necrosis 
than PEI (90% compared with 80%). Moreover, RF has the benefit or only requiring a single 
session whereas PEI required up to five sessions for tumour ablation on average (Livraghi, 
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Goldberg et al. 1999). Some authors have proposed percutaneous RF as an alternative to 
repeat hepatectomy for treatment of liver tumour recurrence since it is much less invasive 
(Elias, De Baere et al. 2002). A surgical approach, however, allows more accurate 
assessment of the intrahepatic disease and the abdominal cavity. Furthermore, concerns 
have been raised recently by a reported 12% incidence of neoplastic seeding along the 
needle tract after percutaneous RF, particularly if it is to become a ‘bridge’ therapy to liver 
transplantation (Llovet, Vilana et al. 2001). Longer follow-up and precise indications are 
needed to assess the place of RF in the treatment of HCC. 
With all these procedures, it is essential that treatment of the tumour be complete to be of 
any benefit, in the absence of widespread intrahepatic or extrahepatic disease.  
1.3.7 The role of liver transplantation 
Total hepatectomy followed by orthotropic liver transplantation (OLT) removes the tumour 
and the underlying end-stage liver disease and avoids the risk of synchronous nodules or 
metachronous nodules. Nevertheless, until recently liver resection has been the treatment 
of choice for small tumours leaving OLT for large and irresectable tumours. This has led to 
poor initial results after OLT, mainly from high mortality rates of around 24–30% (Iwatsuki, 
Gordon et al. 1985) and high recurrence rates of up to 70% (O'Grady, Polson et al. 1988). 
As a result the use of OLT for malignant disease dropped from 29% in 1983-1987 to 15% in 
1988-1992 (Pichlmayr, Weimann et al. 1992). Interestingly, a small number of transplanted 
patients in whom HCC was detected incidentally in the hepatectomy specimen were found to 
have had a good outcome (Iwatsuki, Starzl et al. 1991). This finding is consistent with a 
retrospective study in which patients with small HCC had significantly better disease-free 
survival after liver transplantation when compared with similar patients who had liver 
resection. This highlights the importance of adequate selection of the patients who are 
candidates for OLT (Bismuth, Chiche et al. 1995). Patients in whom extrahepatic disease 
has been ruled out, with fewer than three nodules <3cm in diameter and without portal vein 
invasion are considered to have the best indication for OLT, according to one unit achieving 
83% disease-free survival at 3 years compared with 18% after liver resection (Azoulay, 
Samuel et al. 2000). Better outcome after OLT for small HCC has shown liver resection to 
be second best and has restricted the indication for liver resection to the treatment of 
patients with contraindications to liver transplantation (age, extra-hepatic disease and 
psycho-social factors or patients with good liver function and easily localised resectable 
lesions). Similar strict criteria have been followed by other groups such as Mazzaferro et al. 
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(a tumour of 5 cm or less or no more than three nodules less than 3 cm) (Mazzaferro, 
Regalia et al. 1996) giving fresh impetus to OLT in patients with HCC. For patients with 
tumours >3cm and with three or more nodules, poor results after liver transplantation may 
be due to the fact that the tumour may have already spread outside the liver (Bismuth, 
Chiche et al. 1993). 
A new approach in dealing with intrahepatic recurrence after resection is total hepatectomy 
followed by OLT. With the present organ shortage this has been studied in a statistical 
theoretical model only. It appears that the strategy of primary resection followed by 
“salvage OLT” may be a rational way to cope with lengthening waiting lists (particularly for 
patients with low risk of recurrence after partial hepatectomy, when results of liver resection 
are good and stringent follow-up can detect early, “transplantable” recurrences). This 
approach has been supported by other clinical studies (Poon, Fan et al. 2002). 
Improvement in imaging methods and surgical techniques have made it possible to detect 
HCC at earlier stages, particularly in patients predisposed by pre-existing underlying liver 
disease. This in turn has lead to an increase in the number of patients in whom treatment is 
aimed to be curative. Long-term survival after surgical treatment of HCC can be achieved by 
careful selection of patients presenting with lesions of favourable size, location and number 
and with good liver function. 
The main limit to surgical resection is recurrence, and close post-operative follow-up to 
detect this early is of paramount importance. Aggressive management of postoperative 
recurrence may improve the outcome after resection. 
1.4 RF-assisted resection: the Hammersmith experience 
With improvements in liver surgery and an increased knowledge of liver anatomy, 
physiology and hepatic cell biology, the mortality and morbidity associated with liver 
surgery have significantly decreased. Different techniques have been developed to allow 
safer liver resection (Tranberg, Rigotti et al. 1986; Nuzzo, Giuliante et al. 1996; Hansen, 
Isla et al. 1999; Yamamoto, Ikai et al. 1999). Surgeons can decrease intraoperative blood 
loss by using hypotensive anaesthetics, Pringle’s manoeuvre or total vascular exclusion. 
Parenchymal division can be performed with the scalpel, crushing the tissue with the finger 
or clamps, ultrasonic dissectors, hydrodissectors or stapling devices. Nevertheless, liver 
resection remains a formidable surgical procedure and safe performance requires a high 
level of training and skill. Intraoperative blood loss remains a major concern for surgeons 
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operating on the liver (Bismuth, Castaing et al. 1989) and is associated with a higher rate of 
postoperative complications and shorter long-term survival. In this setting, a novel 
technique for liver resection using radiofrequency (RF) energy to coagulate the liver 
resection margins has also been developed. A 2-cm-wide coagulative necrosis zone is 
created before division of the parenchyma with a surgical scalpel (Weber, Navarra et al. 
2002). 
1.4.1 The procedure 
 
Under general anaesthesia, a modified right subcostal incision is made and the peritoneal 
cavity examined for evidence of extrahepatic disease. Intra-abdominal adhesions and the 
falciform ligament are divided. The liver is then mobilized according to the size and site of 
the lesion to be resected. An intraoperative ultrasonogram is always performed before liver 
resection to reveal previously undetected lesions.  
In step 1 (Figure 2), an inner line is made on the liver capsule with argon diathermy to 
mark the periphery of the tumor, assisted by bimanual palpation and intraoperative 
ultrasound. It is important to do this first, as after RF has been applied the parenchyma is 
hardened and it becomes difficult to palpate the tumor edge. Also, after RF intraoperative 
ultrasound fails to visualize the tumor edge due to the increased echogenicity resulting from 
RF.  
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Figure 2: The sequential steps involved in RF assisted liver resection as pioneered at 
Hammersmith Hospital 
 
 
In step 2, a second or outer line, again using argon diathermy, is made on the liver capsule 
2cm outside the inner line to mark the site where the probe is positioned to achieve 
coagulative necrosis. 
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In step 3, coagulative necrosis is produced along a line that follows the second or outer line 
using the cooled-tip RF probe and a 500-kHz RF Generator (Model RFG-3D, Radionics 
Europe, N.V., Wettdren, Belgium) which produces 100W of power and allows measurements 
of the generator output, tissue impedance, and electrode tip temperature. The probe 
contains a 3cm exposed electrode, a thermocouple on the tip to monitor temperature and 
impedance, and two coaxial cannulae through which chilled saline is circulated during RF 
energy application to prevent tissue boiling and cavitation immediately adjacent to the 
needle. 
The number of probe applications required to obtain a zone of necrosis is related to the 
depth of the liver parenchyma to be resected. For example, to obtain a zone of necrosis in a 
core of tissue with a 1cm radius and 3cm in depth, each application of RF energy will need 
to be applied for about 60 seconds. Thus, for a core of tissue 12cm in depth, four 
applications will be needed in vertical succession (step 4). 
Application of the RF energy begins with the area deepest and farthest from the upper 
surface of the liver. The surgeon checks that each probe is correctly positioned with 
ultrasound. The preferred technique is to have the tip of the probe pierce the liver capsule 
of the inferior surface of the liver and to feel it with the middle finger of the left hand while 
holding the probe with the right hand. The areas of coagulative necrosis can be monitored 
using intraoperative ultrasound to show the change in tissue impedance and the formation 
of microbubbles in the tissue. 
Once the deepest 3cm of tissue is coagulated, the probe is withdrawn by 3 cm to coagulate 
the next cylinder of tissue, and so on until the upper surface of the liver is reached. Each 
application requires about 60 seconds of RF energy. For example, a cylinder of tissue 12cm 
in depth will require four applications, each application coagulating 3cm of tissue, and will 
take about 4 minutes to produce. Once an area is coagulated, the probe is withdrawn 
completely and placed 1 to 2cm away from the previous application. This allows complete 
coagulation of a band of parenchyma extending along the second line. The points of entry of 
each probe are kept close to each other at 1cm to achieve some overlap of the areas to be 
coagulated and to ensure that the coagulation has been complete. Just before each probe 
removal, the saline infusion is stopped to increase the temperature close to the electrode. 
This results in coagulation of the needle tract during withdrawal and reduces the possibility 
of bleeding from the probe tract and liver capsule. Pringle’s manoeuvre is not needed. 
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In step 5, the liver parenchyma is divided using the scalpel. The plane of division should be 
situated midway between the first and second line so as to leave a 1cm resection margin 
away from the tumor and leave in situ 1cm of burned coagulated surface. 
Coagulative necrosis from inside the resection margin is applied to stop any potential point 
of bleeding and to increase the safety margin. A drain is placed at the site of resection and 
the abdomen is subsequently closed in layers. 
This innovative technique uses RF energy for bloodless liver resection without the use of 
sutures, surgical knots, clips, or glue. When this procedure is used carefully, the surgeon 
can perform a liver resection with minimal blood loss. It is easy to teach, and surgeons with 
a good knowledge of liver anatomy can apply it to segmental resections.  
The technique reduces the anesthetic and operative time and also the amount of blood loss. 
These are significant improvements for both the patient and the surgeon. Liver resection is 
less hazardous and it reduces the need for intensive care unit facilities with less 
postoperative mortality and morbidity because of the smaller surgical insult to the patient. 
The technique was developed at a time when liver resection had become unpopular because 
of competitive therapeutic modalities based on novel engineering technologies to achieve 
local tumor control and improved chemotherapeutic regimens. As it is a simple technique to 
teach, it may encourage surgeons to perform more liver resections and popularize liver 
surgery as a ‘safe’ therapeutic modality in the management of liver tumours. Indeed, 
application of this technique is now widespread and represents a considerable step in 
making laparoscopic liver resection safer and more feasible for many liver surgeons.  
The concept of using heat to cause coagulative necrosis is not new and many authors have 
published series of RF tumour ablation for malignant tumours (Curley, Izzo et al. 1999; 
Cuschieri, Bracken et al. 1999; Jiao, Hansen et al. 1999; Gazelle, Goldberg et al. 2000). The 
innovative feature of this technique is that coagulation of normal liver parenchyma is very 
fast, in contrast to coagulation of liver tumour tissue. Typically, achieving coagulative 
necrosis in tumour tissue takes about 20 minutes for one probe application and only 40 
seconds to coagulate the same amount of normal liver tissue. 
There are two obvious limitations to the technique. The first is that RF energy cannot be 
applied near the hilus or the vena cava for fear of damaging these structures. The second is 
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that it sacrifices parenchymal tissue that is usually spared using other resectional 
techniques.  
1.5 Modern surgical advances: laparoscopic surgery 
 
Cholecystectomy (removal of the diseased gall bladder), has been a common major 
abdominal operation since it was first performed in 1882 by Carl Langenbuch. It was the 
laparoscopic removal of this organ that heralded the use of this fibre optic instrument in 
general surgery. The first laparoscopic cholecystectomy was carried out by Erich Muhe, of 
Boblingen, Germany in September 1985, using a sigmoidoscope, but the operation was met 
with scepticism. Phillipe Mouret, a gynaecologist in Lyons, performed the next 
cholecystectomy the following year, using his gynaecological laparoscopic instruments, and 
was given credit for getting the operation accepted. Thereafter, it was adopted with 
enthusiasm by Edward Reddick and Douglas Olsen in Nashville Tennessee and in the UK by 
Professor Cuschieri in Dundee (Ellis 2009).  
 
Today, minimal access surgery, or to give it its popular name, ‘key-hole’ surgery, with fibre 
optic telescopes, allows many types of operation to be carried out without the extensive 
‘surgery of approach’ that was previously required to access the diseased organ. Operations 
on the gall bladder and gynaecological procedures are the most common example but many 
abdominal and thoracic operations from appendicectomy to major tumour resections are 
now routine (Ellis 2009).   
 
1.6 Laparoscopic liver surgery 
 
The first reported laparoscopic liver resection was by Gagner et al. in 1992 (Gigot, Glineur 
et al. 2002). Since then, over 700 laparoscopic liver procedures have been reported. The 
vast majority (70%) of procedures performed are for benign lesions. The use in the 
remaining 30% for malignant tumour resections, such as HCC and liver metastases, 
remains controversial. There are also concerns over possible tumour cell exfoliation and port 
site metastases (Gigot, Glineur et al. 2002). Overall, the usual benefits of laparoscopic 
surgery, such as cosmetic aspect, rapid recovery and short post-operative stay, have to be 
balanced with overall disease-free survival, the paramount oncological objective.  
 
In benign lesions, the main objectives of laparoscopic surgery are low mortality, low 
morbidity rate, the absence of heterologous blood transfusions and a satisfactory long term 
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outcome. More recently, in resections of malignancies, the short term survival rates 
compare favourably with the open technique for both overall and disease-free survival and 
furthermore experimental in vivo and in vitro studies have shown decreased tumour growth 
after laparoscopy compared to laparotomy (Dahn, Schwalbach et al. 2005). However, there 
are currently no randomised control trials comparing the two approaches, nor long term 
oncological follow up in those series to date. Despite early favourable survival data, 
resection margins <1cm, a poor prognostic marker, are found in up to 30% of patients 
resected laparoscopically and port site metastases have been described (Gigot, Glineur et 
al. 2002). These findings support the need for a multicentre randomised control trial.  
Radiofrequency-assisted liver resection was originally described for ‘bloodless’ liver resection 
without the need for vascular clamping or the use of suture, surgical knots, or clips (Weber, 
Navarra et al. 2002). Because of this unique feature, it would seem ideal to use this device 
for laparoscopic liver resection.  
Careful preoperative staging and selection of patients are the keys to success in 
laparoscopic surgery for cancer. The size and location of the liver tumour is fundamentally 
important in determining the feasibility of resection with laparoscopic approach. Although no 
reports exist on major liver resection (Vibert, Perniceni et al. 2006) it is believed that 
laparoscopic technique can only be performed safely for reasonably small tumours located 
peripherally. For resection of large liver tumours, the liver must be mobilized completely 
and the risk of bleeding is high.  
The benefits of the laparoscopic approach over open surgery, such as decreased 
postoperative analgesia requirement, shorter delay to oral intake after surgery, and a 
decreased hospital stay, are well known. In early RF series (Jiao, Navarra et al. 2005), 
patients were mobilized more quickly and had a much shorter duration of hospital stay (6 
days) compared with those undergoing open resection (10 to 14 days), which is consistent 
with later reported series (Lesurtel, Cherqui et al. 2003; Jiao, Navarra et al. 2006).  
The risk of tumour seeding during laparoscopic surgery has long been debated in the 
literature. The potential mechanisms for this event include direct contamination from 
technical errors during laparoscopic resection, cell exfoliation, and cytokine activation 
secondary to pressure effects from pneumoperitoneum (Neuhaus, Texler et al. 1998). No 
patients developed either port-site or intraperitoneal metastases at postoperative follow-up 
after RF assisted resection (Jiao, Navarra et al. 2005; Ayav, Jiao et al. 2007). Promotion of 
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tumour growth by carbon dioxide gas insufflations has also been cited as a reason against 
the application of laparoscopic technique for oncologic surgery (Volz, Koster et al. 1999; 
Takiguchi, Matsuura et al. 2000; Whelan 2001). However, clinical data suggest that the 
incidence of recurrence between laparoscopic and conventional open operation for cancer is 
similar and the immune system may also be better preserved in patients undergoing 
laparoscopic surgery (Vittimberga, Foley et al. 1998; Whelan 2001). In a recent prospective 
randomised study, Lacy showed better long-term survival in patients who underwent 
laparoscopic resection for colonic cancer than those who underwent open resection (Lacy, 
Garcia-Valdecasas et al. 2002). 
Fong et al. (Heredia, Ricart et al. 2002) described a number of problems related to 
laparoscopic liver resection, including the difficulty in identifying tumour margins and 
mobilizing the liver, in addition to the inherited problems of dense adhesions from previous 
surgery for primary cancer. Meticulous surgical technique and care are crucial to prevent 
any inadvertent damage to abdominal organs during induction of pneumoperitoneum and 
insertion of ports. Although previous abdominal surgery should not be considered as a 
contraindication for laparoscopic liver resection, adhesions are a major reason for 
conversion to open procedure and accounted for 2 out of 3 early converted cases. 
Biertho et al. (Biertho, Waage et al. 2002) reviewed 186 laparoscopic liver resections 
performed between 1991 and 2001 and concluded that it would be feasible and safe to 
perform laparoscopic liver resection in a group of selected patients at an established 
hepatobiliary centre with highly trained surgeons in advanced laparoscopic techniques. 
However, this should only be applied to minor resections involving less than 2 segments. 
Their reported mortality and morbidity rates were 0.5% and 16% in 1991 and 2001, 
respectively, with a conversion rate of 7%.  
Since our first description of RF ablation for unresectable liver cancer, we have expanded 
the role of RF in liver surgery from mere ablation to actual liver resection (Jiao, Hansen et 
al. 1999; Weber, Navarra et al. 2002). This technique has now been applied to laparoscopic 
liver resection. In our experience, this is a safe and feasible technique for laparoscopic liver 
resection and has little intraoperative blood loss and zero transfusion of either blood or 
blood products during or after surgery. Although only a small number of have been 
reported, RF has established itself as one of the current techniques for laparoscopic liver 
resection (Bachellier, Ayav et al. 2007). 
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1.7 The Pneumoperitoneum: what do we know?
 
One of the key manoeuvres that allows laparoscopic surgery logistical success is the use of
a ‘pneumoperitoneum’. This is 
pressurised gas to enable more space to use the telescopic camera (lapa
visualise the liver.  
 
Figure 3: The process of insufflation of the abdomen to establish pneumoperitoneum for 
laparoscopic abdominal surgery. In this case the use of Veress needle is shown.
1.7.1 Pneumoperitoneum: The G
 
The gas most commonly used for laparoscopy is carbon dioxide (CO
al. 2005). It is colourless, non
easily absorbable allowing increased protection from gas embolism which can occur in 
laparoscopy with room air. However
operation times. The use of iner
increasingly discussed. Helium has the same positive qualities as carbon dioxide but no 
metabolic effect. Previous studies indicate that helium pneumoperitoneum used for 
laparoscopic surgery suppresses pos
metastatic disease. However, the mechanism of decreased tumour growth by helium is 
unknown. The only known detriment of usage of helium is the increased risk of gas 
embolism compared to carbon dioxide pneumoper
the inert gases and has the same positive qualities. 
inhibition of cell cycle (Dahn, Schwalbach et al. 2005)
suppressive effect on tumour growth. However, these gases are not generally used for 
laparoscopy because of poor availability and high primary costs. CO
Hammersmith Surgical Unit. Room air, the gas with best availability, is no longer in use for 
pneumoperitoneum because of its negative effects, principally the risk of air embolism. 
 
process involves the insufflation of the abdominal cavity with 
 
 
as 
2) (Dahn, Schwalbach et 
-explosive and has good availability. Carbon dioxide is also 
, it can also lead to metabolic acidosis during longer 
t gases such as helium for laparoscopic surgery is 
toperative tumour growth and may lead to less 
itoneum. Xenon belongs, like helium, to 
Studies have shown a xenon
 suggesting that xenon 
2 is the gas used in the 
Page | 36 
 
roscope) to 
 
-induced 
also has a 
 
CHAPTER 1: INTRODUCTION 
 
 
1.7.2 Pneumoperitoneum: i
 
There are many studies both in humans and animal models assessing the impact of the 
increased intra-abdominal pressure (IPP) caused by insufflations 
1994; Eleftheriadis, Kotzampassi et al. 1996; Jakimowicz, Stultiens et al. 1998; Ishida, 
Murata et al. 2000). One representative study involved 11 patients undergoing laparoscopic 
procedures for benign disease and use
changes in the portal flow observed at different pressure levels of 0, 7, and 14 mmHg (as 
outlined in Figure 4). Importantly, at an IPP level of 14 mmHg (routinely used in most 
laparoscopic procedures) the flow of blood in the portal vein (which suppl
to the liver) sustained a mean drop to 440 ± 56 mmHg. This corresponds to a 53% 
reduction compared to the initial baseline value 
finding has been replicated in other clinical series and is supported by animal models 
(Eleftheriadis, Kotzampassi et al. 1996)
 
Figure 4: Increasing intraabdominal pressure reduces portal venous flow. 
 
 
 
 
 
Research suggests that the insufflation pressure can significantly alter the growth of cancer 
cells. For example, one model showed a significant correlation between the insufflation 
0mmHg
(before op)
nsufflation pressures  
(Hashikura, Kawasaki et al. 
d duplex Doppler ultrasonography to demonstrate 
ies >80% of blood 
(Hashikura, Kawasaki et al. 1994)
.  
 
 7mmHg 14mmHg 0mmHg 
             (after op)  
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pressure and area of the liver affected by metastases after portal vein inoculation of colon 
cancer cells in mice (Ishida, Murata et al. 2001; Ishida, Hashimoto et al. 2002). A rabbit 
model assessed the effect of the pneumoperitoneum on established liver metastases and 
demonstrated a similar correlation that was not present in an open laparotomy group 
(Ishida, Murata et al. 2000; Ishida, Murata et al. 2000).  
 
1.8 Hypoxia and cancer: a poor prognostic marker 
 
The oxygen concentration in solid neoplasms is generally lower than in the adjacent non-
neoplastic tissue. As a consequence of increased cellularity and proliferation, as well as 
enhanced metabolism within a tumour (Harris 2002; Vaupel 2004). Histopathological 
examination of carcinomas frequently reveals hypoxic areas within the tumour mass, mostly 
in the form of necrotic regions. 
 
In cancer, invasion and metastasis are key issues in terms of prognosis and the ability of 
surgery to be curative. This is partly because hypoxic regions are relatively inaccessible to 
chemotherapy, as they are poorly perfused (Young 1990), and radiotherapy, as oxygen-
dependent radical production is required for efficient cell killing (Airley, Phillips et al. 2005; 
Williams, Telfer et al. 2005). However, prognosis is also poor when patients are treated by 
surgery alone (Garden, Rees et al. 2006) and this reflects the reaction to hypoxia whereby 
tumour cells can alter their metabolism and activate survival mechanisms. Associations 
between microenvironmental hypoxia, activation of hypoxia pathways, and aggressively 
malignant phenotypes are observed across a range of cancers (Colpaert, Vermeulen et al. 
2003; Giatromanolaki, Sivridis et al. 2003; Chang, Qin et al. 2006; Generali, Berruti et al. 
2006; Shyu, Hsu et al. 2007; Yasuda, Shimizu et al. 2007; Chai, Chen et al. 2008; Evens, 
Schumacker et al. 2008; Kolev, Uetake et al. 2008; Rajaganeshan, Prasad et al. 2008; 
Shimogai, Kigawa et al. 2008; Wigfield, Winter et al. 2008; Xie, Song et al. 2008). These 
findings have focused attention on the molecular dissection of the hypoxia pathways and 
how these contribute to tumour biology. Important insights have been gained through the 
definition of hypoxia-inducible factor (HIF) as a key transcription factor regulating oxygen-
dependent gene expression. 
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1.9 The cellular response to hypoxia: HIF 
 
1.9.1 Introduction 
 
Oxygen is the substrate of multicellular life. Reduced oxygen availability (hypoxia) is sensed 
and triggers homeostatic responses, which impact on virtually all areas of biology and 
medicine. Since the purification and molecular cloning of hypoxia-inducible factor 1 (HIF-1) 
in 1995, the scientific community has witnessed the explosive expansion of this field, 
(Zhang and Semenza 2008). 
1.9.2 HIF-1 
HIF-1 is a heterodimeric protein composed of HIF-1α and HIF-1β subunits (Wang, Jiang et 
al. 1995; Wang and Semenza 1995) which modulates the regulation of hundreds of genes 
according to the cellular O2 concentration (Manalo, Rowan et al. 2005). HIF-1α levels 
increase dramatically as O2 concentration declines (Jiang, Semenza et al. 1996). Under 
normoxic conditions, HIF-1α is subjected to ubiquitination and proteasomal degradation 
(Salceda and Caro 1997; Huang, Gu et al. 1998; Kallio, Wilson et al. 1999) due to the 
binding of the von Hippel-Lindau tumor suppressor protein (Maxwell, Wiesener et al. 1999) 
which is the substrate recognition subunit of an E3 ubiquitin-protein ligase (Kamura, Sato et 
al. 2000). VHL binds to HIF-1α only when the latter is hydroxylated on proline residue 402 
and/or 564 (Ivan, Kondo et al. 2001; Jaakkola, Mole et al. 2001; Yu, White et al. 2001). 
The hydroxylation reaction is performed by prolyl hydroxylases (PHDs) that utilize O2 and α-
ketoglutarate as substrates and generate carbon dioxide and succinate as 
byproducts(Epstein, Gleadle et al. 2001). Under hypoxic conditions, hydroxylation, 
ubiquitination and degradation are inhibited, leading to the accumulation of HIF-1α (Figure 
5). Under normoxic conditions, asparagine residue 803 is also hydroxylated. This reaction, 
which is mediated by factor inhibiting HIF-1 (FIH-1), prevents the binding of the co-
activators CBP and p300 to HIF-1α (Lando, Peet et al. 2002). Thus, O2-dependent 
hydroxylation regulates both the stability and transcriptional activity of HIF-1. Once 
activated, HIF-1 mediates a variety of adaptive responses to hypoxia. Two general classes 
of responses exist: firstly, those that serve to increase O2 delivery (for example, by 
stimulating angiogenesis by activation of the gene encoding vascular endothelial growth 
factor [VEGF]); and secondly, those that serve to regulate O2 utilization. Recent findings in 
connection with the latter responses are described below. 
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1.9.3 Intratumoral PO2, lactate, and pH 
The mean PO2 in human tumours is significantly reduced compared to surrounding normal 
tissue and tumours with the greatest reduction in PO2 are most likely to invade, 
metastasise, and kill the patient (Vaupel and Mayer 2007). Many carcinomas also manifest 
an increased concentration of lactate which is also associated with increased risk of 
metastasis (Vaupel and Mayer 2007). The increased lactate production is associated with 
increased expression of lactate dehydrogenase A (LDHA) (Koukourakis, Giatromanolaki et 
al. 2006) and the monocarboxylate transporter MCT4 which transports lactate out of cancer 
cells (Koukourakis, Giatromanolaki et al. 2007). Cancer cells also overexpress the sodium–
hydrogen exchanger NHE1 and carbonic anhydrase 9 which maintain an alkaline intracellular 
pH and an acidic extracellular pH (Fang, Gillies et al. 2008). Expression of the LDHA, MCT4, 
NHE1, and CA9 genes is induced by hypoxia through the activity of HIF-1 (Kroemer and 
Pouyssegur 2008). Thus, along with its control of genes encoding glucose transporters and 
glycolytic enzymes (Iyer, Kotch et al. 1998), HIF-1 coordinately regulates all of the proteins 
required for glucose uptake and its conversion to lactate (Figure 4). The induction of CA9, 
MCT4, and NHE1 allows cancer cells to maintain an alkaline intracellular pH and an acidic 
extracellular pH, critical for cell proliferation and invasion, respectively. 
1.9.4 The molecular basis of the Warburg effect in renal clear-cell carcinoma 
Although many cancer cells utilize the physiological responses to hypoxia described above, 
in some, genetic alterations can result in a fixed and O2-independent reprogramming of 
metabolism. Warburg noted increased production of lactate in the tissue culture media of 
liver tumour explants as compared to normal liver explants cultured under aerobic 
conditions (Warburg 1930). In renal cell carcinoma lines in which VHL is inactivated by 
mutation, HIF-1α and HIF-2α are constitutively expressed and mediate glycolytic 
metabolism. Reintroduction of WT VHL into the cell results in loss of HIF-1α and HIF-2α 
expression under aerobic conditions and a dramatic increase in mitochondrial mass and O2 
consumption (Zhang, Gao et al. 2007). In VHL-deficient renal carcinoma cells, HIF-1 blocks 
the biogenesis of mitochondria through inhibition of MYC which would otherwise activate 
transcription of the gene encoding PGC-1β, a transcription factor that controls mitochondrial 
biogenesis. Loss of VHL activity and the subsequent dysregulation of HIF-1 represents the 
most well understood mechanism through which cancer cells can be reprogrammed from 
oxidative to glycolytic metabolism (the Warburg effect) as a result of a single genetic 
alteration. Many other mutations that either activate oncoproteins or inactivate tumor 
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suppressors also lead to increased HIF-1 activity (Semenza 2003), suggesting that 
upregulation of HIF-1 represents a general mechanism underlying the Warburg effect in 
human cancer. 
Figure 5: The outline of regulation of stability and transcriptional activity of HIF-1α. In the 
presence of O2 and cofactors Fe
2+ and 2OG, PHDs hydroxylate HIF-α, allowing its 
recognition by the E3 complex that is followed by E2/E1-mediated ubiquitylation and 
degradation in the 26S proteasome. FIH-1-mediated N-hydroxylation prevents recruitment 
of p300/CBP transcriptional coactivators. In the absence of O2, PHDs and FIH-1 are 
inactivated, non-hydroxylated HIF-α translocates to the nucleus, dimerizes with HIF-β, 
recruits p300/CBP, and induces the expression of its target genes via binding to the HRE. 
BTM, basic transcriptional machinery; E1, ubiquitin-activating enzyme; E2, ubiquitin-
conjugating enzyme; E3, ubiquitin ligase; FIH-1, factor inhibiting HIF-1; HRE, hypoxia-
response element; 2OG, 2-oxoglutarate; PHDs, prolyl hydroxylases; Ub, ubiquitin; VHL, von 
Hippel–Lindau protein. 
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Genetic experiments with tumour models performed by Professor Maxwell and others, have 
clearly established that the HIF system is important in tumour growth (Maxwell, Wiesener et 
al. 1999; Mandriota, Turner et al. 2002). Importantly, cancer cells often have an 
upregulated HIF response, with partial activation of the HIF system when they are supplied 
with oxygen and a greater level of HIF activation in hypoxia than untransformed cells. 
Consistent with this, activation of many different oncogenes or inactivation of tumour 
suppressor genes upregulate the HIF system via variety of mechanisms. A striking example 
of this process is the loss of VHL tumour suppressor gene associated with a familial cancer 
syndrome with a very high risk of clear cell renal cancer. According to Knudson’s two hit 
hypothesis, biallelic VHL inactivation underlies the majority of sporadic clear cell renal 
cancers, the commonest form of kidney cancer. Indeed, renal carcinoma cells lacking VHL 
and stably complemented sublines provide a very powerful system to identify the 
consequences of HIF activation. 
 
 
1.10 HIF and liver cancer: 
 
1.10.1 HIF and liver metastases  
 
Activation of HIF-1α has been reported in many solid tumours including carcinomas of the 
gastrointestinal tract (Zhong, De Marzo et al. 1999; Talks, Turley et al. 2000; Jiang, Fan et 
al. 2003; Kuwai, Kitadai et al. 2003; Yoshimura, Dhar et al. 2004; Koukourakis, 
Giatromanolaki et al. 2006; Lu, Xing et al. 2006; Yu, Cui et al. 2006; Wincewicz, Sulkowska 
et al. 2007). However, the role of HIF-1α in tumour progression of colorectal carcinomas is 
still unclear and the published data so far are controversial. The expression of HIF-1α in 
some studies was correlated with increased tumour aggressiveness, whereas in other 
studies a direct contribution to tumour progression was not demonstrated.  
 
HIF-1α is one of the key factors promoting carcinogenesis independently of histogenetical 
origin. An enhanced expression of HIF-1α from normal tissue through premalignant lesions 
to carcinomas has already been observed in prostate (Zhong, Semenza et al. 2004), gastric 
(Griffiths, Pritchard et al. 2007), breast (Bos, Zhong et al. 2001), oral cavity (Costa, 
Coradini et al. 2001), cervical (Acs, Zhang et al. 2003) and endometrial (Horree, van Diest 
et al. 2007) carcinogenesis. So far, detailed studies about the role of HIF-1α in the 
development of colorectal cancer are limited. In the case of colorectal carcinogenesis two 
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major pathways with different morphological features of the precursor lesions have been 
described (Vogelstein, Fearon et al. 1988; Longacre and Fenoglio-Preiser 1990): the 
conventional "adenoma-carcinoma pathway" and the alternative "serrated pathway", in 
which serrated polyps replace the traditional adenoma as the precursor lesion. The 
incidence of colorectal cancer did not differ significantly between serrated and traditional 
adenoma. 
In addition to hypoxia, more recent evidence suggests that non-hypoxic pro-inflammatory 
stimuli, including cytokines and growth factors, can also activate HIF-1α under normoxic 
conditions and modulate the transcription of hypoxia-associated genes (Frede, Berchner-
Pfannschmidt et al. 2007). This phenomenon is well documented in inflammatory cells such 
as macrophages and monocytes (Blouin, Page et al. 2004; Frede, Stockmann et al. 2006; 
Peyssonnaux, Cejudo-Martin et al. 2007) but similar observations have also been made in 
tumour cell lines. In this context, the very potent pro-inflammatory bacterial 
lipopolysaccharide (LPS) may be of particular importance as a possible stimulator of HIF-1α 
in the gut under normoxic conditions (Liu, Kirschenbaum et al. 2002; Frede, Freitag et al. 
2005). Because LPS is a component of the cell wall of gram-negative bacteria ubiquitously 
present in the colon, normal and neoplastic intestinal cells are continuously exposed to this 
factor (Morrison, Lei et al. 1993). Previous studies suggest that LPS could influence the 
progression of colorectal cancer through its receptor TLR4 (Toll-like receptor 4) 
(Simiantonaki, Kurzik-Dumke et al. 2007) and the downstream transcription factor nuclear 
factor-κB (NFκB) (Simiantonaki, Kurzik-Dumke et al. 2007), leading to release of factors 
from colon carcinoma cells capable of up-regulating endothelial cell adhesion molecules 
(Simiantonaki, Jayasinghe et al. 2002). Interestingly, a study investigating gut ischemia, 
has found that LPS can induce HIF-1α expression in enterocytes under normoxic conditions 
(Koury, Deitch et al. 2004). However, a potential activation of HIF-1α in colorectal 
carcinoma cells after exposure to LPS has not been reported. 
1.10.2 HIF and primary hepatocellular carcinoma 
 
Although hepatocellular carcinomas (HCC) are one of the leading causes of cancer death in 
the world, the molecular mechanism of hepatocarcinogenesis, especially in the early stage, 
is still not sufficiently understood. During the early stage of hepatocarcinogenesis, focal 
lesions called hyperplastic or dysplastic hepatocytic foci emerge. These lesions exhibit a 
number of altered gene expression and higher proliferating capacity compared with the 
surrounding normal hepatic tissue and grow into grossly visible lesions called hepatic 
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adenomas or dysplastic nodule
development of these lesions, the gradual accumulation of genetic changes
preneoplastic hepatocytes, leading to the final
cellular signalling enabling the early preneoplastic hepatocytes to exhibit the
advantage occurs, is not exactly known. 
1α and activation of its 
hepatocarcinogenesis. In particular
under the influence of HIF-
preneoplastic hepatocytes (Tanaka, Yamamoto et al. 2006)
be crucial in the progression of hepatocarcinogenesis by expanding preneoplastic hepatocyte
populations, which in turn increase the chance for accumulation
within the populations. Intervention
the development of HCCs. 
 
1.11 HIF target genes 
Historically, the HIF target genes have been identified on the basis of one or more of the 
following strategies: identification of a functional HRE containing a HIF
(HBS); comparison of patterns of gene expression in HIF
treated with siRNA targeting HIF
cells or cells transfected with a HIF
Expression profiling experiments indicated the heterogeneity of gene subsets induced by 
hypoxia, some of which could be explained by different cell types examined and the relative 
level or duration of hypoxia (Denko, Fontana et 
hypoxia-responsive profiles cannot be explained by the genetic instability of the tumo
lines used, as normal stromal and epithelial cells also display distinct hypoxic profiles 
(Denko, Fontana et al. 2003). The 
genes that are consistently induced by hypoxia and 
cell-type specific induction. This conclusion underscores the importance of studying hypoxic 
gene expression in a cell type
induces HIF activity in almost all cell types and
cell-type specific gene expression. Instead, the cell
appears to be determined by functional interactions of HIF with other trans
(Semenza 2003). 
s in the later stage. It is thought that, during the 
 may occur in the 
 development of HCC cells. However, how the 
A recent study showed that overexpression of 
target genes are changes in the early stages of 
, activation of PI3K/Akt signalling, IGF
1 activation may be important for the proliferation of 
.Therefore, HIF-1 activation may 
 of oncogenic mutations 
 of the HIF-1 pathway may then be effective to prevent 
-binding sequence 
-α wild-type and nu
-α); screening for increased gene expression using VHL
-α expression vector (Kaluz, Kaluzova et al. 2008)
al. 2003). However, the differences in 
growing consensus is that there exists
then there are other genes exhibit
 dependent context (Denko, Fontana et al. 2003)
 therefore, HIF alone cannot account for the 
 type specific induction by hypoxia 
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Estimates of the total number of HIF target genes induced by hypoxia in one or more cell 
types vary, from more than 200 (Wenger, Stiehl et al. 2005) to as many as 1–5% of all 
human genes (Semenza 2003), although not all of them may be regulated directly through 
HREs. Other transcription factors have also been implicated in hypoxia-inducible gene 
expression, for example, HIF-activated transcription factors (DEC 1 and 2, ETS-1) also 
contribute to the pool of hypoxia-induced genes. General stress-responsive transcription 
factors, such as AP-1, NF-κB, and Egr1 are also up-regulated by hypoxia although their 
sensitivity to mild hypoxia and the duration of their transcriptional response are much less 
than that of HIF (Denko, Fontana et al. 2003). 
Table 2: Selected HIF target genes grouped according to their function 
Group Gene Protein function 
O2 supply Transferrin Iron transport 
 Transferrin receptor Iron transport 
 VEGF Angiogenesis 
 Flt-1 (VEGF receptor) Angiogenesis 
 Plasminogen activator inhibitor 1 Blood flow 
 Erythropoietin Erythropoiesis 
Cellular 
metabolism 
Enolase 1 Glycolysis 
 Lactate dehydrogenase A Glycolysis 
 Phosphoglycerate kinase 1 Glycolysis 
 GAPDH Glycolysis 
 Phosphofructokinase L Glycolysis 
 Glucose transporter 1 Glucose uptake 
 Carbonic anhydrase 9 pH regulation 
 MDR1 Xenobiotic metabolism 
Transcription DEC 1 and 2 Transcription factors 
 ETS-1 Transcription factor 
 ID2 Transcriptional repressor 
 CITED2/p35srj Transcriptional cofactor 
Apoptosis NIP3 Pro-apoptotic 
 BNIP3 Pro-apoptotic 
 Noxa Pro-apoptotic 
 Mcl-1 Anti-apoptotic 
Other PHD2 O2 sensing 
 PHD3 O2 sensing 
 
The HIF pathway directly activates an array of at least 70 genes in which functional HREs 
were experimentally confirmed (Wenger, Stiehl et al. 2005). In general, HIF induces 
expression of proteins that specifically help meet the metabolic and survival needs of 
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hypoxic cells. For practical purposes, these proteins are grouped according to their function 
(Semenza 2003; Wenger, Stiehl et al. 2005) and the major groups with selected 
representatives are shown in Table 2. Interestingly, HIF activates genes coding for the pro-
apoptotic proteins such as BNIP3 (Kothari, Cizeau et al. 2003) as well as the anti-apoptotic 
protein Mcl-1 (Piret, Minet et al. 2005). This has led to the concept that the ratio of pro- and 
anti-apoptotic factors could play a role in the differential response of various cell types to 
hypoxia. In the context of solid tumours, it could contribute to the process in which the 
most malignant cells are selected (Denko, Fontana et al. 2003). The presence of HREs in the 
regulatory regions of PHD2 and PHD3 (Metzen, Stiehl et al. 2005) allows activation of 
corresponding proteins by hypoxia and provides a negative feedback on HIF activity. 
1.12 Regulation of target genes by HIF-1α and HIF-2α 
The existence of three members within the HIF-α family, HIF-1α, HIF-2α (also called EPAS1, 
MOP2 or HLF), and HIF-3α, raises questions about the role of individual isoforms in 
regulation of hypoxic transcription. All α subunits exhibit high conservation at the protein 
level, domain structure, and hypoxia-dependent mechanisms of regulation, they 
heterodimerize with HIF-1β and bind to the same cis-element, HBS (Huang and Bunn 
2003). Yet, despite similar biochemical properties, distinct patterns of cellular expression 
appear to be responsible for distinct physiological roles of HIF-1α and HIF-2α (Huang and 
Bunn 2003). For instance, both isoforms are abundantly expressed in the kidney but in 
different types of cells: HIF-1α is predominantly expressed in epithelial cells whereas HIF-2α 
is predominantly detected in interstitial fibroblast and endothelial cells (Rosenberger, 
Mandriota et al. 2002). The fact that neither HIF-1α−/− nor HIF-2α−/− embryos can survive 
suggests that HIF-1α and HIF-2α are functionally non-redundant and unable to functionally 
complement each other (Huang and Bunn 2003). Inactivation of HIF-1α or HIF-2α by siRNA 
elicits remarkably different cell-specific effects: hypoxia-inducible gene expression is 
critically dependent on HIF-1α in endothelial and breast cancer cells whereas in renal 
carcinoma cells it was critically dependent on HIF-2α (Sowter, Raval et al. 2003). HIF-α 
isoforms display unexpected suppressive interactions in renal cell carcinoma, where up-
regulation of HIF-2α suppresses HIF-1α and vice-versa (Raval, Lau et al. 2005). 
Several studies have suggested that HIF-1α and HIF-2α differ in their capability to 
transactivate hypoxia-inducible genes. An earlier study found that some genes were 
transactivated exclusively by HIF-1α (notably genes coding for glycolytic enzymes), some 
genes were transactivated by both isoforms but no genes were transactivated only by HIF-
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2α (Hu, Wang et al. 2003). In a different study, using siRNA, a small group of genes was 
found to be preferentially regulated by HIF-2α. Promoter analysis revealed that these genes 
have binding sites for the ETS family of transcription factors in common and knock-down of 
ELK-1, the most abundant member of ETS family, significantly reduced hypoxic induction of 
the HIF-2α-dependent genes (Aprelikova, Wood et al. 2006).  
In summary, available data support the notion that, of the two HIF-α isoforms, HIF-2α is the 
more selective activator of hypoxia-inducible genes. However, the question of how HIF-1 
and HIF-2 discriminate between the target genes is far from settled. The observed 
significant difference in the magnitude and/or specificity of activation of target genes does 
not appear to depend on the sequence of the relevant HBS. Instead, these differences could 
be accounted for by preferential cooperation of one of the isoforms with certain subsets of 
transcription factors, coactivators or corepressors, and/or tissue-specific expression of HIF-α 
isoforms (Wenger, Stiehl et al. 2005). 
1.15 E-cadherin 
 
Intercellular adhesion in the context of epithelia is mediated by specialized structures 
termed intercellular junctions (Esteban, Tran et al. 2006). The adherens junction is mainly 
composed of transmembrane calcium-dependent glycoproteins called cadherins. E-cadherin 
is the classic epithelial cadherin, and by dimerizing with other E-cadherin molecules on 
adjacent cells, it seals the basolateral intercellular space, helping to maintain tissue integrity 
and architecture (Conacci-Sorrell, Zhurinsky et al. 2002; Esteban, Tran et al. 2006). Besides 
this structural role, E-cadherin also exerts important effects on cell signaling, through the 
interaction of its cytoplasmic domain with the catenin family of proteins (Conacci-Sorrell, 
Zhurinsky et al. 2002; Bienz 2005). Although α-catenin connects E-cadherin to the actin 
cytoskeleton, γ-catenin and particularly β-catenin have the ability to interact with the T-cell 
factor family of transcription factors, whose transcriptional activity they increase (Bienz 
2005). By controlling the amount of β-catenin available in the cytoplasm, E-cadherin can 
regulate the expression of critical genes involved in cell death/proliferation (e.g., cyclin D1 
and c-myc). Taken together, it is thus not surprising that loss of E-cadherin expression is a 
hallmark feature of cancers of epithelial origin (Paraskeva, Ridgway et al. 2005). There is a 
substantial amount of clinical and experimental data indicating that hypoxia within solid 
tumours has a profound impact on malignant progression by initiating a rapid and 
progressive down-regulation of cell adhesion molecules (including E-cadherin). Furthermore 
the process has been shown in colorectal and renal carcinoma cell lines to be (at least in 
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part) mediated by HIF (Paraskeva, Ridgway et al. 2005; Esteban, Tran et al. 2006). The 
ability of hypoxic cells to lose and regain homotypic and matrix adhesion, has significant 
implications for the potential behaviour of tumours in the laparoscopic (hypoxic) surgical 
environment. 
 
1.14 Aims 
It has been postulated that because haematogenous spread usually occurs in a stepwise 
fashion, initially to the liver, with subsequent intrahepatic spread via the portal vein and 
further spread to the systemic circulation, surgical resection of isolated hepatic metastases 
from colorectal cancer may be curative. Nonetheless a majority of patients undergoing 
curative resection for HCC have intrahepatic recurrence within 5 years and even more 
patients have recurrence after resection for colorectal liver metastases. I aim to assess the 
cellular markers of resected liver tumour tissue in order to specifically analyse the role of 
hypoxia and HIF target genes in the development of liver metastases and in orchestrating 
further tumour spread.  
I will study 10 paired tissue samples from liver resections to analyse whether there is any 
significant difference in tumour biology attributable to the nature of the resection surgical 
approach, laparoscopic or open. 
I will use a recognised model for analysing potential HIF target genes; specifically CD10 
after recent research has shown it may represent a prognostic indicator of liver metastases 
in primary colorectal carcinoma. 
I will assess the effects on circulating tumour cells of liver resection using the new 
Hammersmith technique, radiofrequency assisted laparoscopic and open liver resection. 
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2.1 Cell culture 
 
2.1.1 Cell lines 
 
I used three VHL defective human renal cancer cell lines, RCC4, RCC10 and 786-O and the 
corresponding sublines transfected with wild-type VHL, RCC4/VHL, RCC10/VHL and 786-
O/VHL. The RCC10 and RCC10/VHL cell lines were a gift from Dr. K. Plate and Dr. T. Acker 
(Frankfurt University Medical School, Frankfurt). The RCC4 and RCC4/VHL were previously 
described by Maxwell et al. (Maxwell, Wiesener et al. 1999). The 786-O and 786-O/VHL 
cells were a gift from Prof. W. Kaelin (Dana-Farber Cancer Institute, Boston).  
 
2.1.2 Maintenance of cell lines 
 
Tissue culture reagents used for the experiments in this thesis were purchased from Gibco 
(Invitrogen, UK), unless otherwise stated.  
 
In order to culture the renal cancer cell lines, RPMI 1640 was used as the basal media. It 
was supplemented with 10% FCS, 2mM L-Glutamine, 50 IU/mL penicillin and 50µg/mL 
streptomycin. Stock cell cultures were maintained in 100mm tissue culture dishes (TPP, UK) 
in a GalaxyR CO2 incubator (Wolf Laboratories, UK) with a humidified atmosphere of 5% 
CO2 at 37
oC. Cells were passaged using trypsin-EDTA solution. Cells were transferred to a 
15ml falcon tube and spun at 1,000 rpm for 5mins to pellet the cells. After spinning cells 
were resuspended into single cell suspensions in the appropriate volume and re-plated into 
tissue culture dishes.  
 
2.1.3 Preparation of frozen cell stocks 
 
In order to store the cells for long term purposes, cells from a confluent 100mm tissue 
culture dish were trypsinised as described in section 2.1.2. Cells were spun to form a pellet 
and were resuspended in 3mLs of FCS. An equal amount of 2x freezing medium (20% 
dimethyl sulphoxide (DMSO) and 80% FCS) was added drop wise to the cells. 2mL aliquots 
of cells were prepared in labelled cryovials. These cryovials were placed in a freezing box 
containing isopropanol and then transferred to -80oC overnight prior to being transferred to 
liquid nitrogen for long-term storage.  
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2.1.4 Manipulating HIF-α protein levels in culture 
 
2.1.4.1 Hypoxia 
 
Cells were plated near to confluence into tissue culture dishes and subjected to hypoxic 
conditions using a GalaxyR tissue culture incubator (Wolf Laboratories, UK). Hypoxic cells 
were cultured in an atmosphere of 1% O2, 5% CO2 balanced with N2 at 37
0C. The exposure 
periods pertaining to the individual experiments are quoted in the relevant results section. 
The same number of control dishes were cultured under normoxic conditions, 20% O2, 5% 
CO2 balanced with N2 at 37
0C. 
 
2.1.4.2 DMOG  
 
Cells were plated at near to confluence. A 1M stock solution of DMOG (Frontier Scientific) 
was prepared in DMSO. Cells were stimulated in a final concentration of 1mM DMOG, which 
is sufficient to activate HIF in cell cultures. As comparable controls, the same numbers of 
dishes at the same density were cultured under normoxic conditions.  
 
2.2 RNA procedures 
 
2.2.1 Extraction of RNA from tissue culture cells  
 
All reagents used to extract RNA were purchased from Sigma unless otherwise stated. 
During all RNA procedures care was taken to ensure that all reagents and consumables as 
well as the working environment were RNAse free. Prior to extracting RNA, cells were plated 
in 60mm tissue culture dishes and were allowed to reach confluence for 24hrs. The 
monolayers of the cells were trypsinised and pelleted. The supernatant was carefully 
removed from the cell pellet and then vortexed to loosen the pellet before adding 500µl of 
RNA-Bee (AMS biotechnology) to the falcon tube. The respective tubes were then vortexed 
for 15 seconds and aliquoted into 1.5mL RNAse free tubes. Then 100µl (20%) chloroform 
was added to the tubes and vortexed thoroughly for at least 30 seconds and incubated on 
ice for 5mins. Next the samples were centrifuged at 13,000rpm for 15mins at 4oC in a 
chilled microcentrifuge (Eppendorf, UK). Following centrifugation the mixture is separated 
into three phases. The upper aqueous phase containing the RNA was transferred into fresh 
RNAse free 1.5ml tubes. Care was taken not to disrupt the lower organic phases. In the 
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next step, RNA was precipitated by adding equal volumes of propan-2-ol. The samples were 
mixed gently by vortexing and incubated at room temperature for 10mins. Samples were 
then centrifuged at 13,000rpm for 10mins at 4oC to pellet the RNA. RNA pellets were 
washed with 1,000µl of 70% ethanol and the RNA pellet was dislodged by flicking the tube. 
The samples were centrifuged again at 13,000rpm for 5mins at 4oC. The 70% ethanol was 
carefully removed from the tube and the pellets were air-dried for 5mins prior to 
resuspending them in the appropriate volume of RNAse free water. Finally, to ensure that 
the RNA pellet was dissolved properly, the samples were placed in a hot block (Wolf 
laboratories, UK) for 5mins at 55oC with intermittent vortexing. 
 
2.2.2 Reverse transcription (RT-PCR) 
 
The RNA extracted was used to synthesise cDNA using an avian myeloblastosis virus (AMV) 
RT-PCR kit (Roche, Indianapolis). A total of 2µg/µl of RNA was reverse transcribed into 
cDNA. A master mix excluding the RNA was prepared and aliquoted into the individually 
labelled tubes. Once the RNA template was added, the tubes were placed on a thermal 
cycler (MJ Research). The reaction and thermal cycler conditions are summarised in the 
Table 3. Note, that the samples were incubated at 25oC to allow primer annealing to the 
RNA template, followed by reverse transcription at 42oC for 60mins. Finally, the samples 
were incubated at 99oC for 5mins to denature the AMV reverse transcriptase enzyme. The 
cDNA mixes were then diluted 1:2 in RNAse free water prior to performing quantitative real-
time PCR analysis.   
 
RT- Reagents                    
Volume/20µl 
  RT – PCR Conditions 
Buffer 5x      2   
Mg2+ (25mM)                             4 Incubate at 25oC for 10mins 
Incubate at 42oC for 60mins 
Incubate at 99oC for 5mins 
Incubate at 4oC for 5mins 
 
RNAse inhibitor                            1 
Radom primers                            2 
dNTP (10mM)                              2 
Enzyme AMV Reverse 
Transcriptase                              0.8 
RNAse free water                        8.2 
Total reaction volume               20  
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Table 3: Reagents and conditions used for the reverse transcription reactions. 
 
2.2.3 Quantitative real-time PCR analysis (qRT-PCR) using SYBR Green 
 
For quantitative real-time PCR analysis, SYBR Green (ABgene) was used. Analysis was 
performed on an Opticon 2 PCR machine (MJ research). Similar to taqman analysis, samples 
were analysed in triplicate and the mean presented. Expression of β-actin was not 
influenced by VHL status and was therefore used for normalisation. All statistical analysis 
was performed using the Student’s t-test. 
 
Table 4 shows the components mixed together in a single reaction. For the purpose of SYBR 
Green analysis, all primers were diluted to a 2.5µM concentration. A melting curve was 
included for the SYBR Green assay to check that a single PCR product was formed and that 
there was no evidence of primer dimer formation.  
 
 
Table 4: Chemical reagents and conditions used for SYBR green qRT-PCR analysis. 
 
The primers used for SYBR Green analysis are listed in Table 5. 
 
Table 5: SYBR Green qRT-PCR primer sequences. 
 
 
qRT-PCR Reagents       Volume / 25µl 
 SYBR Green mix                                   
13.75 
 Primer Mix                                            
0.77 
 (2.5µM F+R primer mixed) 
 cDNA                                                   
10.48 
 (diluted in 750µl water) 
qRT-PCR Conditions 
Denaturation:   95oC for 16mins 
Amplification:   95oC for 30secs      
                         60oC for 1min 
                         72oC for 1min 
Melting Curve: 65oC to 94oC every 
0.2secs   
Total                                             25  
x39 
cycle 
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2.3 Protein procedures 
 
2.3.1 Solutions for immunohistochemistry 
 
2.3.1.1 Tris buffered saline (TBS) (pH 7.6) 
 
A 10x stock solution of TBS (50mM H2NC(CH2OH)3 and 300mM NaCl) was prepared and 
stored at room temperature. 
 
The 10x stock solution prepared was diluted in deionised water to give a 1x TBS solution, 
which was then adjusted to pH 7.6 with 1M HCl. For wash buffer, TBS-Tween (TBS-T) was 
used. To the 1x TBS solution Tween 20 was added at a concentration of 0.1% to produce 
TBST.  
 
2.3.1.2 Target-antigen retrieval solution (TRS) 
 
The TRS was purchased as 10x concentrate (Dakocytomation, Germany). Therefore, for the 
purpose of heat induced antigen retrieval (HIER), TRS was diluted in deionised water to 1x 
TRS solution.  
 
 
 
 
Gene Primer sequence Annealing 
temperature 
(oC) 
β-actin F 5’-CCCAGAGCAAGAGAGAGG-3’ 
R 5’-GTCCAGACGCAGGATG-3’ 
60 
Glut-1 F 5’-TGGCATGGCGGGTTGT-3’ 
R 5’-CCAGGGTAGCTGCTCCAGC-3’ 
60 
Phd3 F 5’-GATGCTGAAGAAAGGGC-3’ 
R 5’-CTGGCAAAGAGAGTATCTG-3 
60 
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2.3.2 Microtomy and tissue preparation 
 
For the purpose of my experiments, it was important for the tissue sections to be serial 
sections to enable a direct comparison of between adjacent slides. Tissue blocks were 
paraffin embedded at the histology service at Cancer Research UK, (CRUK). I cut sections 
from the formalin fixed paraffin embedded tissue blocks at 3µm thickness using a standard 
microtome (Anglia Scientific, Cambridge, UK). Sections were then placed in a deionised 
water bath at 40oC (Lamb, Middlesex, UK). These were then transferred onto labelled 
Snowcoat Xtra slides (Surgipath, Peterborough, UK). Slides with the tissue section were 
immediately dried by incubating at 37oC overnight. 
 
2.3.3 Immunohistochemistry  
 
All immunohistochemistry incubations were performed in a humidified chamber at room 
temperature unless otherwise stated. For all immunohistochemistry protocols, TBST was 
used as the wash solution.  
 
Prior to performing the respective incubations, sections were always dewaxed in two xylene 
(VWR) baths for 5mins each and rehydrated in graded ethanol (VWR) washes (100%, 100% 
and 70%) for 5mins each. Slides were immediately placed in deionised water and washed. 
For the purpose of antigen retrieval, either protein digestion or heat induced epitope 
retrieval (HIER) was performed where necessary (Table 2.14). HIER was performed by 
immersing slides into pre-heated 1x Dako target retrieval solution (Dakocytomation, 
Germany) and subjected to pressure cooking (Delicio, Tefal, London, UK)  for 30mins using 
a hot plate (Prima Hotplate, Model PDS200, Prima-International, Leeds UK). At the end of 
the 30mins, once slides had completely cooled down, slides were removed and rinsed with 
TBST. The relevant immunohistochemistry protocol and incubation periods were then 
performed (Table 6).  
 
The sections analysed contained both tumour and adjacent normal liver parenchyma. This 
provided an important internal control. As an additional negative control, the primary 
antibody was substituted with either antibody diluent or rabbit/mouse IgG (Dakocytomation, 
Germany).  
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2.3.3.1 Dako Envision kit 
 
The Dako Envision kit is a HRP-polymer linked secondary antibody kit which was used for 
most immunohistochemistry protocols presented in this thesis unless otherwise stated. This 
kit is based on an immunoperoxidase method of signal detection. To reduce non-specific 
signal by quenching the endogenous peroxidase activity, slides were incubated with 0.03% 
hydrogen peroxide (Dakocytomation, Germany) after antigen retrieval. After applying block 
to the slides, they were washed in TBST and the primary antibody at the appropriate 
concentration was applied to the sections. For antibody conditions, concentrations and 
incubation period see Table 6. Primary antibody diluted in antibody diluent 
(Dakocytomation, Germany) was usually applied to the sections for 1hr at room 
temperature. Alternatively, if the signal was weak in the positive control slides with high 
antibody dilutions, I would then progress to a lower dilution together with a 1hr incubation 
period at 37oC, using the Dako Envision kit. Following incubation with the primary antibody 
or the appropriate control, sections were washed in TBST (3x 10mins) before incubating the 
slides with the appropriate peroxidise labelled polymer (rabbit-HRP or mouse-HRP) for 
30mins. After this incubation period, slides were washed in TBST (3x 10mins) and the 
antigen/antibody complexes were detected using 3, 3’Diaminobenzidine tetrahydrochloride 
(DAB). Each slide was individually developed under the light microscope (Olympus, 
Hertfordshire) for the same period of time. Sections were then counterstained with Harris 
haematoxylin for 30secs, followed by a rapid destain in acid/alcohol (1% acetic acid and 
70% ethanol) before being dehydrated through graded ethanol washes (70% ethanol, 
100% ethanol, 100% ethanol) and mounted in DePX (RALamb, Sussex). Slides were then 
visualised using a BX-41 optical microscope (Olympus, Hertfordshire). 
 
2.3.3.2 Catalysed Signal Amplification (CSA) kit 
 
For the purpose of HIF-1α and HIF-2α detection on human sections, the Dako Envision kit 
was not sensitive enough to detect the proteins, therefore I used an ultra-sensitive Dako 
Catalysed Signal Amplification Kit (CSA) which is based on the peroxidise catalysed 
deposition of a biotinylated antibody followed by a secondary reaction with streptavidin 
peroxidase (Dakocytomation, Germany). Similar to the Dako Envision kit, all sections were 
dewaxed and rehydrated in graded ethanol. HIER was performed on the sections. Once 
sections had cooled and rinsed in TBST, an Avidin/Biotin block is applied to the sections for 
10mins each. After each blocking step the slides are washed in TBST. This is an important 
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blocking step as it quenches all exogenous biotin from the sections. In the next step, a 
peroxidase block is applied to the sections for 10mins, after which sections are washed in 
TBST. This is followed by a protein block which was applied for 10mins to suppress non-
specific binding of subsequent reagents. Once the protein block was tapped off, the 
appropriate primary antibody diluted to the required concentration (Table 6) was incubated 
on the sections for 1hour at room temperature. At the end of the incubation period sections 
were washed in TBST and the secondary biotinylated link (rabbit or mouse) was applied to 
the sections for 15mins. Sections were washed in TBST and subsequently the streptavidin-
biotin-peroxidase complex and amplification reagent was applied to the sections for 5mins 
only. Slides were extensively washed in fresh buffer between each step (4x 10min washes 
in TBST). Finally, sections were incubated with streptavidin-HRP for 10mins and followed by 
washing with TBST. Sections were developed with DAB chromagen under the light 
microscope (Olympus, Hertfordshire), counterstained and dehydrated in graded ethanol. 
Slides were mounted in DePX and analysed.  
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Table 6: Summary of antibodies used and optimised protocols. HIER using pressure cooker 
method; *using DAKO Target retrieval solution, 1Na Citrate PH 6, 2 Na Citrate PH 7.  
+ CAIX mAb – kind gift from Dr Pastorek. 
Some antibodies were not commercially purchased.   
Incn: Primary incubation period 
 
 
 
2.3.3.3 Haematoxylin and Eosin (H&E) staining 
 
To examine cell morphology and architecture slides were H&E stained. Sections were 
dewaxed and rehydrated in graded ethanol. After washing sections in deionised water, they 
were immersed into H&E solution (Sigma) for 5mins. Sections were immediately destained 
in acid/alcohol, dehydrated and DePX mounted. Sections were analysed using light 
microscopy (Olympus BX-41, Hertfordshire).  
Antibody Clone Species Source Dilution 
Antigen 
Retrieval 
Detection Inc
n 
CD10 56C6 Mouse Novacastra 1:100 HIER* Envision 
30 
mins 
ECAD 
HECD
1 
Mouse CRUK 1:100 HIER* Envision 
1 
hour, 
37oC 
Cyclin D1 SP4 Rabbit Neomarkers 1:200 HIER Envision 
45 
mins 
+CAIX M75 Mouse +Non-com 1:50 N/A Envision 
30 
mins 
HIF2α PM8 Rabbit Non-com 1:20000 HIER* CSA 
25 
mins 
HIF1α Hi67α Mouse Neomarkers 1:1000 HIER* CSA 
25 
mins 
BNip3 
Ana4
0 
Mouse Sigma 1:200 HIER* Envision 
30 
mins 
GLUT-1 - Mouse Dako 1:250 HIER* Envision 
30 
mins 
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2.3.4 Solutions for Western blotting and immunodetection 
 
2.3.4.1 Cell lysis buffer 
 
Cells were harvested in an appropriate volume of urea/SDS lysis buffer (8M Urea, 1/10 vol 
glycerol, 1/20 vol 20% SDS, 1/200 vol 1M DTT, 1/100 vol 1M Tris (pH 6.8)). Prior to cell 
lysis an appropriate amount of the buffer was placed in a separate tube and 1/100 vol of a 
500µM stock (stored at -20oC) of phenylmethylsulfonyl fluoride (PMSF) and protease 
inhibitor was added. 
 
2.3.4.2 (4x) TrisCl/SDS (pH 8.8) 
 
To make a 4x TrisCl/SDS buffer, 91g of Tris base was dissolved in 300mLs of deionised 
water. The pH of the solution was then adjusted to 8.8 with 1M HCl. Next deionised water 
was added to give a total volume of 500mLs prior to filtering the solution through a 0.45µm 
filter. 2g of SDS was then added and the buffer was subsequently stored at 4oC for a 
maximum of 1 month. 
 
2.3.4.3 4x TrisCl/SDS (pH 6.8) 
 
To make 4x TrisCl/SDS 12.1g of Tris base was dissolved in 80mLs of deionised water.  The 
pH was then adjusted to 6.8 with 1M HCl and more deionised water was added to give a 
total volume of 200mls. The solution was then filtered using a 0.45µm filter, prior to 
addition of 0.8g SDS. The final solution was stored at 4oC for up to 1 month. 
 
2.3.4.4 4x SDS loading buffer 
 
The sample buffer was prepared by mixing 12.5mLs 4x TrisCl/SDS (pH 6.8), 10mL glycerol, 
2g SDS and 1.55g DTT.  Deionised water was added to give a total volume of 50mls. The 
buffer was then aliquoted and stored at -20oC. 
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2.3.4.5 (5x) Electrophoresis running buffer 
 
Running buffer was prepared as a 5x stock solution (25mM TrisCl, 200mM glycine, 0.1% 
SDS) and stored at 4oC. The 1x buffer was prepared by diluting the stock solution with 
deionised water as required.  
 
2.3.4.6 (10x) Transfer buffer 
 
A 10x transfer buffer stock solution of 100mM glycine and 100mM TrisCl was prepared and 
stored at 4oC. 1x transfer buffer was prepared as required by diluting the 10x stock solution 
with deionised water and adding 10% methanol and 0.005% SDS.  
 
2.3.4.7 Phosphate buffered saline (PBS) (pH 7.4) 
 
A 10x PBS stock was made as described in section 2.3.1.5. 1x PBS solution was made by 
diluting the 10x stock in deionised water. PBS-Tween (PBST) was prepared from a 1x PBS 
solution by adding Tween 20 to a final concentration of 0.1%.  
 
2.3.4.8 Blocking solution 
 
Blocking solution was prepared by mixing 5g dried skimmed milk (Marvel, UK) and 1g 
bovine serum albumin (BSA) in 100 mL of PBST. 
 
2.3.5 Preparations of protein extracts 
 
2.3.5.1 Cell extracts 
 
Cell extracts for western blotting were prepared by urea/SDS lysis. The monolayers of the 
cells grown on 60mm tissue culture dishes were removed and immediately placed on ice 
and a sufficient volume of ice-cold PBS was added to the cells for 30secs. Subsequently, two 
other washes in PBS were performed before removing any residual PBS. Cells were 
harvested by scraping into 150-200µL of urea/SDS lysis buffer. Lysates were sonicated for 
15secs (Soniprep 150, Sanyo, USA) and briefly centrifuged at 13,000rpm for 1min and kept 
on ice. Protein extracts were assayed for protein concentrations and aliquots were stored at 
-20oC. 
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2.3.5.2 Protein extracts from tissue 
 
All tissue for protein extraction was snap frozen and stored at -80oC. A small amount of the 
frozen tissue, between 100-200mg was placed into an eppendorf containing urea/SDS to 
which an EDTA free protease inhibitor tablet (Roche) was added. Subsequently, protein 
lysates were prepared by homogenising the tissue (Homogeniser, IKA, UK). Following 
homogenisation, samples were centrifuged at 13,000rpm for 5mins at 4oC and the 
supernatants were aliquoted into fresh clean eppendorfs which were stored at -80oC.  
 
2.3.5.3 Determination of protein concentration 
 
A commercially available BCATM Protein Assay (Pierce, USA) was used to estimate the 
protein concentration in accordance with the manufacturer’s instructions. The protein 
concentration of the cell lysates was determined by comparing the colour absorbance values 
of test extracts to the colour values derived from a standard curve of BSA that was run in 
parallel. 200µl of the BCA Working Reagent (200µl BCA Working solution: Mix 50 parts of 
BCATM Reagent A with 1 part BCATM Reagent B) was added to 25µl of sample (3.5µl of BSA 
standard, plus 3.5µl of SDS/urea lysis buffer and 18µl of deionised water or 3.5µl of cell 
extract plus 21.5µl deionised water) in a 96 well ELISA plate. The plate was then covered 
put on a shaker for 30secs and incubated at 37oC for 30mins. Once the plate had cooled to 
room temperature, the absorbance was read at 550nm on a plate reader (Anthos HT-II, 
Anthos Labtec Instruments, Austria). 
 
2.3.5.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Electrophoretic separation of proteins was performed using the Mini-Protean apparatus 
system (BioRad). Resolving gels were prepared using 30% acrylamide: bis-acrylamide 
(37.5:1) mix and TrisCl/SDS (pH8.8) buffer (350mM Tris-Cl, and 0.1% SDS) to the desired 
specification e.g. 6% gels were used for HIF-1α and HIF-2α. Ten percent gels were used for 
α-tubulin (Table 2.16) for formulations used for gel preparation. For stacking gels, the 
acrylamide concentration was 3.9% in Tris/SDS (pH6.8) buffer (125mM Tris-Cl (pH6.8), and 
0.1% SDS). Gels were polymerised by the addition of 0.05% ammonium persulphate (APS) 
and 0.07% N,N,N’,N’-tetramethylethylenediamine (TEMED). For a typical run, protein 
extracts at 2 µg/µL were mixed with 4x SDS loading buffer and heated at 95oC for 5mins, 
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followed by brief centrifugation at 13,000 rpm for 30secs before loading 12µL of protein 
sample (18µg) onto a polyacrylamide mini-gel. Gel electrophoresis was performed at a 
constant 120volts in electrophoresis buffer. Coloured molecular weight standards (ProSieve 
Colour protein markers, Cambrex, USA) were also run on every SDS-PAGE gel to monitor 
electrophoresis, and were used to calibrate the mobility and hence apparent mass (kDa) of 
test proteins. 
 
2.3.5.5 Stacking gel  
 
Stacking gel was prepared by mixing 0.65mL 30% Acrylamide/0.8% Bis-acrylamide, 
1.25mLs 4xTrisCl/SDS (pH 6.8), 3.05mLs deionised water, 6.7µl TEMED and 33µl 10% APS. 
 
% Gel 30% 
Acrylamide/0.8% 
Bis 
4x Tris-
Cl/SDS 
(pH 8.8) 
dH20 10% APS TEMED 
6 
10 
12 
2mL 
3.3mL 
4mL 
2.5mL 
2.5mL 
2.5mL 
5.5mL 
5.2mL 
3.5mL 
47µl 
47µl 
47µl 
9.4µl 
9.4µl 
9.4µl 
 
Table 7: Resolving gel formulas. Volumes specified are for 3 gels using the BioRad 
MiniProtean systems. 
 
2.3.5.6 Immunoblotting and immunodetection 
 
Proteins resolved by SDS-PAGE were transferred to PVDF membrane (Immobilon, Millipore, 
USA) by tank transfer (Mini-Transblot Apparatus; BioRad) in accordance with the 
manufacturer’s recommendations. The transfer cassette consisting of the pre-equilibrated 
gel and PVDF membrane was sandwiched between chromatography paper (Whatman, UK) 
and Scotch-Brite pads. The cassette was then placed in a transfer tank, immersed in pre-
chilled transfer buffer, and electrophoresed constantly at 30V overnight at 4oC, followed by 
1hr at 85V the following day. 
 
For immunodetection, membranes were transferred to blocking solution for 1hr on a rocking 
platform (Platform Rocker STR6, Bibby, UK) at ~20rpm at room temperature to prevent 
non-specific antibody binding. Primary antibodies were diluted in blocking solution to the 
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dilution specified in Table 8 and applied to the membrane for 1hr at room temperature. 
After three 10mins washes in PBST solution on a rocking platform set at 40rpm at room 
temperature, membranes were incubated with secondary antibodies conjugated to 
horseradish peroxidase (HRP) (Dako) for 1 hr (diluted 1:2000 in blocking solution), followed 
by at least five 10min washes on a rocking platform set at 40rpm. Bound HRP activity was 
visualised by enhanced chemiluminescence (ECL for α-tubulin, or the higher sensitivity 
ECLplus: for all other antigens such as HIF-1α and HIF-2α, Amersham Pharmacia Biotech) 
using Kodak MXB film (GRI autoradiography film, Blue sensitive, GRI, UK). 
 
Equivalent protein loading was verified using two approaches, firstly by immunodetection of 
α-tubulin (Sigma), and secondly, after immunoblotting PVDF membranes were stained with 
Coomassie blue (50% MeOH, 10% acetic acid, 0.05% Coomassie Brilliant Blue R-250) for 
15mins followed by destaining (5% MeOH, 10% acetic acid) for approximately 20mins. 
 
Table 8: Protocol and antibody conditions used for detecting the specified proteins. 
 
Protein Clone Source Primary 
antibody 
dilution 
Relative 
Molecular 
weight 
Secondary 
Incubation 
% 
Acrylamide 
in gel 
HIF-1α NB-449 Novocastra 1:500 120 Goat 
polyclonal 
anti-rabbit 
HRP 
6% 
HIF-2α  PM8  - 1:1000 118 Goat 
polyclonal 
anti-rabbit 
HRP 
6% 
GLUT-1 
 
 
CD10 
 
α-
tubulin 
GT11A Alpha 
Diagnostics 
1:500 
 
1:500 
 
1:500 
55 
 
54 
 
55 
Goat 
polyclonal 
anti-rabbit 
HRP 
Goat 
polyclonal 
anti-rabbit 
HRP 
10% 
 
10% 
 
12% 
  
 
TAT-1 
Gift from 
Prof 
Dominic 
Withers 
CRUK 
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2.4 CTC Detection 
The CellSearch system was used to enrich and enumerate the CTCs, as described previously 
(Slade, Payne et al. 2009). A 7.5mL blood sample was taken in a CellSave preservative 
tube, kept at room temperature and processed within 72 hours. The system enriched for 
EpCAM (epithelial cell adhesion molecule) positive epithelial cells by incubating the sample 
with ferrofluid conjugated to anti-EpCAM antibodies. Cells were stained with the following 
fluorescent labelled monoclonal proprietary antibodies: CD45-APC to distinguish the CTCs 
from leukocytes and pan-cytokeratin 8, 18 and 19 (CK-PE) to stain epithelial cells, and 
epidermal growth factor-receptor (EGF-R) antibodies as we have recently described (in 
press (Payne, Yague et al. 2009)). Nucleic acids were stained using 4,6-diamidino-2-
phenylindole (to exclude red blood cells). Samples were then scanned on the CellTracks 
analyzer II fluorescent microscope for analysis. 
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3.1 Introduction 
 
Since the introduction of laparoscopic cholecystectomy in 1987, the increased acceptance of 
laparoscopic strategies in the management of intra-abdominal pathologies has heralded a 
new philosophy in surgery: one of minimizing the insult delivered by the intervention. 
Laparoscopy offers significant healthcare benefits over the conventional open approach; 
decreased post-operative pain and shorter hospital stay resulting in an earlier return to 
normal activity (Sain 1996). Laparoscopy also provides reduction in the inflammatory and 
neuroendocrine stress responses (Jakeways, Mitchell et al. 1994), lesser suppression of the 
cell-mediated immune response (Kloosterman, von Blomberg et al. 1994) and a significant 
reduction in adhesion formation when compared with conventional surgery (Reissman, Teoh 
et al. 1996). A reduction in the surgically induced immune paresis and access related 
trauma encountered after open surgery (Ng, Whelan et al. 2005) should convey an 
advantage to patients undergoing surgery for malignant disease.  
 
After the introduction of laparoscopic assisted colectomy in the management of colorectal 
cancer, unexpected reports of port-site and peritoneal metastases raised early concerns 
about the safety of the approach. The incidence ranged from 1.5% to 21% (Wexner and 
Cohen 1995) and carried a short-term mortality rate of at least 50%, even with treatment 
(Paolucci, Schaeff et al. 1999). The maximum rate of wound tumour implantation post 
standard open laparotomy ranges from 0.6% to 0.8% (Hughes, McDermott et al. 1983; 
Lacy, Garcia-Valdecasas et al. 2002). These initial reports were personal series and did not 
constitute high-level evidence to base further practice on. However, this heralded a period 
of caution in the application of laparoscopic colectomy and the establishment of large 
mulitcentre prospective randomised trials in the UK, Europe and the USA. Many surgeons 
believed that the observed incidence of recurrence was a technical issue and subsequently 
performance of laparoscopic colectomy has often been part of a randomised trial where 
surgeons operated in recognised laparoscopic centres, having demonstrated their 
competency by video assessment. Lacy et al. (Lacy, Garcia-Valdecasas et al. 2002) 
presented the first results of a randomized trial comparing laparoscopic assisted with open 
colectomy for non-metastatic colon cancer. It was shown that the laparoscopic approach 
was more effective than open for the treatment of colon cancer from the point of view of 
morbidity, length of hospital stay, tumour recurrence and cancer related survival. Further 
randomized control trials have reported their results, for example in the UK the 
MRCCLASICC trial reported the results of 794 patients in 27 centres randomised to either 
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open or laparoscopic assisted colectomy. Investigators concluded that laparoscopic 
colectomy was as effective as open colectomy and was likely to produce similar long-term 
outcomes (Guillou, Quirke et al. 2005). In light of the evidence from these randomised 
trials, it would appear that earlier concerns about the safety of laparoscopic colectomy were 
unfounded and it was likely to be related to the surgical and technological learning curve.  
 
Liver surgeons have been even slower to adopt the laparoscopic technique for liver 
resections. Laparoscopy was initially used only for minor procedures, such as biopsy and 
staging of liver tumour or fenestration of non-parasitic liver cysts (Morino, De Giuli et al. 
1994). Concerns regarding the difficult mobilization and transection of the liver, the risks of 
major haemorrhage and of air embolus have been responsible for this initial slow 
development. However, in the last decade, this technique has been increasingly used for 
liver resection (Bismuth, Castaing et al. 1989; Gigot, Glineur et al. 2002; Vibert, Perniceni 
et al. 2006). In the case of hepatic malignancies the same concerns that have been 
addressed with randomized control trials in laparoscopic resection of primary colonic cancer 
(oncological clearance and intraperitoneal tumour seeding) persist (Gagner, Rogula et al. 
2004; Kaneko 2005). Nonetheless, more than a thousand laparoscopic liver resections have 
been performed worldwide since 1992, after Gagner et al. performed the first 
nonanatomical resection of a liver tumour (Gagner, Rogula et al. 2004). Most of these 
involved resections of only one or two liver segments (Gigot, Glineur et al. 2002; Mala, 
Edwin et al. 2005; Cherqui, Laurent et al. 2006) although major hepatectomies have also 
been achieved laparoscopically (O'Rourke and Fielding 2004; Dulucq, Wintringer et al. 2005; 
Vibert, Perniceni et al. 2006). Improving technology and the development of advanced 
laparoscopic skills have increased the interest in laparoscopic liver surgery. Subsequently, 
multiple small series have reported the safety and feasibility of laparoscopic hepatic 
resection (Gigot, Glineur et al. 2002; Morino, Morra et al. 2003; Robles, Abellan et al. 2005; 
Belli, Fantini et al. 2007; Dagher, Proske et al. 2007; Lee, Cheung et al. 2007; Aldrighetti, 
Pulitano et al. 2008; Buell, Thomas et al. 2008; Polignano, Quyn et al. 2008; Topal, Fieuws 
et al. 2008; Bryant, Laurent et al. 2009; Carswell, Sagias et al. 2009; Ito, Ito et al. 2009; 
Rowe, Meneghetti et al. 2009; Sarpel, Hefti et al. 2009; Tsinberg, Tellioglu et al. 2009). 
Indeed, Koffron et al. reported on 300 cases at one academic centre reinforcing the fact 
that laparoscopic techniques for resection have matured (Koffron, Auffenberg et al. 2007). 
 
One such technique is radiofrequency-assisted liver resection. After development at 
Hammersmith Hospital it was originally described for ‘bloodless’ liver resection without the 
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need for vascular clamping or the use of suture, surgical knots, or clips (Weber, Navarra et 
al. 2002; Ayav, Navarra et al. 2005; Ayav, Bachellier et al. 2007; Ayav, Navarra et al. 
2007). This unique feature has deemed it ideal for laparoscopic liver resection. Indeed, 
recent studies have shown its technical feasibility (Bachellier, Ayav et al. 2007; Ayav, Jiao 
et al. 2008; Jiao, Ayav et al. 2008; Pai, Navarra et al. 2008). Laparoscopic liver resections 
are now accepted as a safe and feasible option for selected patients. However, oncological 
outcome and longer term follow up data are lacking. Against this background, we used a 
pair-matched design to compare the results of laparoscopic hepatectomy with those of the 
open approach using radio-frequency assisted liver resection. 
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3.2 Methods 
 
We reviewed oncological outcome from 10 early consecutive cases of laparoscopic liver 
resection for hepatic malignancy, performed by the same surgeon at Hammersmith Hospital 
between June 2003 and March 2005 and matched them to patients who had undergone 
similar open hepatic resections for the same disease.  
 
3.2.1 Preoperative diagnostic imaging and patient selection 
Careful preoperative staging and selection of patients are the keys to success in 
laparoscopic surgery for cancer (Cherqui, Soubrane et al. 2002). The size and location of 
the liver tumour is fundamentally important in determining the feasibility of resection with 
laparoscopic approach. In our unit, all patients under consideration for surgery are 
discussed at a multidisciplinary team meeting in which a minimum of either CT and/or MR 
imaging modality was used to characterise the anatomy of the hepatic tumour and 
suitability for resection. The affected liver segments were agreed by consensus (minimum of 
2 radiologists and 1 consultant surgeons) and recorded in the HPB database. In cases where 
consensus was difficult, 3-D reconstruction software was used to aid interpretation. 
Indications for laparoscopic resection were patients who required segmentectomy or left 
lateral hepatectomy without major hepatectomy. Exclusion criteria were extrahepatic 
disease, (including the unexpected finding of additional tumours on intraoperative 
ultrasound scan), patients requiring venous or biliary reconstruction, and the presence of 
dense adhesions precluding both visualisation and intraoperative ultrasound of the liver.  
3.2.2 Surgical technique 
Laparoscopy was performed under carbon dioxide pneumoperitoneum, with the abdominal 
pressure maintained between 12 and 14 mmHg. The initial step was visual and 
ultrasonographic exploration of the liver. The technique employed was radiofrequency 
assisted liver resection as described previously (Weber, Navarra et al. 2002; Ayav, Navarra 
et al. 2005; Bachellier, Ayav et al. 2007) and resected liver was placed in a endocatch bag 
and withdrawn through the most accessible or appropriate port site. A maximum of 5 
laparoscopic ports were used (of which no more than 4 were 12mm). In cases in which it 
was impossible to remove the resected specimen through a laparoscopic port, a single 
12mm port site would be extended to accommodate swift exteriorisation. 
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3.2.3 Routine tissue analysis 
Postoperatively, tissue was collected in formalin and sectioned for a consultant pathologist 
to report. From this report, the macroscopic and microscopic features of the resected tissue, 
including number of lesions, size of lesion, level of differentiation, positivity of resection 
margins and histopathological type were input into the surgical database.  
3.2.4 Criteria for matching open resections 
The patients were matched to equivalent open operations using the Hammersmith RFA Liver 
Resection database using the following inclusive search criteria: tumour pathological type, 
grade and Couinaud segment resected. In the absence of an exact match, the closest match 
was accepted. This prioritised, in the following decreasing order, tumour type, anatomical 
site and grade. 
3.2.5 Clinical Outcome 
 
We compared clinical outcome in terms of operative time, inpatient length of stay, disease-
free and overall survival after surgery. Patients were followed up 3 monthly for the first 18 
months and 6 monthly thereafter. Clinical suspicion of a disease recurrence resulted in 
CT/MRI imaging. This was otherwise performed routinely at 6 monthly intervals in the first 2 
years and annually thereafter. All radiological imaging was reviewed at an MDT meeting. 
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Table 9: Data for 10 pilot laparoscopic and paired open liver resections 
Patient 
code 
Sex 
(M/F) 
Age 
(yrs) 
Primary pathology Differentatn 
(well/ 
moderate/ 
poor) 
Liver 
tumour site 
(acc. 
Couinaud) 
No.s of 
lesions 
Operative 
time, 
(hrs:mins) 
RM +ve 
(Y/N) 
In-
patient 
stay 
(dys) 
LapA F 59 Colonic adenocarcinoma Moderate IV 1 03:08 N 10 
LapB F 56 Colonic adenocarcinoma Moderate/Well IV,VII 2 05:15 N 6 
LapC M 55 Colonic adenocarcinoma Poor II,III 1 03:37 N 6 
LapD F 55 Small cell carcinoma of Lung Poor VIII 1 03:00 Y 3 
LapE M 63 Colonic adenocarcinoma Poor V,VI 1 08:25 Y 23 
LapF M 66 Colonic adenocarcinoma Poor V,VI 1 06:13 N 14 
LapG M 69 Colonic adenocarcinoma Moderate VII 1 05:45 Y 7 
LapH F 64 Colonic adenocarcinoma Moderate II,III 2 05:32 N 11 
LapI M 69 Hepatocellular carcinoma Moderate II 2 05:03 Y 15 
LapJ M 69 Hepatocellular carcinoma Well II 1 04:27 N 13 
 
Patient 
code 
Sex 
(M/F) 
Age 
(yrs) 
Primary pathology Differentatn 
(well/ 
moderate/ 
poor) 
Liver 
tumour 
site, (acc. 
Couinaud) 
No.s of 
lesions 
Operative 
time, 
(hrs:mins) 
RM +ve 
(Y/N) 
In-
patient 
stay 
(dys) 
OpenA M 57 Colonic adenocarcinoma Moderate IV 1 04:05 N 22 
OpenB F 55 Colonic adenocarcinoma Moderate VII 1 04:15 N 13 
OpenC M 52 Colonic adenocarcinoma Poor III 1 03:32 Y 12 
OpenD M 77 Small cell carcinoma of Lung Poor V,VI 1 04:45 Y 8 
OpenE F 65 Colonic adenocarcinoma Moderate/Poor V 1 02:15 N 7 
OpenF F 58 Colonic adenocarcinoma Moderate/Poor V,VI 3 04:15 Y 11 
OpenG F 52 Colonic adenocarcinoma Poor VII 1 04:33 N 9 
OpenH M 76 Colonic adenocarcinoma Poor II,III 1 04:25 N 7 
OpenI F 81 Hepatocellular carcinoma Poor VI 1 02:20 Y 30 
OpenJ M 54 Hepatocellular carcinoma Well II 1 02:23 N 11 
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3.3 Results 
 
Demographical data, histopathological classification, resected tumour site, grade, number of 
lesions, resection margin positivity and operative time are shown for both cohorts of 
patients in Table 9 above. Table 10 below shows the two groups are well matched in terms 
of histopathological type, tumour site and procedure. There were no significant differences 
between the 2 groups in terms of male: female ratio, age and pre-operative Child’s score. 
Post-operative data shows no significant difference between tumour number, size and 
resection margins. However, there is a significant difference between the groups when 
comparing length of operation (p<0.05) There was no difference in inpatient length of stay.  
 
There is notable difference in the Kaplan-Meier survival data for the two groups both for 
overall survival however, chi squared analysis of the survival curve shows no significant 
difference (p>0.05). 
 
Figure 6: Kaplan-Meier curve comparing overall survival after laparoscopic and case-
matched open liver resection for malignant disease. 
 
 
 
Table 10: Patient demographics, operative time, resection margin status and tumour 
details for ten patients undergoing laparoscopic resection and ten matched* open cases, 
(*see methods above for matching criteria and rules). 
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Characteristic/Outcome Laparoscopic Open P value 
Sex (M:F) 6:4 5:5 0.67 
Age 62.5 (±1.9) 62.7 (±3.6) 0.96 
Child’s Grading:   1.0 
A 9 9  
B 1 1  
C 0 0  
Tumour Characteristics:    
Histological type:   1.0 
HCC 2 2  
CLM 7 7  
Other Metastasis (e.g.: 
Lung) 
1 1  
No. of tumours:   0.68 
1 7 9  
2 3 0  
3 0 1  
Tumour site:   1.00 
Segment 2-3 4 3  
Segment 5-6 2 4  
Segment 4b 2 1  
Segment 7-8 2 2  
Tumour size (cm) 3.44 (±0.81) 6.56 (±1.22) 0.068 
Procedures:   1.0 
Wedge/Subsegmentectomy 3 3  
Segmentectomy 4 3  
Bisegmentectomy 3 4  
Outcome:    
Resection Margin <1cm 4 4 1.0 
Operative Time (mins) 303 (±30.8) 220 (±18.8) 0.036 
Inpatient Stay (dys) 10.8 (±1.8) 13.0 (±2.3) 0.47 
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To compare disease free survival for the two groups during the post-operative period, we 
eliminated all resections with a positive resection margin, as time to ‘recurrence’ would be 
contentious. 5 matched pairs of RM-ve laparoscopic and open resections remained, shown 
below in Table 11.  
 
Table 11: R0 resections laparoscopic vs. open compared 
Group Time to recurrence 
(months) 
Paired Group Time to recurrence 
(months) 
LapA 21 
OpenA 
N/A 
LapB 9.5 
OpenB 
N/A 
LapF 5.5  
OpenF 
N/A 
LapH 16 
OpenH 
N/A 
LapJ N/A 
OpenJ 
N/A 
 
Chi-squared analysis of the survival curves shows significant difference between 
laparoscopic and open disease free survival rates after initial R0 resection (p=0.0455). In 
pairs, A,B,F and H-there is earlier recurrence of colorectal adenocarcinoma and in pair J, 
earlier recurrence after laparoscopic resection of hepatocellular carcinoma.  
 
Figure 7: Kaplan-Meier survival curve comparing disease free survival in 5 patients 
undergoing laparoscopic and 5 matched open liver resection patients. 
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3.4 Discussion 
 
There are currently 7 published individual case-matched series comparing laparoscopic and 
open liver resection (Rau, Buttler et al. 1998; Morino, Morra et al. 2003; Belli, Fantini et al. 
2007; Lee, Cheung et al. 2007; Aldrighetti, Pulitano et al. 2008; Polignano, Quyn et al. 
2008; Carswell, Sagias et al. 2009). A number of series compare similar groups of patients 
and assess the relative benefits of minimal access approach over the resection of hepatic 
malignancies (Farges, Jagot et al. 2002; Gigot, Glineur et al. 2002; Lesurtel, Cherqui et al. 
2003; Robles, Abellan et al. 2005; Dagher, Proske et al. 2007; Buell, Thomas et al. 2008; 
Topal, Fieuws et al. 2008; Belli, Limongelli et al. 2009; Bryant, Laurent et al. 2009; Ito, Ito 
et al. 2009; Rowe, Meneghetti et al. 2009; Sarpel, Hefti et al. 2009; Tsinberg, Tellioglu et 
al. 2009).  Many of these series have supported the technical feasibility of laparoscopic 
resection of hepatic malignancies in selected cases but few have reported on follow-up and 
oncological outcomes. In this chapter we have performed the first case matched pilot study 
to compare laparoscopic RF-assisted liver resection to historic matched open resections.  
 
We identified a significantly longer operative time required for laparoscopic resection 
compared to their matched open cases (p<0.05). Operative time was downloaded from a 
surgical theatre database and represented time into theatre, after induction of anaesthetic 
and time and out of theatre, with the patient awake and self-ventilating. There will be an 
inevitable extra variable, dependent on anaesthetic factors such as ASA, airway, respiratory 
reserve and perioperative analgesic regime (for example, epidural use). Nonetheless, other 
series that demonstrated no underlying difference in ASA, have also shown independently a 
significantly longer operation time in laparoscopic resection (Rau, Buttler et al. 1998; Belli, 
Fantini et al. 2007). Indeed in the majority of published data, operative time was equivalent 
or slower. Few studies actually demonstrated a shorter operative time (Koffron, Auffenberg 
et al. 2007; Buell, Thomas et al. 2008). In these series, an endovascular stapler was the 
primary resection tool to transect the liver parenchyma. Certainly, one of the more time 
consuming parts of RF-assisted liver resection is the meticulous positioning of the probe 
under IOUS guidance prior to application of current and transection of tissue with 
laparoscopic dissecting scissors, (Weber, Navarra et al. 2002; Bachellier, Ayav et al. 2007). 
Positioning is less challenging under direct vision at laparotomy. 
 
Laparoscopic liver resection presents several technical challenges which must be factored 
into the operative time: the liver must be atraumatically retracted and the parenchyma 
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must be accurately divided so that vascular and biliary structures can be safely divided, 
thereby avoiding inadvertent injury to the vital structures of the remnant liver. There is 
growing experience with technicological advances in laparoscopic transection devices, for 
example, ultrasonic dissectors, articulating vascular staplers, water-jet dissectors, harmonic 
scalpel and vessel sealing systems (Poon 2007). In several case series a significantly 
reduced blood loss was witnessed with laparoscopic surgery (Lesurtel, Cherqui et al. 2003; 
Belli, Fantini et al. 2007; Koffron, Auffenberg et al. 2007; Aldrighetti, Pulitano et al. 2008; 
Buell, Thomas et al. 2008). There is evidence to suggest blood transfusion is associated with 
earlier tumour recurrence in resections for malignant disease, so the importance of 
minimising blood loss should not be underestimated in long term outcome measures 
(Nielsen 1995; Dionigi, Boni et al. 2009). RF-assisted liver resection has been well received 
since its introduction in 2002 for similarly significant low blood loss intraoperatively, such 
that the technique is often described as ‘bloodless’ (Weber, Navarra et al. 2002; Ayav, 
Navarra et al. 2005; Ayav, Jiao et al. 2007; Ayav, Navarra et al. 2007). Its adaptation and 
use in laparoscopic resection has yielded similarly encouraging results, and in this respect 
we have not included blood loss as an outcome measure in this pilot, (Bachellier, Ayav et al. 
2007; Jiao, Ayav et al. 2008; Pai, Navarra et al. 2008).  
 
There was no significant difference in length of inpatient stay between our laparoscopic and 
open resection patients in our study, which is consistent with only a minority of previous 
reports (Laurent, Cherqui et al. 2003; Lesurtel, Cherqui et al. 2003). Of note, these reports 
were predominantly in smaller series ((Laurent, Cherqui et al. 2003; Lesurtel, Cherqui et al. 
2003)with N=27 and N=38, respectively). More commonly, laparoscopic liver resection 
results in a significant reduction in length of hospital stay (Rau, Buttler et al. 1998; Farges, 
Jagot et al. 2002; Morino, Morra et al. 2003; Kaneko 2005; Mala, Edwin et al. 2005; Belli, 
Fantini et al. 2007; Koffron, Auffenberg et al. 2007; Aldrighetti, Pulitano et al. 2008; Buell, 
Thomas et al. 2008).   
 
In laparoscopic resection for malignancies, the same oncologic rules of open surgery are 
applied, including the ‘no-touch’ technique, radical resection and achievement of a 1-cm 
margin. Resection margins were positive in 4/10 laparoscopic resections. Possible 
explanations for this include direct contamination from technical errors during laparoscopic 
resection, cell exfoliation, or cytokine activation secondary to pressure effects from 
pneumoperitoneum (Neuhaus, Texler et al. 1998). Importantly, this is a small sample size 
and more recent larger series have shown lower rates (6-14%) of positive resection margins 
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(Mala, Edwin et al. 2005). Certainly, in well established laparoscopic centres, resection 
margin positivity is comparable to matched open resections (Tsinberg, Tellioglu et al. 2009) 
and an equivalent positive resection margin rate was demonstrated in the open matches in 
our pilot study. There is significant difficulty in interpreting resection margin positivity when 
using the RF assisted resection technique because the ‘true’ resection margin will inevitably 
lie in a cylindrical zone of coagulative necrosis around the tumour deposit and this may not 
be preserved during tissue preparation, such as paraffin embedding, or in subsequent 
sectioning.  
 
Laparoscopic liver resection took longer to complete. The risk of tumour seeding during 
laparoscopic surgery has long been debated in the literature. In this series, none of the 
patients developed either port-site or intraperitoneal metastases at postoperative follow-up 
at 32months. However, clinical data suggest that the incidence of recurrence between 
laparoscopic and conventional open operation for cancer is similar, and the immune system 
may also be better preserved in patients undergoing laparoscopic rather than open surgery 
(Vittimberga, Foley et al. 1998; Whelan 2001). In a recent prospective randomised study, 
Lacy showed better long-term survival in patients who underwent laparoscopic resection for 
colonic cancer than those who underwent open resection (Lacy, Garcia-Valdecasas et al. 
2002). Two further trials have concluded similarly (group 2004; Guillou, Quirke et al. 2005). 
Despite several large case series advocating a role for laparoscopic resection of liver 
malignancies, no randomised control trial exists. In our pilot series there is a markedly 
different overall survival rate in the 2 groups. For example, at 2 years follow-up, mortality is 
nearly 40%, almost double that in the open group. Furthermore, when we compared the 5 
paired ‘curative’ resections, which were resection margin negative, there was a significantly 
poorer outcome: those undergoing laparoscopic resection had earlier disease recurrence 
(p<0.05). We chose these patients, and in so doing took an even smaller sample, as it was 
important to minimise the confounding factors. Surgical resection margin positivity (R1) 
causes a significantly reduced overall and disease-free survival (Nuzzo, Giuliante et al. 
2008). In our pilot we defined any clearance ≥1mm as negative, and in other larger series 
such a narrow clearance has also been significantly correlated to poorer prognosis when 
compared to groups >5mm resection margins for example (Nuzzo, Giuliante et al. 2008). 
Unfortunately the limitations of our sample size precluded a more in-depth breakdown of 
size of resection margin that may have also offered further insight to the technical 
challenges of laparoscopic approach in this important oncological prognostic parameter. 
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So far, we have compared clinical data for 2 matched groups undergoing liver resection. 
Laparoscopic resection takes significantly longer, results in the same length of time in 
hospital and for those that achieve curative resections, an earlier disease recurrence.    
Although a majority of published data suggests laparoscopic liver resection may have some 
advantage in the short term over open surgery, this may reflect publication bias. Data on 
the impact of this procedure on long term outcome is lacking (Vibert, Perniceni et al. 2006). 
This pilot study supports the need for further studies on the effects of RF-assisted resection. 
In particular, a randomized control trial is warranted to compare the effects of laparoscopic 
and open resection in terms of oncological outcome. 
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4.1 Introduction 
In liver surgery, laparoscopy was initially used only for minor procedures, such as biopsy 
and staging of liver tumour (Morino, De Giuli et al. 1994) or fenestration of non-parasitic 
liver cysts (Morino, De Giuli et al. 1994). However, in the last decade, this technique has 
been increasingly used for liver resection (Bismuth, Castaing et al. 1989; Katkhouda, 
Hurwitz et al. 1999; Cherqui, Soubrane et al. 2002; Gigot, Glineur et al. 2002; Vibert, 
Perniceni et al. 2006). 
Liver resection remains a high-risk procedure with significant morbidity and mortality rates. 
Intraoperative bleeding and perioperative blood transfusion are usually considered to be the 
major reasons affecting these rates (Bismuth, Castaing et al. 1989; Capussotti, Borgonovo 
et al. 1994; Fong, Cohen et al. 1997). In laparoscopic liver surgery, access to the liver is 
limited and control of intraoperative bleeding is inevitably difficult. Conversion to an open 
procedure is often required to achieve haemostasis and complete the resection when 
bleeding occurs. 
RF-assisted liver resection was originally described for ‘bloodless’ liver resection without the 
need for vascular clamping or the use of suture, surgical knots or clips (Weber, Navarra et 
al. 2002; Ayav, Navarra et al. 2005; Ayav, Bachellier et al. 2007; Ayav, Navarra et al. 
2007). This unique feature has deemed it ideal for laparoscopic liver resection. Recent 
studies have shown its technical feasibility (Bachellier, Ayav et al. 2007; Ayav, Jiao et al. 
2008; Jiao, Ayav et al. 2008; Pai, Navarra et al. 2008). 
The benefits of the laparoscopic approach over open surgery, such as decreased 
postoperative analgesia requirement, shorter delay to oral intake after surgery and a 
decreased hospital stay, are well known. However, none of the rare articles reporting limited 
experience with laparoscopic resection for HCC or liver metastases provide information 
concerning the late outcome of such patients (Gigot, Glineur et al. 2002). 
We undertook a study looking at our early experience of 10 cases of laparoscopic liver 
resection with the main aim of assessing oncological outcome. The pilot clinical data for the 
2 matched groups undergoing RF-assisted liver resection showed laparoscopic resection 
takes significantly longer, results in the same length of time in hospital and for those that 
achieve curative (R0) resections, an earlier disease recurrence as discussed in Chapter 3. 
Using resected tissue from this pilot study we attempted to explain these findings at a 
cellular level. Although this may be a multifactorial cumulative effect, the single most 
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obvious physiological difference between the 2 techniques is the pneumoperitoneum. The 
insufflation of the peritoneal cavity necessary to obtain the endoscopic exposure means 
these patients are being subjected to an artificially elevated intraperitoneal pressure (IPP) 
for several hours. The adverse effects of this elevated IPP on the systemic circulation and 
cardiac, pulmonary, and renal functions have been well documented in experimental and 
clinical studies (Smith, Benzie et al. 1971; Marshall, Jebson et al. 1972; Kotzampassi, 
Kapanidis et al. 1993). In the last decade, the changes in the splanchnic circulation such as 
decreased mucosal blood flow and the effect of a sustained elevated IPP on the flow to the 
solid intraabdominal organs has been reported in both animal and human experiments 
(Ishida, Murata et al. 2000). It was hypothesised by us that the pneumoperitoneum 
required in laparoscopic surgery may have an effect on tumour cell biology allowing an 
enhanced metastatic phenotype. 
 
4.2 Methods 
4.2.1 Immunohistochemistry 
Immunohistochemical staining of paraffin embedded tissue blocks was performed on all 10 
laparoscopic and the paired open resection blocks as described in Chapter 2. Blocks were 
selected to include ‘normal’ liver as internal controls. Thereafter slides were scored on the 
strength of the staining on 5 separate random high power fields of view. Scoring was 
performed by 2 blinded technicians. For nuclear molecules (e.g.: HIF), scoring was as a 
percentage of total nuclei in the field of view that stained positive and for cell surface 
proteins, (e.g.: GLUT-1 membrane transporter), scoring was as percentage of the area of 
whole cells in the field of view staining positively. 
Table 12: Scoring system for immunohistochemical staining. 
Score Descriptive term Percentage positively 
staining 
0 No/Weak staining 0-25% 
+ Mildly positive 25-50% 
++ Moderately positive 50-75% 
+++ Strongly positive >75% 
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For the purposes of statistical analysis, each group was allocated a number based on the 
maximum percentage positive staining, for example for the weak/no staining category 
above a number of 25 was used in each sample. T-test statistical analysis was performed 
using GraphPad prism and SPSS software thereafter and only p<0.05 was considered 
significant.  
 
4.3 Results 
 
Table 13 below summarises all the immunohistochemical staining performed on the 20 
resected liver tumours. HIF-1α and HIF-2α, (the active HIF subunits of HIF-1 and HIF-2 
respectively) and recognised hypoxia-inducible genes CaIX, GLUT-1 and Cyclin D1 were 
stained for. CD10 has been used as a marker of hepatocellular cell differentiation and to 
delineate non hepatocellular tumour margins when these are not easily identifiable. CD10 
also has been implicated in adenoma-carcinoma sequences.  
 
4.3.1 Carbonic Anhydrase IX (CaIX) 
 
CaIX was mildly positive in more samples from the laparoscopic group than open, but not 
significantly (p>0.05). Only one colorectal metastasis stained anything more than mildly 
positive staining (LapB-strongly). Hepatocellular resected tissue was only weakly positive in 
all 4 cases, whereas both resected lung carcinomas were mildly positive. 
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Table 13: Immunohistochemical staining profiles for 10 laparoscopic and 10 paired open 
resected liver cancer specimens 
 
 Patient 
Code 
Primary 
Pathology 
CaIX GLUT-1 HIF-1α HIF-2α CD10 Cyclin 
D1 
LapA CLM + + 0 + + + 
LapB CLM +++ + 0 ++ + 0 
LapC CLM + + 0 ++ + 0 
LapD Small Cell 
Lung 
+ + + +++ 0 0 
LapE CLM + + 0 ++ + 0 
LapF CLM + + 0 ++ + 0 
LapG CLM + + 0 + + + 
LapH CLM 0 + 0 + + + 
LapI HCC 0 + ++ ++ +++ 0 
LapJ HCC 0 + ++ ++ ++ 0 
        
OpenA CLM + + 0 + + + 
OpenB CLM 0 0 0 + 0 + 
OpenC CLM + + 0 + + + 
OpenD Small Cell 
Lung 
+ + + +++ 0 0 
OpenE CLM 0 0 0 + 0 + 
OpenF CLM + + 0 + + + 
OpenG CLM + 0 0 ++ + 0 
OpenH CLM + + 0 + + + 
OpenI HCC 0 + + + ++ 0 
OpenJ HCC 0 + + + + 0 
        
P value* 
(lap vs. 
open) 
 0.39 0.08 0.17 0.024 0.037 0.19 
*Two-tailed paired t-test 
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Figure 8: Carbonic anhydrase IX expression in a colorectal liver metastatic margin showing 
the brown staining of the colorectal epithelial metastases at the tumour margin, abutting 
the normal pink liver parenchyma. (x50) 
 
4.3.2 GLUT-1 
 
GLUT-1 is a high affinity glucose transporter and a recognized hypoxia inducible gene 
(otherwise known as HIF target). All 10 laparoscopic cases demonstrated mild positivity for 
GLUT-1, but only 7/10 in the open group demonstrated the same level. These included both 
hepatocellular and the lung carcinoma; 3 openly resected CLM showed weak or no staining. 
This difference between laparoscopic and open resection specimens only approached 
significance (p=0.08). 
 
The pattern of GLUT-1 expression in the normal liver demonstrates a canalicular pattern, 
(control). The expression in the CLMs was more diffuse but most prominent in pseudoclefts, 
the areas representing luminal surface in normal colorectal architecture and between 
metastatic columnar crypt cells. In 4/4 resected hepatocellular carcinomas GLUT-1+ 
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staining was conserved in a similar canalicular pattern to the control, despite differing 
degrees of differentiation (see Table 9). 
 
Figure 9: GLUT-1 expression in two colorectal liver metastases with parallel CaIX 
expression. 
 
 
What is evident when assessing serial sections for GLUT-1 and CaIX positive staining is that 
there are areas of complementary staining as shown in Figure 9, although these were 
mostly found in areas of low differentiation, high mitotic rate (H+E not shown). 
 
4.3.3 HIF-1α and HIF-2α 
 
The HIF-2α isotype was mildly positive in all (20/20) resected tumours. Laparoscopically 
resected tissue demonstrated significantly higher levels of HIF-2α staining when compared 
to the matched open tissue (p<0.05). For example, 57% (N=7) of CLM resected 
laparoscopically demonstrated moderately positive staining compared to only 14% in the 
open group (p<0.05). 
 
CHAPTER 4: A RETROSPECTIVE IMMUNOHISTOCHEMICAL STUDY 
Page | 86 
 
Figure 10: Colorectal liver metastatic tissue stains positively for HIF-2α. Tissue resected 
laparoscopically shows significantly stronger staining for HIF-2α than matched open 
resection tissue. 
 
 
The strength of HIF-2α expression was not tumour-specific as both HCC and lung Ca in the 
lap group showed equivalent or stronger staining. All CLM resected demonstrated weak or 
no staining for HIF1α (positive control: VHL-defective renal cell carcinoma, see Chapter 2). 
Only the non-CLM tumours expressed a positive level of the HIF1α isotype- small cell lung 
carcinoma metastases and primary HCC HIF-2α expression patterns are shown in Figure 11 
below. The HCC shows characteristic islands of malignant hepatic parenchyma. The 
bronchial metastases show fewer features to delineate origin but the deep purple on H+E 
are likely to represent malignant cells with high mitotic index. 
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Figure 11: (A-D): Primary HCC (A,B) and metastatic small cell carcinoma of Lung (C,D) 
express HIF-2 isotype, (x50)  
 
 
Figure 12: HCC shows concurrent HIF-1α positivity in parallel with HIF-2α. 
 
 
 
4.3.4 Cyclin D1 
 
Cyclin D1 is a HIF-2 target gene as characterised by experiments using CCRCC with pVHL- 
and wt, (Sowter, Raval et al. 2003). In our pilot study it showed mildly positive expression 
H+E HIF-1α HIF-2α 
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in 64% of CLM (N=9) and none in either HCC or small cell lung. There was no significant 
difference in expression between those samples resected laparoscopically vs. open. 
 
4.3.5 CD10 
 
CD10 expression was evident in all HCC resected and to a significantly higher level in CLM 
resected laparoscopically compared to those samples resected via open technique.  It was 
not expressed in small cell lung carcinoma. The results of CD10 expression are discussed in 
Chapter 6. 
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4.4 Discussion 
 
4.4.1 Markers of hypoxia in resected liver tissue 
 
GLUT-1 is a high-affinity glucose transporter (others include GLUT-3 and -4) (Zimmerman, 
Fogt et al. 2002). It has a Michaeli’s constant (Km) below the normal blood glucose 
concentration, allowing transporting function at rates close to maximal velocity. Therefore, 
the level of cell surface expression greatly influences the rate of glucose uptake into the 
cells. High-affinity transporters are found in almost every tissue but their expression is 
higher in cells with high glycolytic activity. The basal hepatocyte phenotype is conferred by 
the expression of liver-specific genes. In the adult liver, the basal hepatocyte phenotype is 
further modified by transcriptional and post-transcriptional regulation of genes which results 
in the appearance of specific proteins in selected hepatocytes, these include GLUT-1 
(Zimmerman, Fogt et al. 2002). The GLUT-1 protein is detected in the plasma membrane of 
hepatocytes located at the end of the liver cell plate, contiguous to the hepatic venule, 
resulting in the characteristic canalicular pattern demonstrated in our liver controls. It has 
been noted that GLUT-1 is expressed in a variety of carcinomas although its expression in 
HCC has not been studied extensively (Zimmerman, Fogt et al. 2002). One group studying 
the cellular mechanism of chemoresistance in HCC has shown that GLUT-1 expression was 
low in HCCs but was significantly higher in poorly differentiated HCCs compared to 
moderately differentiated HCCs (Seo, Hatano et al. 2009).  All the resected HCC tissue, 
independent of both level of differentiation or resection technique, demonstrated only mild 
GLUT-1 positivity although the sample size of purely HCC tissue in our pilot is likely to 
preclude any significant findings.  
 
Recent microarray analysis of both primary and secondary colorectal disease demonstrated 
significantly higher GLUT-1 expression at tumour margins when compared to core tissue 
(Rajaganeshan, Prasad et al. 2009). However, a similar sized study showed the reverse on 
the basis of immunohistochemical data, with strongest GLUT-1 expression at the centre of 
primary and secondary foci (Gu, Yamamoto et al. 2006). In our pilot we took random fields 
of view to quantify intensity of staining. It was felt that for the purpose of assessing the 
effect of pneumoperitoneum on tumour cells, and given that the 2 groups were matched 
(mean size of lesions in the 2 groups p>0.05, see Chapter 3), this would likely reflect any 
significant trend without introducing further bias or confounding factors. 
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GLUT-1 was present in low levels in all liver metastases of small cell carcinoma of lung and 
to identical levels of HIF-1α. Data on GLUT-1 expression in small cell carcinoma are scarce. 
In one series from 1998, 24 resected primary small cell lung carcinomas expression Glut-1 
immunostaining was stronger in the central area of tumour cell nests corresponding to the 
hypoperfused region, although they did not look at HIF-1α expression or indeed use it as a 
marker of hypoxia (Ito, Noguchi et al. 1998). However, small cell lung carcinoma lines have 
been demonstrated to upregulate GLUT-1 under hypoxic stress in vitro (Pedersen, Holm et 
al. 2001), The small cell carcinoma lesions in our pilot were both poorly differentiated but 
expression of HIF-1α and GLUT-1 were no more than mildly positive.  
 
Carbonic anhydrase isoenzyme IX (CaIX) is a transmembrane protein which is thought to 
maintain acid-base balance and intercellular communication. Previous studies have 
demonstrated that Ca IX is expressed in the basolateral plasma membrane of normal biliary 
epithelial cells but not in hepatocytes (Saarnio, Parkkila et al. 1998; Saarnio, Parkkila et al. 
2001). This may explain the absence of CaIX in the resected hepatocellular carcinomas in 
our study. Increased expression of Ca IX has been observed in certain epithelial tumours. 
We investigated the expression of Ca IX in CLMs of which there was positive staining in 79% 
of cases, (N=14). A larger series looked at 69 colorectal neoplasms of varying stages 
(Saarnio, Parkkila et al. 1998). Dysplastic polyps showed weak or moderate reaction for 
CaIX only in the cryptal epithelium, as did the normal intestinal mucosa. Adenomas showed 
immunoreactivity mainly in the superficial part of the mucosa whereas the distribution in 
the carcinomas and metastases was more diffuse. Comparative immunostaining of serial 
sections for Ki-67, a well established marker of cell proliferation, confirmed that CaIX is 
expressed in areas with high proliferative capacity. Marked parallel expression of CaIX and 
GLUT-1 was noticed in our series. These are both recognized HIF targets therefore they may 
serve to mark areas of hypoxia. However, although in van Laarhoven’s study he 
demonstrated the consistent expression of CaIX in primary colorectal resection tissue and 
its paired resected metastatic tissue, no such continuity was observed for GLUT-1 
expression (van Laarhoven, Kaanders et al. 2006). Furthermore, there was no correlation 
between combined GLUT-1/CaIX positive areas and hypoxic areas measured through 
pimonidazole binding. This raises the issue of whether CaIX and GLUT-1 are endogenous 
markers of hypoxia in CLMs. Interestingly, there was no significant correlation between HIF-
1α and GLUT-1 or CaIX in either primary or metastatic disease in one study (Rajaganeshan, 
Prasad et al. 2009). 
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The two HIF isoforms, HIF-1α (HIF-1) and HIF-2α, (HIF-2) are widely expressed by various 
cancers and have proved to be significant prognostic markers in selected cancers. Currently, 
there are no studies assessing HIF expression in metastatic liver disease. We have shown 
that the isoform HIF-2 is strongly expressed in 14/14 CLMs and also in the 2 bronchial 
cancer liver metastases analysed. Furthermore, HIF-2 was expressed in the normal tissue in 
all CLMs to a lesser degree. In contrast, HIF-1 had a much lower expression and was only 
isolated in HCCs. Yoshimura et al. first investigated the significance of both HIF isotypes in 
colorectal carcinoma (Yoshimura, Dhar et al. 2004). They compared expression levels of the 
isotypes in 87 resected primary tumours and correlated their findings to clinicopathological 
features, including patient prognosis. HIF-1α expression showed a trend towards early 
tumour stages but had no significant correlation to any of the parameters measured. In 
contrast, HIF-2 expression had significant correlation with advancement of T stage, Dukes 
stage, lymphatic/vascular invasion, reduced differentiation status and microvessel density. 
Essentially, they successfully identified a subgroup of patients with colorectal cancer in 
whom HIF-2 expression was an independent poor prognostic indicator and marker of 
aggressive phenotype (Yoshimura, Dhar et al. 2004). In our data series, we have assessed 
patients with primary curative resection who later developed metastatic liver disease. This 
introduces a selection bias towards a more aggressive phenotype. Hence, HIF-2 may play a 
role not only in the invasiveness of primary colorectal carcinoma but also in haematogenous 
or otherwise spread and development of colorectal liver metastases. In support of 
preferential expression of one isotype in advanced cancer, an experimental study involving 
Maxwell et al. has compared the effects of HIF-1 and HIF-2 isoform activation (Raval, Lau et 
al. 2005). It demonstrates that, despite close similarities between the HIF-isoforms, 
differential activation of HIF-1 or HIF-2 pathways in VHL-defective RCC cells has non-
equivalent or even opposing effects on gene expression and experimental tumour growth. 
HIF-2 had positive effects on tumour growth and HIF-1 negative effects on tumour growth 
in this setting. Suppressive interaction between HIF-isoforms was also found therefore, at 
present, it is not possible to conclude whether suppression of tumour growth by HIF-1 
arises from direct effects, indirect effects through downregulation of HIF-2, or a combination 
of these mechanisms.  
 
Although the majority of published data suggests laparoscopic liver resection may have 
some advantage in the short term over open surgery, it cannot be discounted that this may 
reflect publication bias. There are no data to indicate the impact of this procedure on long 
term outcome (Vibert, Perniceni et al. 2006). Indeed, evidence from this pilot study would 
CHAPTER 4: A RETROSPECTIVE IMMUNOHISTOCHEMICAL STUDY 
Page | 92 
 
suggest further studies on the effects of RF assisted resection are required, and a 
randomized control trial is warranted to compare the effects of laparoscopic and open 
resection in terms of oncological outcome. Nonetheless, as disease recurrence is common 
after resection of colorectal hepatic metastases, identification of prognostic factors that 
predict the outcome following surgical resection of colorectal hepatic metastases would 
assist in the identification of those patients most likely to benefit from this intervention. 
Importantly, this would assist in the identification of patients who are unlikely to benefit. 
Clearly, further work characterising HIF’s role in metastatic liver disease would be of 
significant clinical benefit. 
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5.1 Introduction 
 
Constant availability of molecular oxygen is crucial for the structure and function of any 
mammalian cell. Therefore, cellular responses to reduced oxygen tensions (hypoxia) play an 
important role in development and many aspects of physiological homeostasis. Many 
important disease processes, including cancer, involve reduced tissue oxygenation and 
cellular adaptation to this is implicated in disease progression and clinical outcome.  
 
Hypoxic conditions have been detected in several human malignancies, including cancers of 
the breast, prostate, lung, pancreas, rectum, uterine cervix, vulva, head and neck, brain 
tumours, melanomas, soft tissue sarcomas, non-Hodgkin lymphomas, metastatic liver 
tumours and renal cell cancer (Vaupel and Mayer 2007). Hypoxic or anoxic areas, usually 
found as heterogeneously distributed areas within solid tumours, may depend either on 
poor/altered vascularisation (perfusion-limited O2 delivery), deterioration of diffusion 
geometry (diffusion-limited O2 delivery) or to a lesser extent to conditions of tumour-or 
therapy-associated anaemia (Vaupel and Mayer 2007; Dellas, Bache et al. 2008). Although 
low oxygen tension may even contribute to kill some tumour cells (Vaupel and Mayer 2007) 
hypoxia more probably provides a strong selective pressure able to regulate tumour growth 
and eventually favour survival of the most aggressive malignant cells (Graeber, Osmanian 
et al. 1996). Hence, hypoxia within a neoplastic mass is considered as an independent 
prognostic indicator of poor outcome with a significant risk to develop metastasis that may 
escape therapy (Vaupel and Mayer 2007; Dellas, Bache et al. 2008). Indeed, neoplastic cells 
surviving hypoxia exhibit enhanced invasive propensity, suggesting that hypoxia may favour 
cancer progression (Ishikawa, Sakurai et al. 2004; Le, Denko et al. 2004). However, the 
precise mechanisms by which this occurs remain incompletely understood (Cannito, Novo et 
al. 2008). Both E-cadherin downregulation and increased EMT have been shown to be 
hypoxia-inducible and a role for HIF in this promalignant adaptive response is likely. 
 
HIF is a central mechanism responding to low cellular oxygenation and mediates a variety of 
systemic and local adaptive responses (Maxwell, Wiesener et al. 1999). In most normal 
tissues in vivo and in vitro under standard cell culture conditions, activation of the HIF 
pathway is minimal (Esteban, Tran et al. 2006). One of the first tumours studied to 
demonstrate a mechanism for hypoxia mediated tumourigenesis and metastatic potential 
was clear cell renal cell carcinoma (CCRCC), which is the commonest form of kidney cancer. 
The great majority of CCRCC involve biallelic inactivation of VHL. As a consequence of pVHL 
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inactivation, the HIF pathway is constitutively active (please refer to Chapter 1, 
Introduction). pVHL knockdown experiments have allowed analysis of the effects of HIF-1 
activation. Indeed down-regulation of the cell adhesion molecule E-cadherin both in vivo 
and in vitro has been shown to be mediated, at least in part, by HIF (Esteban, Tran et al. 
2006; Krishnamachary, Zagzag et al. 2006; Evans, Russell et al. 2007). Since this 
discovery, further experiments specifically demonstrating HIF-1-mediated downregulation of 
E-cadherin have been performed in ovarian (Imai, Horiuchi et al. 2003), prostate (Luo, He 
et al. 2006) and breast (Chen, Imanaka et al. 2010) cancer cell lines in vitro. 
 
One of the tumours most studied for the role of hypoxia in pathophysiology is uterine 
cervical cancer (Jeffers, Paxton et al. 1997; de Boer, van Dorst et al. 1999; Acs, Zhang et 
al. 2003; Hutchison, Valentine et al. 2004; Kaplanis, Kiziridou et al. 2005; Rodriguez-
Sastre, Gonzalez-Maya et al. 2005). Tissue hypoxia is a characteristic property of cervical 
cancers that makes tumours chemo and radiotherapy resistant (Jeffers, Paxton et al. 1997; 
de Boer, van Dorst et al. 1999; Acs, Zhang et al. 2003; Hutchison, Valentine et al. 2004; 
Kaplanis, Kiziridou et al. 2005; Rodriguez-Sastre, Gonzalez-Maya et al. 2005). Following 
established work on VHL-deficient renal cell carcinomas this mechanism is at least in part 
mediated by HIF. However the consistency of this relationship and role in benign or 
premalignant epithelial conditions is less well characterised. Research has used HIF as a 
marker of hypoxia in these tissues although it shows only weak correlation with low pO2 
(Hutchison, Valentine et al. 2004). The multistage nature of carcinogenesis in cervical 
epithelium makes it possible to follow the events for a number of intermediate stages 
leading from a disturbance in proliferation and differentiation of squamous metaplasia, via 
low and high grade intraepithelial lesions, to carcinoma. The aim of this experiment is to 
evaluate differences in the distribution of HIF-1α and the cell adhesion molecule E-cadherin 
during various stages of neoplastic progression in cervical cancer.  Using 
immunohistochemistry, we examined the expression of E-cadherin and HIF-1 in both benign 
and dysplastic cervical epithelium.  
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5.2 Materials and Methods 
5.2.1 Cervical tissue 
Formalin-fixed paraffin-embedded sections of human uterine dysplastic/carcinomatous 
cervical tissue from 27 patients were a kind gift of Dr M.Esteban, (Servicio de Inmunología, 
Hospital de la Princesa, Departamento de Medicina, Universidad Autónoma de Madrid, Diego 
de León 62, 28006 Madrid, Spain) and 21 premenopausal benign formalin-fixed paraffin-
embedded sections were kindly provided by Human Biomaterials Resource Centre, 
Department of Histopathology, Hammersmith Hospital, Imperial College, London. 
Table 14: Summary of clinicopathological features of banked cervical tissue used to 
examine HIF expression in increasing dysplasia of CIN. 
 
 Benign CIN I CIN II CIN III ISCC 
Total number of 
samples (n) 
21 6 8 6 7 
Median age of 
Patient 
44.3 (42.1) 26.1 (27) 31.0 (31) 37.5 
(38.3) 
43.4 (45) 
Mean size of 
tumour (cm, range) 
N/A N/A N/A N/A 3.5 (0.4-11) 
Mean depth of 
invasion: 
     
Depth (cm) N/A N/A N/A N/A 1.42 (0.4-
2.8) 
Percent of 
cervical wall 
N/A N/A N/A N/A 82 (20-100) 
Grade of tumour      
Intermediate N/A N/A N/A N/A 3 
High N/A N/A N/A N/A 4 
 
5.3 Methods 
 
5.3.1 Immunohistochemical Staining 
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Immunohistochemical assays were performed on formalin-fixed paraffin-embedded sections 
as described previously (Esteban, Tran et al. 2006). Five-µm-thick sections were cut and 
deparaffinised in xylene and rehydrated in graded alcohols. SurePath cytological slides were 
de-cover slipped in xylene, rehydrated in graded alcohols, and postfixed in 10% phosphate-
buffered formaldehyde for 30 minutes. All slides were steamed in 0.01 mol/L of sodium 
citrate buffer (pH 6.0) for 20 minutes. Endogenous peroxidase activity was blocked by 
3%hydrogen peroxide in methanol for 20 minutes. Slides were incubated with the 
antibodies against E-cadherin and HIF-1α (clone H1alpha67, mouse monoclonal, 1:10,000; 
Neomarkers) overnight at 4°C and incubated for 30 minutes at room temperature with 
horseradish peroxidase-labelled dextran polymer coupled to anti-mouse antibody (DAKO 
Envision + System HRP, DAKO). Slides were then washed three times with TBST, developed 
with diaminobenzidine for 10 minutes, and counterstained with haematoxylin. For HIF-1α 
the DAKO CSA signal amplification kit was used according to the manufacturer’s 
recommendations. For HIF-1α slides of VHL deficient renal cell carcinoma, known to show 
HIF-1α overexpression were used as positive control (Esteban, Tran et al. 2006). A negative 
control was done in each case by omission of the primary antibody.  
5.3.2 Interpretation of immunohistochemical stains 
Immunohistochemical stains for E-cadherin and HIF-1α were interpreted semi quantitatively 
by assessing the intensity and extent of staining on the entire tissue sections present on the 
slides according to a four-tiered (0 to 3) scale. For E cadherin membrane immunoreactivity 
was considered positive. For HIF-1α nuclear staining was considered positive. In the case of 
dysplasias or in situ carcinomas, first, the percentage of total epithelial thickness showing 
positive staining was determined (e.g., 50% if the basal half or 75% if the basal three-
fourths of the squamous epithelium showed positive immunostaining, and so forth). In the 
case of invasive tumors, first the total percentage of positively staining tumor cells was 
determined. Then the percentage of weakly (1), moderately (2), and strongly (3) staining 
cells was determined, so that the sum of these categories equated with the overall 
percentage of positivity. A staining score was then calculated as follows: score (out of 
maximum of 300) = sum of 1 x percentage of weak, 2 x percentage of moderate, and 3 x 
percentage of strong staining. To assess the immunostaining for HIF-1α adjacent to areas of 
tumour cell necrosis and keratinization, immunostaining was scored as described above in 
at least 10 high-power fields of viable tumor cells within 1 mm of necrotic or keratinized 
areas, and in tumor regions away from such areas. Immunohistochemical stains were 
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evaluated independently by two pathologists and slight differences in interpretation were 
resolved by simultaneous viewing. 
5.3.3 Statistical analysis 
The Wilcoxon signed rank test was used for the comparison of median HIF-1α and E-
cadherin immunohistochemical expression levels in dysplastic epithelia and benign 
squamous epithelium, and for the comparison of the normal versus abnormal distribution of 
HIF-1α expression in benign and dysplastic epithelia. Statistical significance was determined 
if the two-sided P value of a test was less than 0.05. Graphpad Prism software was used for 
statistical analysis. 
5.4 Results 
 
5.4.1 Immunohistochemistry 
To further investigate the potential role of HIF and E-cadherin expression in benign cervical 
tissue, squamous dysplasia and carcinoma we examined their expression by 
immunohistochemistry in a series of clinical samples. The results of the 
immunohistochemical assays are summarized in Table 15. 
Table 15: Expression of E-Cadherin and HIF-1α in Benign Squamous Epithelium, Squamous 
Dysplasia (CIN I-III), and Invasive Squamous Cell Carcinoma (ISCC) 
 
 Benign CIN I CIN II CIN III ISCC 
HIF-1α      
No.pos 21 6 8 6 7 
Median 48 75.50 138 177 190 
Mean 47.3 (1.5) 72.8 (4.6) 151.8 (11.3) 174.7 (5.18) 191 (5.03) 
p† <0.0001 0.0156 0.0039 0.0156 0.0078 
E-cadherin      
No.pos 21 6 8 5 5 
Median 134 84 45.0 33.0 22 
Mean 136.5 (4.71) 84.8 (3.38) 45.4 (3.817) 45.6 (3.82) 19.6 (5.55) 
p† P<0.0001 0.016 0.0039 0.015 0.0078 
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† Wilcoxon signed rank test, with two-sided P value of a test was less than 0.05 
 
Figure 13: Expression of HIF-1α (A) and E-cadherin (B) in benign cervical squamous 
epithelium, cervical dysplasia (CIN, grades I to III), and ISCC, determined by 
immunohistochemistry. Bars indicate median immunostaining score values 
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All of the 21 benign squamous and dysplastic epithelia showed expression of nuclear HIF-
1α, although it was more widely expressed with increasing degree of dysplasia. HIF-1α 
expression was significantly increased in all grades of dysplasia (P = 0.0156 for CIN I, P = 
0.0039 for CIN II, and P = 0.0156 for CIN III, see Table 15, Wilcoxon signed rank test).  
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Whereas strong membrane immunostaining for E-Cadherin was present in all benign 
samples and early dysplastic epithelia (CIN I and II), membranous expression was only 
evident in 5 of 6 and 5 of 8 CIN III and ISCC tissues respectively, (Table 2 and Figures 1B 
and 2). Furthermore, membranous E-Cadherin expression decreased significantly with 
increasing degree of dysplasia, (Table 1, Figures 1(B)). 
 
Figure 14: E-Cadherin and HIF-1α expression in benign, moderate dysplasia (CIN II) and 
ISCC (X50) 
 
 
 
HIF-1α immunostaining was predominantly nuclear, although in a few cases of ISCC weak 
cytoplasmic reactivity was also observed (Figure 14). In benign squamous epithelia, HIF-1α 
immunostaining was seen in the parabasal cells and in the middle third of the epithelium 
(Figure 14). In addition, in dysplastic epithelia HIF-1α immunostaining was not restricted to 
the middle third of the epithelium as in benign cases but was also present in the basal 
and/or the superficial portions. In invasive carcinomas, HIF-1α expression was seen in all 
cases but expression was more focal (less than 50% of tumour cells). When focal, HIF-1α 
immunostaining was concentrated to areas surrounding necrotic regions and the infiltrating 
edge of tumours.  
 
In benign squamous epithelia membranous E-Cadherin expression was confined to the basal 
and parabasal cell layers. In contrast, in squamous dysplasia, membranous E-Cadherin 
expression was significantly reduced. Indeed the E-Cadherin expression was confined to the 
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basal cell layer where increasingly the staining was cytoplasmic, in contrast to HIF-1 
expression for the same level of dysplasia, which demonstrated expression in all layers of 
the epithelium.  
The mean E-Cadherin staining score decreased with increasing grade of dysplasia (slope -
27.22 ± 5.410, r2= 0.894,P = 0.0151, linear regression).  
The mean HIF-1α staining score increased with increasing grade of dysplasia (slope 38.93 ± 
6.108, r2 = 0.9312,P = 0.0078, linear regression).  
5.5 Discussion 
 
The major finding of this study is that HIF-1α expression is inversely related to the 
membranous expression of the cell-cell adhesion molecule E-cadherin in stratified cervical 
epithelium. Interestingly, the expression and role of HIF-1α in benign cervical epithelium 
has, until now, been poorly characterised (Mayer, Hoeckel et al. 2010). The presence of 
HIF-1α in the middle third of benign epithelium may have a physiological role in 
downregulating cervical E-Cadherin to facilitate cell migration in normal epithelial 
homeostasis. We have shown that in increasing degrees of dysplasia HIF-1α expression is 
upregulated, although which of these two factors represents the primary stimulus is unclear. 
A similar HIF-1α expression pattern has been demonstrated previously (No, Jo et al. 2009). 
The relatively dynamic expression of E-Cadherin has been demonstrated in a number of 
epithelia as a result to injury, for example, ulceration or fibrosis (Hanby, Chinery et al. 
1996; Zhou, Dada et al. 2009). The subsequent phenotypic change with its downregulation 
EMT is thought to be integral in the early reparatory ability of such epithelia. The role of HIF 
in this context has not previously been investigated. In this study HIF-1α expression may 
reflect a local hypoxic stimulus although even in early ISCCs (using the ‘gold standard’ 
Eppendorf histography system for clinical assessment of tumour oxygenation) there is no 
correlation between pO2 and HIF-1α expression (Dellas, Bache et al. 2008; Mayer, Hoeckel 
et al. 2010). Furthermore, Vaupel et al., in a recent experiment on large uniformly hypoxic 
solid uterine leiomyomas, showed that neither HIF-1α or HIF-2α or their respective target 
genes were upregulated and their non-expression was not a function of elevated prolyl 
hydroxylase activity. Conversely, their malignant tumoural form leiomyosarcomas, show 
abundant expression of HIF-related markers despite a similar microvascular density. The 
results indicate that the strong activation of the HIF system observed in solid malignant 
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tumours may be linked to their transformed phenotype, rather than being a physiological 
reaction activated in a pathological context. 
 
The role of E-Cadherin in EMT and its importance in neocarcinogenesis and the ability of 
primary tumours to metastasise is well documented. The importance of HIF-1α in 
orchestrating an adaptive response to the common environmental stimulus of hypoxia in 
such tumours is also well recognised (Dellas, Bache et al. 2008). However, the 
interrelationship between HIF-1α and E-Cadherin and its combined role in carcinogenesis 
remains complex and a fertile area of research (Chuang, Sun et al. 2008; Bendinelli, 
Matteucci et al. 2009; Sun, Ning et al. 2009; Du, Huang et al. 2010). In premalignant 
conditions, such as cervical dysplasia, the exact roles of HIF-1α and E-Cadherin remain 
unclear. One novel paradigm for HIF-1α in multistage carcinogenesis stems from evidence 
that HIF-1α facilitates cervical cancer progression in HPV type 16 infected transgenic mice. 
This suggests that it interacts with viral oncogenes to induce multiple genomic networks in 
premalignancy and fosters the development of advanced cervical cancer (Lu, Wright et al. 
2007). Conversely, another group silenced E7 oncogene in transformed keratinocytes and 
restored functional E-Cadherin expression (Caberg, Hubert et al. 2008). Unfortunately, the 
viral status of our cervical tissue was unknown and this may represent a significant 
weakness in our ability to extrapolate the true significance of the HIF profile. 
 
As HIF response to hypoxia is seen in all cell types examined to date, this study raises the 
interesting possibility that E-cadherin expression in settings other than renal epithelium and 
kidney cancer may also be influenced by HIF. Importantly, recent studies have shown that 
hypoxic incubation was able to suppress E-cadherin protein expression in pancreatic, colon 
and hepatoblastoma cell lines (Imai, Horiuchi et al. 2003; Esteban, Tran et al. 2006; 
Krishnamachary, Zagzag et al. 2006; Cannito, Novo et al. 2008). The mechanism by which 
hypoxia and/or HIF represses E-cadherin expression is not clear. Genetic, epigenetic, and 
transcriptional changes have been implicated (Peinado, Olmeda et al. 2007). For example, 
the HIF target gene lysyl oxidase (LOX) has been implicated in involvement in E-cadherin 
regulation (Erler, Bennewith et al. 2006). Cannito et al. exposed 4 human cancer cell lines 
to hypoxia and suggests that early EMT-related events, such as down regulation of E-
Cadherin, are dependent on transient intracellular increase in ROS, whereas late migration 
and invasiveness were sustained by HIF-1α. Other experiments have highlighted the 
relevant Notch intracellular signalling molecules involved, for example the increased 
expression of Slug and Snail, Mitochondrial ROS, HIF-1α induces Twist (Sun, Ning et al. 
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2009), NF-kappa B, TNFα (Chuang, Sun et al. 2008), Snail and SIP1 (Evans, Russell et al. 
2007) correlated with the decreased expression of E-cadherin (Chen, Imanaka et al. 2010) 
in 6 breast carcinoma cell lines. In their series of intraepithelial and invasive cervical 
squamous lesions, Carico et al. (Carico, Atlante et al. 2001) also describe a statistically 
significant correlation between the site at which E-cadherin localized and the histological 
diagnosis. This alteration in the site at which these molecules are detected in benign and 
neoplastic endocervical epithelia may reflect an alteration in cell–cell interactions associated 
with disease progression and ultimately invasion. This possibility could offer an insight into 
why mutations in E-cadherin are infrequent in cancers in general, because HIF activation is 
very common in solid tumours and may thus provide a reliable epigenetic route to down-
regulating E-cadherin efficiently. It would also explain why expression of E-cadherin in 
tumours is frequently patchy (as it commonly happens with areas of hypoxia) rather than 
homogeneous. Our study demonstrates that during the development of cervical lesions 
substantial qualitative (subcellular localization-membrane to cytoplasmic) and inverse 
quantitative alterations (changes in expression) occur in the protein expression of E-
cadherin and HIF1 in cervical cancer.  
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6.1 Introduction 
 
6.1.1 What is CD10/CALLA/NEP? 
 
Common acute lymphocytic leukemia antigen (CALLA) is a 100-kD glycoprotein and an 
important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL) 
(Letarte, Vera et al. 1988). 
 
6.1.2 Where is it expressed? 
 
CALLA is present on leukemic cells of pre-B phenotype, which represent 85% of cases of 
ALL, and is absent from normal PBMC. However, it is not restricted to leukemic cells and is 
found on a variety of normal tissues (Metzgar, Borowitz et al. 1981) including the kidney 
(Platt, LeBien et al. 1983). There it is present on the brush border of proximal tubules and 
on glomerular epithelium (Metzgar, Borowitz et al. 1981; Platt, LeBien et al. 1983).  
 
6.1.3 What does it do? 
 
It was thought CD10 had no functional activity until Letarte et al. cloned a cDNA coding for 
CALLA and showed that the amino acid sequence deduced from the cDNA sequence is 
identical to that of human membrane-associated neutral endopeptidase (NEP), also known 
as enkephalinase (Letarte, Vera et al. 1988). NEP cleaves peptides at the amino side of 
hydrophobic residues and inactivates several peptide hormones including glucagon, 
enkephalins, substance P, neurotensin, oxytocin, bradykinin, and the chemotactic peptide 
fMLF (Kerr and Kenny 1974; Malfroy, Kuang et al. 1988). Letarte et al.’s observation 
opened new avenues for testing the function of this molecule in leukemic cells and its 
potential role in the process of malignancy. 
 
6.1.4 Why is it of interest in carcinogenesis? 
 
CD10 belongs to a ‘superfamily’ of more than 20 zinc matrix metalloproteases (MMPs). 
MMPs are critical for maintaining tissue allostasis. MMPs are active at neutral pH and can 
therefore catalyze the normal turnover of extracellular matrix (ECM) macromolecules such 
as the interstitial and basement membrane collagens and proteoglycans as well as 
accessory ECM proteins such as fibronectin (Malemud 2006). Given the importance of their 
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role in maintaining cell-matrix structure, they have been the subject of extensive research 
into the pathology of carcinogenesis and development of metastases. One example is matrix 
metalloproteinase-9 (MMP-9), which promotes key processes underlying tumour cell 
propagation, from migration and invasion to angiogenesis and tumour growth (Coussens, 
Fingleton et al. 2002). MMP-9 cleaves specific factors constituting or present in the ECM, 
including collagen IV in basement membranes and angiogenic molecules (Fridman, Toth et 
al. 2003), thereby creating a physical and biochemical path for tumour invasion and 
neovascularisation (Curran and Murray 1999). Although significant, the role of MMP-9 in 
metastasis remains controversial. On one hand, MMP-9 regulates most of the rate-limiting 
steps underlying metastasis and could represent an ideal target for effective disruption of 
the metastatic cascade. However, MMP-9 also mediates wound healing and inflammation 
(Okada, Kita et al. 1997; Baker and Leaper 2003) and opposes tumour growth by mobilizing 
angiogenetic inhibitors angiostatin and endostatin (Overall and Kleifeld 2006). MMP-9 is not 
the only MMP implicated in the development of certain cancers, for example, transin is 
induced by oncogenes and is expressed more abundantly in malignant than in benign 
tumors (Matrisian, Leroy et al. 1986).  
 
6.1.5 What do we know about CD10 in colorectal carcinogenesis? 
 
CD10 expression has been reported to correlate with the histologic features and biologic 
behaviour of colorectal carcinomas (Yao, Takata et al. 2002). Yao et al. suggested that 
patients with colorectal adenocarcinoma with CD10 expression are at increased risk of liver 
metastasis (Yao, Takata et al. 2002). More recently Fujimoto et al. confirmed by 
multivariate analysis that there was a significant association between CD10 expression in 
colorectal carcinoma and liver metastases (Fujimoto, Nakanishi et al. 2005). The reason for 
this association is unknown. CD10 expression tends to be seen more frequently at the 
luminal surfaces of the cribriform glands in moderately differentiated adenocarcinoma than 
that in well-differentiated adenocarcinoma and a roles in vascular invasion has subsequently 
been postulated (Fujimoto, Nakanishi et al. 2005). 
 
6.1.6 CD10: a HIF target gene? 
 
It is hypothesised in this chapter that the significant association of CD10 expression in 
colorectal carcinoma and liver metastases may be explained by a HIF mediated mechanism 
and that CD10 may therefore be a HIF target gene. This hypothesis has been in part 
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supported by the observation of close concurrent expression of HIF-1 isotype and CD10 in 
the proximal renal tubule in humans, (Tran, M., Maxwell, P. et al.-private correspondence).  
Furthermore, following Houda et al.’s sequencing of the CALLA (or CD10) gene in 1995, 
(Haouas, Morello et al. 1995) it is possible to identify the prerequisite hypoxia response 
element (HRE) segment. HREs are composite regulatory elements, comprising the 
conserved HIF binding site (HBS) with a core A/GCGTG sequence, and a highly variable 
flanking sequence (Wenger, Stiehl et al. 2005) (Figure 15). 
 
 
 
Figure 15: Alignment of 5’ UTR sequences from CALLA/NEP/CD10 cDNAs, (reproduced with 
permission from D’Adamio et al.). 
 
There are many more sites with the core A/GCGTG sequence in the regulatory regions of 
mammalian genes than are actually used by HIF to regulate gene expression and at the 
moment it is not understood what distinguishes HBSs in the functional HREs from the 
putative, non-functional HBSs that contain the identical core sequence. However, 
encouragingly subsequent analysis of the CD10 promoter region (Ishimaru and Shipp 1995) 
demonstrates that following gene splicing many of these HRE segments and HIF binding 
sites are conserved and expressed at transcription. Our aim to identify whether HIF 
mediates expression of CD10 may help elucidate the respective roles of HIF and CD10 in 
colorectal carcinogenesis.  
 
6.2 Methods 
6.2.1 Cell culture, chemicals, and antibodies 
RCC4, RCC10, and 786-O cell lines and the corresponding stable transfectants with wild-
type pVHL have been described previously in Chapter 2. RCC10 cells were generously 
provided by K. Plate and T. Acker (Institute of Neurology/Edinger Institute, Frankfurt 
University Medical School, Frankfurt, Germany). Cells were cultured in RPMI 1640 (Life 
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Technologies, Gaithersburg, MD) with penicillin/streptomycin, glutamine, and 10%
bovine serum. Each of the 3 cell lines and their respective paired transfected wild type VHL 
cell line were cultured as described in Chapter 2. mRNA was extracted, cDNA and RT
(using the CD10 primer, and B actin control) was performed to assess
CD10 mRNA expression in VHL knockout and wild
we used the CD10 primer sequence 
Desferrioxamine (DFO) and cobalt chloride (CoCl
MO); dimethyl-oxalylglycine (DMOG) was purchased
For hypoxic experiments, cells were exposed to 1% oxygen for the indicated times using
either a hypoxic workstation (INVIVO
incubator Galaxy R (Biotech, Palo Alto,
upregulate HIF in the absence of hypoxia. Its mechanism is demonstrated in the diagram 
below. 
 
 respective levels of 
-type renal cell cancer cell lines. For this 
(5′GGGATCCTCACCAAACCCGGCACTTCTTTT3′)
2) were purchased from Sigma (St. Louis, 
 from Frontier Scientific (Logan, UT). 
2 100, Ruskin, Leeds, United Kingdom) or a hypoxic 
 CA). DMOG is a chemical induction agent that acts to 
DMOG: PHD 
inhibitor 
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Figure 16: Schematic diagram showing the mechanism by which DMOG inhibits HIF 
hydroxylation 
To assess the effects of physiological and chemical HIF stabilization on levels of CD10 mRNA 
expression, the 3 renal cell cancer cell lines (wild type transfectants) were kep
(1% oxygen) for 16 hours, or normoxia and 1mM DMOG for 16
extracted thereafter and levels measured as described already.
HT-29 colorectal cells were cultured as described previously, and similarly were stimulated 
by physiological hypoxia and DMOG to assess CD10 response. Concurrent HIF
expression was measured and results described below.
6.3 Results 
 
6.3.1 CD10 expression in colorectal liver metastases
 
We first verified the reported distribution of CD10 in colo
shows the high level of CD10 positive staining at the margins of colorectal liver metastases, 
(see Chapter 4).  The canalicular pattern of the liver tissue adjacent is also evident but 
more weakly positive. CD10 showed significantly greater positive staining in colorectal liver 
metastases resected laparoscopically as did the 
remains unknown. 
 
 
Figure 17: CD10 expression in colorectal liver metastases margin, (x50).
 
6.3.2 The effect of constitutively active HIF on CD10 mRNA expression in CCRCC 
model 
 
 hours. CD10 mRNA was 
 
 
 
rectal carcinoma. 
HIF-2 isotype, although the 
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Figure 18 below, shows the relative fold induction of CD10 mRNA detected by RT-PCR in 3 
RCC lines (RCC4, RCC10 and 786-O) defective for the pVHL expression. PHD3 was used as a 
control HIF-responsive gene, (data not shown). Means were taken from 3 independent 
experiments. 786-O shows the greatest upregulation in transcription in pVHL negative cells, 
with a mean of 8 fold induction. RCC10 was next greatest and then RCC4 (means of 5 and 4 
respectively, p<0.05-paired Student t-test). 
 
 
 
 
 
 
 
 
 
 
Figure 18: Relative CD10 mRNA levels in pVHL negative CCRCC cell lines compared to wild 
type (pVHL competent). 
 
6.3.3 CD10 protein expression in CCRCC lines with defective pVHL 
 
We next examined CD10 expression in all 3 pVHL-defective cell lines derived from sporadic 
CCRCC (RCC4, RCC10 and 786-O) and corresponding sublines in which pVHL was stably re-
expressed (referred to here as RCC4/VHL, RCC10/VHL and 786-O/VHL). Notably, whereas 
RCC4/VHL and RCC10/VHL cell lines expressed little or no CD10, pVHL-defective RCC4 and 
RCC10 showed substantial levels of CD10 protein on immunoblotting. 
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Figure 19: wtVHL abrogates the expression of CD10 in all three renal cancer cell lines. 
(* indicates a much shorter exposure time) 
(Films developed with kind assistance of Dr M. Tran) 
 
To further investigate the link between pVHL status and CD10, we then analyzed 
CD10mRNA by quantitative real-time RT-PCR in RCC10 and RCC10/VHL. The level of CD10 
mRNA was higher in RCC10 as were mRNA levels of VEGF and PHD3 (two well-characterized 
targets of HIF1 and 2 respectively). Thus, eliminating expression of pVHL (stabilisation of 
HIF expression) in CCRCC cells can increase CD10 expression, and this operates at least in 
part through increasing the level of CD10 mRNA. 
 
6.3.4 CD10 mRNA Expression in pVHL Competent Cells 
 
The above results may be consistent with HIF mediating the expression of CD10 in VHL-
negative CCRCC cells. To further explore this, we tested whether activating HIF in 
RCC10/VHL (i.e.: VHL competent RCC cell line) would upregulate CD10 mRNA. Firstly, we 
used hypoxia (1% oxygen). As expected, this activated the HIF pathway potently, as 
evidenced by the induction of expression (measured by real-time RT-PCR) of VEGF, 
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(recognised HIF-1 target in CCRCC) (data not shown) and PHD3 mRNA, (recognised HIF-2 
target gene in CCRCC, Figure 20). 
 
 
 
Figure 20: Effects of different stimuli on PHD3, (HIF2 target gene) mRNA expression in 
RCC10 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Effects of different stimuli on CD10 mRNA expression in RCC10 
 
In parallel, hypoxia significantly increased mRNA as measured by real-time RT-PCR. 
Secondly, we used three different chemical agents that activate the HIF pathway by 
inhibiting HIF hydroxylation (Schofield and Ratcliffe 2004): (a) the iron chelator 
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desferrioxamine (DFO), (b) the 2
(c) CoCl2. The results show that all 3 upregulate CD10 mRNA expression, the greatest fold 
increase associated with DMOG. Thereafter we used DMOG as the inhibitor of pr
hydroxlase in HT-29. The results 
stimulus. The results are from 3 independent experiments. Hypoxia results in almost a 
mean 4-fold increase in CD10 mRNA (
hydroxylation results over a 5-fold increase (p<0.05).
 
6.3.5 Effects of hypoxia and DMOG on CD10 mRNA expression in HT
carcinoma cell line 
 
We stimulated the HT-29 cell line, which has similar culture requisites to the RCC lines, with 
hypoxia and mmOG. The results are shown below. HT
CD10 mRNA expression when compared to HT
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Figure 22: Effects of hypoxia and DMOG on CD10 mRNA expression in HT
carcinoma cell line 
 
6.4 Discussion 
 
Years of research looking at hereditary and sporadic pVHL
as a consequence of pVHL inactivation, the HIF pathway is constitutively active.
of pVHL in otherwise defective 
 subunits and also suppresses tumour growth in xenograft models 
2003). The three VHL-/- RCC cell lines used in this chapter 
type RCC (VHL+/+), have been used extensively in the characterisation of HIF target genes. 
 
-oxoglutarate analogue dimethyl-oxalylglycine (DMOG) and 
are shown in Figure 22 below alongside hypoxia as a 
paired Student t-test) whereas inhibiting HIF
 
-29 demonstrates an upregulated 
-29 untreated cells (control). 
HT-29
Hypoxia DMOG (1mM)
Conditions
 
-defective CCRCC has shown that 
CCRCC-derived cell lines restores normal degradation of HIF
(Kondo, Kim et al. 
(and their VHL transfected wild 
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Most recently they were used to highli
CCRCC (Esteban, Tran et al. 2006)
nephron as a marker of the proxim
Analysis by Tran et al. (private correspondence) in VHL deficient CCRCC showed that CD10 
expression and proximal tubule cell type corresponded significantly to areas of HIF 
positivity. In Chapter 2, I analysed stained CLMs for CD10 
expression. Furthermore, similarly high levels of HIF
demonstrated (see Chapter 4). A correlation between CD10 positivity and HI
primary colorectal carcinoma has been demonstrated 
previous studies have suggested that HIF
primaries (Yoshimura, Dhar et al. 2004)
may be hypoxia regulated in expression and more specifically a HIF target gene.
In this chapter we have demonstrated using these 3 CCRCC cell lines that both CD10 mRNA 
and CD10 protein expression are upregulated in VHL deficient cell lines
constitutively active HIF expression. Furthermore, we demonstrated that this upregulation 
could be replicated in wtCCRCC cell lines by exposure to 16hr hypoxia and inhibiting prolyl 
hydroxylation, the mechanism of normoxia
level of mRNA of VEGF and PHD3 was analyzed in parallel
upregulation pattern for genes whose expression is
respectively, in CCRCC (Raval, Lau et al. 2005)
line HT 29 to subject to culture in hypoxia and inhibition of HIF hydroxylation and 
demonstrated through RT-PCR upregulation of CD10 mRNA expression. Further work to 
differentiate more specifically whether the CD10 exp
combination of both HIF-1 and 2
Importantly, overexpression of a modified 
pVHL, is sufficient to override the tumor suppressor
Furthermore, knock down of 
tumourigenic potential (Kondo, Kim et al. 2003)
of HIF-2  is necessary and sufficient for pVHL's action as a tumor suppressor in fully
transformed CCRCC cells. To directly test the role of HIF isotypes in regulating CD10 
expression, one might infect RCC10/VHL cells with retroviral vectors encoding
active forms of either HIF-1
mutations of the two prolyl residues, which are targets for oxygen
and pVHL capture. A similar experiment with constitutively active HIF1 and 2 isotypes would 
 
ght HIF dependent control of E cadherin expression in 
. Paraf et al. characterised CD10 as a marker in the renal 
al tubule cell type (Paraf, Chauveau et al. 2000)
and found significant upregulated 
-2 isotype in the same tissues were 
(Fujimoto, Nakanishi et al. 2005)
-1 is the predominant isotype in colorectal 
. In this clinical context, we hypothesised that CD10 
-mediated HIF downregulation, using DMOG. The 
 and showed the expected 
 increased by HIF-1 and 2 isotypes
. Finally, we selected a colorectal tumour cell 
ression is under HIF
, is needed.  
HIF-1α molecule, which cannot be
 effects of VHL (Kondo, Kim et al. 2003)
HIF-1α in pVHL-negative CCRCC cell lines abrogates their 
. These observations show that suppression 
 or HIF-2 . These engineered HIF molecules contained 
-dependent hydroxylation
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allow further insight into potential specific isotype dependent CD10 transcription control. 
Alternatively, the use of siRNA to HIF 1 and 2 would enable further insight into the role of 
each and their interplay in CD10 expression.  Current challenges are to understand (1) the 
key downstream targets of HIF involved in tumorigenicity, and (2) the extent to which these 
HIF-mediated changes in fully transformed cancer cells reflect tumor initiation and 
progression in the epithelium (Esteban, Tran et al. 2006).  
Similarly, both isoforms are abundantly expressed in the kidney but in different types of 
cells: HIF-1α is predominantly expressed in epithelial cells whereas HIF-2α is predominantly 
detected in interstitial fibroblast and endothelial cells (Rosenberger, Mandriota et al. 2002). 
We have demonstrated HIF-2 propensity in colorectal liver metastases, with conserved 
CD10 expression. The question of how HIF-1 and HIF-2 discriminate between the target 
genes is far from settled. The observed differences could be accounted for by preferential 
cooperation of one of the isoforms with certain subsets of transcription factors, coactivators 
or corepressors, and/or tissue-specific expression of HIF-α isoforms. 
CD10 is normally widely distributed in a number of organs including the kidney, small 
intestine and liver (Haouas, Morello et al. 1995). It has been shown to exhibit a 
characteristic canalicular pattern in the liver (Lin, Abdallah et al. 2004). This was also 
evident in our series. Recent studies have demonstrated CD10 expression in a range of 
neoplasms including carcinomas of the pancreas, kidney, bladder, prostate and uterus. 
Studies by Lin et al. and Borscheri et al. have shown that the canalicular expression pattern 
CD10 in the liver is conserved in primary hepatocarcinogenesis (Borscheri, Roessner et al. 
2001; Lin, Abdallah et al. 2004) and CD10 has been proposed as a diagnostic marker of 
HCC in liver biopsies and fine needle aspirates. In our series (in Chapter 4) CD10 was 
expressed in a canalicular pattern in keeping with the neighbouring normal liver tissue. Of 
the series comparing CD10 expression in HCC with metastatic disease, only one looked at 
colorectal liver metastases (a total of two blocks neither positive for CD10). There are two 
large retrospective series that have suggested a role for CD10 in the colorectal 
carcinogenesis. Fujimoto et al. looked at the primary colorectal carcinomas in 505patients 
and showed that CD10 was significantly higher (52% vs 39%) in patients who subsequently 
developed liver metastases. Statistical analysis subsequently confirmed a trend, observed 
previously by Ogawa et al., that CD10 expression in colorectal primary carcinoma is a 
predictor of subsequent liver metastases (Ogawa, Iwaya et al. 2002). How CD10 confers a 
more invasive/malignant potential remains to be elucidated. It must be noted that other 
MMPs (particularly MMP-2 and MMP-9) have been isolated in active isoform in colorectal 
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liver metastases (Okada, Ishida et al. 2001). The same limitations of Fujimoto’s work apply 
to our pilot data set: he has not investigated CD10 expression in liver metastases and we 
do not have the tissue blocks available to look at the primaries from where the CD10+ CLM 
originated. Prospective tissue collection would allow better characterization of timing of 
CD10 upregulation and would allow parallel analysis of HIF expression.  
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7.1 Introduction 
The selection criteria for liver surgery are usually controlled primary tumour, no extra 
hepatic metastases and a resection that is technically feasible with tumour-free margins 
(Hugh, Kinsella et al. 1997). Survival is shortened by the presence of inadequate or 
involved resection margins (Pawlik, Scoggins et al. 2005). It has been postulated that the 
principal mode of colorectal tumour dissemination is via the portal system and therefore 
that surgical resection of isolated hepatic metastases from colorectal cancer may be curative 
in a number of cases (Weiss, Grundmann et al. 1986). Previous data from the Registry of 
Hepatic Metastases, a multi-institutional database of liver resections, suggest that a margin 
>1cm was associated with 45% five year survival, but only 23% survived five years if the 
margin was less (Hughes, Simon et al. 1986).  
The prognostic role of circulating cancer tumour cells (CTCs) is now established 
(Cristofanilli, Budd et al. 2004; Cristofanilli, Hayes et al. 2005) and data support their role 
as more reproducible indicators of disease status than current imaging methods (Budd, 
Cristofanilli et al. 2006). A number of methodologies have been proposed for their 
measurement, including quantitative real time polymerase chain reaction based assays 
(Stathopoulou, Vlachonikolis et al. 2002; Benoy, Elst et al. 2004), immunomagnetic 
separation and laser scanning cytometry (Smith, Slade et al. 2000; Pachmann, Clement et 
al. 2005; Ring, Zabaglo et al. 2005; Pachmann, Camara et al. 2008). The FDA has now 
approved the routine use of the flow cytometry based Veridex CellSearch (Warren, NJ, USA) 
system in a number of clinical settings including breast and prostate cancer, diseases that 
are considered incurable when metastatic (Apostopolous, Giamas et al. 2007; Jiao, 
Apostolopolous et al. 2008; Payne, Yague et al. 2008; Rack, Schindlbeck et al. 2008; Slade, 
Payne et al. 2008). 
 
In colorectal cancer approximately 50% of patients develop metastatic liver disease and 
25% have evidence of this at the time of initial diagnosis (Windsor, Cohen et al. 2008). If 
untreated, the median survival of these patients is less than 12 months. With curative liver 
resection the 5-year survival increases to 40-60% (Meyerhardt and Mayer 2005). 
Increasingly, a variety of loco regional therapeutic modalities have been advocated to treat 
patients with unresectable liver metastases although intraoperative manipulation of organs 
has been reported to promote tumour spread (Gutt, Riemer et al. 1999; Gutt, Riemer et al. 
2001; Schmidt, Koch et al. 2008).  
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RFA is designed to induce tumour destruction by delivering a high frequency alternating 
current through an active needle electrode introduced into the neoplastic tissue. Frictional 
heating is the result when the ions in the tissue attempt to follow the changing direction of 
the alternating current, causing cell death by coagulative necrosis (Napoletano, Taurino et 
al. 2008). Such therapy results in a ‘noxa’ for the body, inducing a strong inflammatory 
response. Studies in recent years have suggested a survival benefit for patients with 
colorectal liver metastases undergoing RFA compared to historical controls undergoing 
chemotherapy alone (Berber, Pelley et al. 2005) and hence RFA has emerged as an 
accepted method for treatment of liver metastases. However, there have been no 
prospective randomized trials comparing RFA with other therapeutic modalities (Hur, Ko et 
al. 2008; Lee, Yun et al. 2008; Nikfarjam, Shereef et al. 2008; Reuter, Woodall et al. 2008).  
 
RF is a novel way of resecting liver parenchyma with minimal blood loss (Ayav, Navarra et 
al. 2005; Jiao, Navarra et al. 2005; Jiao, Navarra et al. 2006; Ayav, Bachellier et al. 2007; 
Ayav, Jiao et al. 2007; Ayav, Navarra et al. 2007; Bachellier, Ayav et al. 2007; Ayav, Jiao et 
al. 2008; Jiao, Ayav et al. 2008; Pai, Jiao et al. 2008; Pai, Navarra et al. 2008). It employs 
the coagulative necrosis effect on healthy liver tissue to ‘seal’ adjacent liver parenchyma 
immediately before sharp resection of the tumour itself.  
 
We have shown that when comparing the oncological outcomes of R0 resections in a small 
pilot population who had undergone RFALR, those that had undergone a laparoscopic 
approach had a shorter time to recurrence and overall life expectancy. We therefore wished 
to compare the overall effect of open and laparoscopic RF assisted liver resection (RFALR) 
on CTC measurements immediately before and after these curative procedures and also 
assess the impact of open RFA alone on CTCs. Furthermore, we used these surrogate 
biomarkers to gain insights into the differential localization or compartmentalization of these 
cells, likely to be en route to further metastasis, an as yet unconfirmed assertion.   
 
7.2 Patients and Methods 
 
Consecutive patients with metastatic colorectal liver metastases, confirmed as 
adenocarcinoma by histology, were recruited to this study from January to November 2008. 
Appropriate local ethics committee approval was obtained. Samples were blinded for 
analysis and patients understood that the results would not be made available to them.  
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The CellSearch system was used to enrich and enumerate the CTCs, as described previously 
(Slade, Payne et al. 2008). A 7.5mL blood sample was taken in a CellSave preservative 
tube, kept at room temperature and processed within 72 hours. The system enriched for 
EpCAM (epithelial cell adhesion molecule) positive epithelial cells by incubating the sample 
with ferrofluid conjugated to anti-EpCAM antibodies. Cells were stained with the following 
fluorescent labelled monoclonal proprietary antibodies: CD45-APC to distinguish the CTCs 
from leukocytes and pan-cytokeratin 8, 18 and 19 (CK-PE) to stain epithelial cells, and 
epidermal growth factor-receptor (EGF-R) antibodies as we have recently described (Payne, 
Yague et al. 2008). Nucleic acids were stained using 4,6-diamidino-2-phenylindole (to 
exclude red blood cells). Samples were then scanned on the CellTracks analyzer II 
fluorescent microscope for analysis. 
 
In all patients, 7.5mL of blood was taken from peripheral venous (PV) and arterial 
circulations (PA), and hepatic (HV) and portal veins (PoV) intraoperatively, before and 20 
minutes after resection (RFALR) or open RFA (ORFA). The arterial sample was taken from 
an indwelling cannula in a radial artery inserted during routine anaesthesia for 
intraoperative monitoring. The portal and hepatic venous blood was obtained from a direct 
venous puncture after mobilization of portal triads and liver to exposed portal vein and right 
hepatic vein during operation. For those undergoing laparoscopic liver resections, 7.5mL of 
blood was taken from peripheral venous and the arterial circulation before and after 
resection following introduction of pneumoperitoneum with a CO2 pressure of 12mmHg. All 
patients were followed-up with our standard practice with microbubble ultrasound at 6 
weeks following RFA, then a CT scan at 3 months and 6 months following resection.  
 
Statistical analysis was carried out using SPSS for Windows (version 16.0, SPSS Inc. 
Chicago, IL). Results are expressed as either median (range) or mean ± SD. Comparisons 
between variables before and after procedures were analyzed using the paired t test. A p< 
0.05 was considered statistically significant. 
 
7.3 Results 
 
A total of 20 consecutive patients requiring intervention for their colorectal liver metastases 
were recruited into this study. These comprised individuals for open RF ablation (ORFA 
(N=5)), open and laparoscopic liver resection, (opRFALR (N=11) and lapRFALR (n=4) 
respectively); there were no significant differences in baseline characteristics between the 
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groups except patients undergoing RFA were generally older (Table 16). One additional 
patient with metastatic carcinoid tumour was also recruited to this study as a negative 
control and no CTCs were detected in this individual. The mean number of CTCs before and 
after intervention in both the systemic and portosystemic circulations is shown in Table 17.  
 
Table 16: Patient characteristics of 20 patients with colorectal liver metastases included in 
this study. Histology confirmed adenocarcinomas in all patients. 
 
Therapeutic 
modality (n) 
Male/ Female Age in years 
(median, range) 
Open resection 
(opRFALR, n = 11) 
8 male, 3 female 53 (30 – 72) 
Laparoscopic 
resection 
(lapRFALR, n = 4) 
3 male, 1 female 55 (41 – 76) 
Open RFA  
(ORFA, n = 5) 
3 male, 2 female 60 (37 – 78) 
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Table 17: The Impact of interventions on CTCs at different vascular sites 
PV, peripheral vein; PA, peripheral artery; PoV, portal vein; HV, hepatic vein; NA, not 
applicable. * denotes a p value < 0.05 compared with before the intervention. 
 
Therapeutic 
modality 
Before Intervention  
Number of CTCs:  
Mean+SD (range) 
After Intervention 
Number of CTCs:  
Mean+SD (range) 
 Systemic 
Circulation 
Portosystemic  
Circulation 
Systemic  
Circulation 
Portosystemic 
Circulation 
 PV PA PoV HV PV PA PoV HV 
Open 
resection 
(opRFALR,  
n = 11) 
 
 
1±2.4 
 
(0-3) 
1.7±
2.8 
(0-6) 
125.7±2
50 
(0-
>500) 
173.3±
299 
(0-
>750) 
0.09±0.3 
 
(0-1)* 
0.5±0.5 
 
(0-1)* 
62.5±
12.5  
(0-
225)* 
22.3±4
4.3 
(0-
112)* 
Laparoscopic 
resection 
(lapRFALR, 
n = 4) 
 
2.3±1.
8 
(0-7) 
0 
0 
NA NA 0.2±0.5 
 
(0-1)* 
0 
0 
NA NA 
Open RFA  
(ORFA,  
n = 5) 
3±2 
 
(0-7) 
5.5±
11 
(0-
16) 
10±4.1 
 
(0-18) 
24±72 
 
(0-
102) 
12.7±9 
 
(1-22)* 
6.5±9 
 
(0-15) 
14.6±
44 
(0-
86)* 
59±31.
4 
(0-
156)* 
 
 
7.3.1 Localization of CTCs and the impact of chemotherapy 
 
Localization of CTCs in the circulation was examined by measuring them at different sites in 
both the systemic circulation, as measured with peripheral venous and arterial blood 
samples, and the portosystemic circulation, as measured with portal venous and hepatic 
venous blood samples, in patients undergoing an open procedure (N=16). This 
demonstrated that the mean number of CTCs immediately prior to intervention in PV, PA, 
PoV and HV measured 1±2.4, 1.7±2.8, 125.7±249.5 and 173.3±298.5 respectively for open 
CHAPTER 7: CIRCULATING TUMOUR CELLS AND RFA-LIVER RESECTION  
Page | 123 
 
resection and 3±2, 5.5±11, 10±4.1 24±72 for open RFA. Thus, a larger number of CTCs 
was observed in the liver macrocirculation, compared to peripheral systemic circulation.  
 
Of the 11 patients who had open surgical liver resections, nine with synchronous liver 
metastases had preoperative chemotherapy, and two with metachronous solitary 
metastases detected approximately 2 years after the initial resection for the colonic primary 
did not have preoperative chemotherapy. Irrespective of chemotherapy or of the type of 
response to systemic cytotoxics, the number of CTCs in the peripheral circulation remained 
remarkably low (N=9, 1.4 ±3.4; N=2, 3.0±4.2, respectively, in the patients who had pre-
operative chemotherapy and in the patients who did not). The number of CTCs in PoV and 
HV was significantly lower in patients who received chemotherapy compared with those who 
did not (0.7±0.9 vs 400.0±141.0; 10±14 vs 500.0±353.5, respectively), indicating, once 
again, that the liver macrocirculation and the lungs appear to be sites where CTCs are 
pooled. Chemotherapy reduced the number of CTCs in the portosystemic system reducing, 
we suggest, the risk of both lung and systemic spread although long-term clinical outcomes 
are still awaited.  
 
7.3.2 Impact of procedural interventions on CTCs 
 
In the case of RF assisted-liver resection (RFALR-both laparoscopic and open), the number 
of CTCs in any blood vessel sampled was significantly lower following the procedure than 
prior to it (p<0.05). Following the open RFA procedure alone (ORFA), the number of CTCs 
significantly increased (p<0.05). Following surgical resection (either open or laparoscopic), 
the number of CTCs in the peripheral blood (PV) decreased, whereas it increased following 
ORFA  as shown in Table 17 and Figure 23. There was a decrease in CTCs throughout the 
circulation following opRFALR and lapRFALR. It is interesting to note that there was no 
difference between these 2 subgroups although patient numbers and CTC numbers are 
small. Similarly, no patients underwent laparoscopic RFA alone to compare with those 
undergoing ORFA (in many of those amenable to laparoscopic RFA, percutaneous is a less 
invasive alternative and was not included in this pilot cohort).  
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Figure 23: Changes in peripheral venous blood (antecubital fossa cannulation) before and 
after surgery (open or laparoscopic) or RFA (open). 
 
 
 
 
 
 
The median follow-up period here measured 154 days (range, 70 – 284 days). Although this 
was a short period of follow-up, two patients developed recurrent liver metastases after 
open liver resection at 3 and 6 months.  Both of them received preoperative chemotherapy 
and they had a higher number of pre-operative PV CTCs before intervention compared with 
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those without recurrence (7.0±1.4 vs 2.0±2.6, respectively), suggesting that CTCs may be 
used as a surrogate maker for determining who should have postoperative chemotherapy to 
prevent recurrence.  
 
CTCs throughout the vasculature were stained for EGF-R as described previously (Payne, 
Yague et al. 2008). Within an individual, when CTCs were obtained from different sites 
before or after procedures, the percent that stained positive for the EGF-R was consistent, 
indicating that CTCs were biologically homogenous within a patient.  
 
7.4 Discussion 
 
In this study of a consecutive series of patients with colorectal liver metastases, we show, 
for the first time, the impact of RFALR or RF ablation the number of CTCs measured in both 
the systemic and portosystemic circulations. The results demonstrate that surgical resection 
immediately reduced the number of CTCs throughout the circulation compared with RFA, 
which was associated with an increased number of CTCs (Table 17 and Figure 23). The 
effect of RFALR on CTCs was unaffected by the type of resection, laparoscopic or open, 
although the sample size was small. To properly assess the effects of surgical approach on 
CTCs, a prospective randomized control trial of patients with disease amenable to 
laparoscopic RFALR is necessary. 
 
This is the first study to examine the differential localization of CTCs in the vasculature, by 
measuring them at different sites in both the systemic circulation, measured by peripheral 
venous and arterial blood samples, and the portosystemic circulation, measured by portal 
and hepatic venous blood samples. Some of these procedures were difficult to undertake: 
the hepatic vein is ‘friable’ and obtaining blood samples directly is difficult requiring 
extensive mobilization of both the liver and vein. These data, however, convincingly show 
that CTCs are localized to the hepatic macrocirculation, whilst the lungs appear to ‘sieve’ 
CTCs and significantly fewer enter the peripheral circulation. While these effects may be 
dilutional in their origin and reflect a concentration gradient close to the main cancer bulk, 
this provides insights into the clinical picture observed in cancer, in which metastases in the 
limbs are seldom seen, compared to liver and lung secondaries. While the exact fate of 
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these CTCs remains unknown, it is clear that they play a role in cancer spread by acting as 
a tumour reservoir.  
 
Despite years of research and hundreds of reports on tumour markers in oncology, the 
number of biomarkers that have emerged as clinically useful is very small with initial 
promise replaced by inconsistent data (McShane, Altman et al. 2005; McShane, Altman et 
al. 2006). The development of guidelines for the reporting of tumour marker studies will 
encourage transparent and complete reporting so that relevant information will be broadly 
available to others and conclusions can be objectively ascertained. We have attempted to 
biologically characterize CTCs here by measuring their gene expression but the amount of 
RNA obtained was insufficient for RT-PCR or expression microarray analyses. Further 
research into the molecular biology of CTCs, their membranous adhesion expression 
characteristics such as E-cadherin, and HIF expression will establish the processes by which 
they are shed and their role in tumour spread.  
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8.1 Introduction 
 
The boundaries of 21st century surgery including surgical skills, patient safety and surgical 
technologies, are dynamic. The abdomen, with its range of interesting and diverse 
pathologies, has always been a fascinating space to a general surgeon. When Phillipe 
Mouret, a French gynaecologist, successfully performed the first laparoscopic procedure, the 
world of surgery underwent a renaissance. Suddenly, general surgeons could circumvent 
the inevitable pain, stress and trauma of a laparotomy by using gas and a telescopic 
camera. This pivotal innovation firmly established laparoscopic surgery and, since then, 
there have been significant advances in the scope and applications of laparoscopy. In 
colorectal surgery, laparoscopic colectomies are well established. As the first 10 year results 
of randomized trials comparing laparoscopic and open colectomies become available, liver 
subspecialists have followed this trend and applied laparoscopic resection to liver cancer. 
The evaluation of laparoscopic resections however, is complex. There remain many aspects 
of the laparoscopic procedure itself which are not fully understood, such as the effect on the 
body of the pneumoperitoneum, the relevance of a particular gas and whether there is an 
optimum pressure. Furthermore, outcome is inextricably linked to surgical expertise and 
human error, and these must be factored in when comparing different techniques. There are 
also difficulties related to how accurately patient samples can be matched and how any 
compromise impacts on findings. The starting point for my research was a simple clinical 
observation: patients undergoing laparoscopic liver resection appeared to be presenting 
earlier with recurrent disease than those undergoing open surgery. This raised an important 
question: is laparoscopic liver resection a safe procedure? The limitations of a two year 
postgraduate research degree are such that it was not realistic or feasible to set up a “gold 
standard” trial. This would ideally involve a multicentred multinational database of liver 
surgery incorporating the blinded randomization of patients into surgical treatment groups 
carefully matched to minimise variables. All operating surgeons would be peer reviewed and 
match up to a minimum technical standard. Instead we analysed 10 early consecutive cases 
of laparoscopic liver resection for hepatic malignancy and matched them to patients who 
had undergone similar open hepatic resections for the same disease. We applied well 
established selection criteria for liver surgery: a controlled primary tumour, no extra hepatic 
metastases and a resection that is technically feasible with tumour-free margins (Hugh, 
Kinsella et al. 1997). The sample size of our study was small and it must therefore be 
qualified as a pilot study. I have presented the findings of our pilot study in Chapter 3.  This 
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final Chapter offers a critical analysis of the study design and discuss the insights gained 
and lessons learnt in a broader clinical context. 
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8.2 Discussion 
 
Case pathologies 
The pathology distribution we observed was the following: colorectal liver metastases 
(N=7), hepatocellular carcinoma (N=2) and small cell lung carcinoma (N=1). This is broadly 
representative of modern liver resection surgery where HCC represents 90% of all primary 
liver malignancy (Kaczynski, Hansson et al. 1996). Of those eligible for surgical resection 
(as opposed to liver transplantation) more than 70% of patients have cirrhosis and 80% 
ASA >II often precluding  laparoscopic resection at anywhere other than specialist 
laparoscopic centres (Dagher, Belli et al. 2010). More commonly, laparoscopic resection is 
performed for colorectal liver metastases. Of new cases, 20–25% of patients will have 
clinically detectable liver metastases at the time of the initial diagnosis and a further 40–
50% of patients will eventually develop liver metastases after resection of the primary, 
most commonly within the first three years of follow up (Scheele, Stangl et al. 1990; 
Sugarbaker 1990; Stangl, Altendorf-Hofmann et al. 1994; Scheele, Stang et al. 1995). The 
liver is often the first site of metastatic disease and may be the only site of spread in as 
many as 30–40% of those with advanced disease. The inclusion of one case of non 
colorectal, non neuroendocrine (NCNNLM) metastasis is admittedly an over-representation. 
Of non-colorectal metastases, neuroendocrine tumours are the most common, thereafter 
patients with NCNNLM cases the incidence of Lung Ca metastases amenable to liver 
resection vary but are often as few as 3% of NCNNLM, (and by extrapolation a much lower 
proportion overall), (Ercolani, Ravaioli et al. 2006).  
Single surgeon, single technique 
Multicentre randomized control trials validated the use of laparoscopic colorectal resection 
by finding equivalent long-term oncological results to open resection (Guillou, Quirke et al. 
2005). Early case series reporting higher rates of port site metastases and recurrence were 
attributed to technical issues and developing surgical skills in the context of a novel and 
technically complex laparoscopic procedure. We have reduced this operator bias by 
analyzing the results of a single operating surgeon. The surgeon in our study has extensive 
operative experience of open resection and laparoscopic procedures and was a member of 
the research team that developed the RF assisted technique and associated technology and 
resection tools. This degree of expertise allowed us to minimise the risk of human error as 
far as possible. Larger multicentre case series have recruited laparoscopic surgical experts 
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on the basis of peer review of technique. This selection criterion however, introduces an 
element of human bias as there has been no international consensus statement identifying 
world authorities in the field until recently (Buell, Cherqui et al. 2009; Ercolani, Ravaioli et 
al. 2006). Throughout the duration of the pilot study the same equipment for resection was 
being used open and laparoscopically, Radionics Cooltip electrode. New parenchymal 
resection devices were introduced at a later stage and therefore do not represent a 
confounding factor in our study. 
Matching criteria and compromise 
In chapter 3 we highlighted the basic demographics of the 2 matched samples. These 
included: sex, age, tumour type, site and grade, number of lesions and size, procedure 
performed, resection margin positivity, operative time and inpatient stay.  We chose tumour 
type, anatomical site and grade as our inclusion criteria when searching for open cases to 
match to our laparoscopic sample and used them in decreasing order of importance when 
‘an exact’ match was not possible. There was no significant difference in demographics 
when comparing means. Further parameters which would be clinically relevant in future 
studies are comorbidities, ASA grade, alcohol history, Hep B and C status (especially in 
cases of HCC), treatment with neoadjuvant chemotherapy, synchronous/metachronous 
metastases, need for blood transfusion and post-operative complications. Although we did 
not specifically measure these criteria, no patients required intraoperative blood transfusion 
nor were there any post-operative surgical complications, such as biliary leak or abscess 
formation. This is important to note because of their effect on the accuracy of our 
measurement of inpatient stay. 
By keeping matching criteria narrow in a retrospective study, we may be skewing our 
sample. For example, colorectal carcinomas that metastasise to the left lobe, (i.e.: those 
most amenable to laparoscopic liver resection) may in some way represent a pathologically 
discreet subset of colorectal carcinomas as a whole. Also, patients with isolated hepatic 
metastases have a better prognosis than those with more extensive metastatic disease 
(Goslin, Steele et al. 1982; Lahr, Soong et al. 1983; Stangl, Altendorf-Hofmann et al. 1994; 
Rougier, Milan et al. 1995) suggesting biological differences in the two settings, yet we did 
not match for number of lesions. While our matching criteria are clinically relevant to the 
study aims, they remain the result of an artificial selection. Another weakness specific to 
this study is where well founded assumptions are made, (laparoscopic surgery allows people 
return to work earlier). This is not something we could assess in a retrospective study. 
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However it is especially relevant when other assumed benefits of the laparoscopic group, 
such as shorter inpatient stay, are not supported by our data (Laurent, Cherqui et al. 2003; 
Lesurtel, Cherqui et al. 2003). 
Operative time was measured from a surgical theatre database. It incorporates time to 
wake from anaesthetic postoperatively and therefore another variable, the effects of 
anaesthesia, is introduced. However, one may assume that this variable exists for both 
laparoscopic and open cases and therefore its impact is negligible. A longer operative time 
for laparoscopic resections has been previously shown (Rau, Buttler et al. 1998; Belli, 
Fantini et al. 2007). Indeed in a majority of published data, operative time was equivalent 
or longer. This finding however, must be closely examined in the context of another 
significant finding in our study: that R0 resections returned earlier than their open matched 
cases. Despite many of the limitations of our small scale pilot, we hypothesised that the 
pathophysiological process that might account for the difference is time dependent. 
We found no difference in the resection margin positivity between the 2 groups, although 
we accept that 40% resection margin positivity is a very high finding in the context of open 
resection. There is a developing consensus worldwide that higher margin positivity in 
laparoscopic resection may be attributed to a technical issue (Buell, Cherqui et al. 2009). 
We generously gave ourselves >1mm for a negative resection margin. This is accepted as 
an adequate margin in RF ablation when a 2-cm-wide coagulative necrosis zone is created 
before division of the parenchyma with a surgical scalpel (Weber, Navarra et al. 2002), 
although alternative liver transection techniques might favour alternative resection margin 
classification. There are technical difficulties with the accurate measurement of resection 
margins following RF ablation. Firstly, RF-ablated tissue will not resemble normal tissue and 
characterizing whether there is a native benign or malignant tumour in the ablated tissue is 
impossible. Secondly, little is known about the degradation of RF-ablated tissue in formalin 
prior to paraffin fixation. Despite this, the pathologists involved in our study were clearly 
able to state whether the tumour extended to the edge of the resected specimen or not. In 
a context where ‘adequate’ resection margin is still a contentious issue, this is of paramount 
importance. The clinical relevance of resection margins is contentious. Data from the 
Registry of Hepatic Metastases, a multi-institutional database of liver resections, suggest 
that a margin >1cm is associated with a 45% five year survival rate, with only a 23% five 
year survival rate where margin were <1cm (Hughes, Simon et al. 1986). However, more 
recent  reports comparing margins <1cm and >1cm conclude there is no significant 
difference in long term survival  (Lordan and Karanjia 2010).   
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When looking at oncological outcome, we excluded all patients with positive resection 
margins, as it is universally recognized that survival is shortened. (Pawlik, Scoggins et al. 
2005; Nuzzo, Giuliante et al. 2008).Some studies however, include positive resection 
margins in their analysis of oncological outcome and define ‘time to recurrence’ as the 
earliest radiologically detectable recurrence. We also relied on radiology post-operatively, 
but chose specifically to analyse the R0 subgroup. The inevitable problem with this criterion 
is that it only takes one case out of each matched pair to be resection margin positive and 
both cases are excluded. Hence, by the end of the pilot, we had only 5 pairs with R0 
resections in both laparoscopic and their matched open.  We found that at 2 years follow-
up, laparoscopic mortality is nearly 40%, almost twice that in the open group. Furthermore, 
there was a significantly poorer outcome with those undergoing laparoscopic resection 
presenting with earlier disease recurrence (p<0.05).  
 
Pilot study IHC Data 
 
Earlier disease recurrence in the laparoscopic resections is an important finding and I looked 
at the role of the pneumoperitoneum. My working hypothesis was that the 
pneumoperitoneal environment is one of relative mucosal and visceral hypoxia. There are a 
number of studies, both in humans and animal models, assessing the impact of the 
increased intra-abdominal pressure, (IPP) caused by insufflations (Hashikura, Kawasaki et 
al. 1994; Eleftheriadis, Kotzampassi et al. 1996; Jakimowicz, Stultiens et al. 1998; Ishida, 
Murata et al. 2000). Under these conditions it is recognized that portal venous flow is 
significantly decreased and a relative hypoxia is conferred on the liver. In a retrospective 
study such as ours, the surgical settings cannot be altered and intra-abdominal pressure 
was a constant parameter with a maximum pressure of 14mmHg under CO2 insufflation). In 
any event, the measurement of liver hypoxia in humans presents significant difficulties and 
actual O2 probing is a technically challenging and invasive procedure requiring rigorous 
ethical scrutiny.  
 
An alternative approach to the study of the effects of the pneumoperitoneum is through the 
analysis of cellular markers of hypoxia. This approach constitutes the basis of my research. 
We analysed resected tissue for markers, including CaIX, GLUT-1, HIF-1 and HIF-2. We also 
assessed CD10 positivity as this had already been postulated as a marker of metastatic 
disease. Within our small pilot sample, we demonstrated a significantly higher expression of 
the HIF-2 and CD10 within liver tissue resected laparoscopically. 
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HIF-1 vs HIF-2 
 
The capacity for mammalian cells to adapt and survive at low oxygen tensions, hypoxia, is a 
prerequisite for successful development of oxygen-dependent multicellular organisms 
(Lofstedt, Fredlund et al. 2007). The backbone of this adaptive response is the stabilization 
of HIF-1 and HIF-2. In well-oxygenated cells and tissues these subunits are degraded via 
the proteosomal pathway described previously in Chapter 1. With oxygen shortage HIF-α 
subunits become transcriptionally active and bind to hypoxia response elements (HREs) of 
target genes. Similar to all mammalian tissues, solid tumours require oxygen to grow. 
However, the uncontrolled proliferation of tumour cells results in an imbalance between 
tumour cell oxygen consumption and tumour neoangiogenesis and overall, most tumours 
are hypoxic relative to the surrounding tissue (Lofstedt, Fredlund et al. 2007). This in turn 
means that most tumour cells have adapted to and can grow in a hypoxic environment. 
Furthermore, as part of their adaptation to hypoxic conditions they become proangiogenic 
and shift towards anaerobic metabolism. In doing so, the hypoxic stimulus is the main 
driving force behind vascularisation and it promotes the expression of genes associated with 
increased cell survival, metastasis and invasion (Lofstedt, Fredlund et al. 2007). Tumour 
cells also seem to lose specialist functions and dedifferentiate during hypoxia, as 
demonstrated earliest by neuroblastoma and breast carcinoma (Jogi, Ora et al. 2002; 
Helczynska, Kronblad et al. 2003). More recently, studies looking at EMT have suggested 
that this occurs in cervical, colon and other tumour types (Lofstedt, Fredlund et al. 2007). 
 
The activation of HIFs frequently observed in tumours seems primarily to be the result of a 
physiological response and adaptation to oxygen shortage. However, a number of reports 
have shown that HIF-1α protein also accumulates in tumour cells as a consequence of 
growth factor signaling and increased HIF-1α  translation (Gordan and Simon 2007). We can 
only speculate about the physiological relevance of this response, but one hypothesis is that 
growth factor stimulated HIF-1α translation reflects a process that occurs during normal 
development. Indeed the relationship between E-cadherin and HIF-1α in cervical stratified 
epithelium, as demonstrated in Chapter 5, may represent an example of how the 
homeostasis and migration of cells through the epithelium is dependent on increasing 
localized hypoxia, HIF-1 upregulation and the concurrent E-cadherin downregulation. It is 
now widely accepted that tumour cells activate and exploit the cellular machinery for 
adaptation to hypoxia by two different mechanisms and that this adaptation, irrespective of 
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whether it is driven by hypoxia or abnormal growth factor signaling results in a more 
aggressive phenotype (Lofstedt, Fredlund et al. 2007).  
 
What makes HIF-2 different? 
 
Despite pronounced similarities between HIF-1 and HIF-2 in structure, function and 
regulation, knock-out of either HIF-1a or HIF-2a clearly show that they are not redundant 
and that they serve different functions during development (Lofstedt, Fredlund et al. 2007). 
HIF-1 remains the most studied factor and is frequently activated by hypoxia and growth 
factor signaling. Research into prognostic markers for primary colon and hepatocellular 
carcinoma have identified HIF-1 as a poor prognostic marker (Dai, Gao et al. 2009; 
Rasheed, Harris et al. 2009). Tumour accumulation of HIF-2 has been less frequently 
investigated although its induction in hypoxia has been demonstrated in vivo and in vitro 
irrespective of the cell background (Wiesener, Jurgensen et al. 2003). An increasing number 
of reports suggest that HIF-2 is important in tumour progression. Certainly, HIF-2 was 
highly expressed in all our resected liver tissue, and significantly more so in the laparoscopic 
subgroup. In contrast, HIF-1 showed weak or no expression in our pilot, irrespective of 
method of tumour resection. We postulated that the environment in which we have 
demonstrated a significantly higher expression of HIF-2 is one of lower partial pressure of 
oxygen relative to those samples resected by open technique. Interestingly, this is not the 
first time contrasting expressions of the two isotypes have been demonstrated in tumour 
tissue. Over recent years the role of the HIF-2 isotype has increasingly been viewed as 
distinct from HIF-1(Le Bras, Lionneton et al. 2007). A number of reports analyzing the 
genes that are regulated by hypoxia, by HIF-1 or HIF-2, have shown that HIF-1 is the main 
inducer of glycolytic genes expression and that it may be considered the main 
transcriptional regulator of the cell ‘hypoxic response’, while paradoxically HIF-2 only 
responsive genes are not all regulated by hypoxia (Hu, Wang et al. 2003; Sowter, Raval et 
al. 2003; Wang, Davis et al. 2005). Wiesener et al. have shown that both isotypes are 
induced by hypoxia. In the liver, for example, there was a clear zonal distribution with an 
increase of HIF signal on IHC towards the central vein. This matches the known decline in 
oxygen tensions from the periphery to the centre of the liver lobule in mice. The authors 
also used epithelial cell lines to demonstrate that in normoxic conditions HIF-2a protein was 
detected to a higher degree than HIF-1 and that exposure to mild hypoxia further 
accentuated this differential expression (Wiesener, Jurgensen et al. 2003). It is interesting 
to note that HIF-2 transcriptional activity is not strongly activated by hypoxia and may even 
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be repressed while HIF-1α transcriptional activity is strongly induced under such conditions 
(O'Rourke, Tian et al. 1999). There are two possible explanations for this. Firstly, 2 of the 3 
prolyl hydroxylases responsible for HIF hydroxylation are inducible by hypoxia and this 
response could form the basis of a negative feedback loop (Epstein, Gleadle et al. 2001). 
Secondly, HIF-α transcriptional activity is oxygen-regulated independently of protein 
stability by a cofactor, factor inhibiting HIF (FIH) that works via the C terminal activation 
domain on HIF-1α. HIF-2a has a relatively higher resistance to this regulation under 
normoxic conditions relative to HIF-1 (Bracken, Fedele et al. 2006). In short, there is strong 
evidence that HIF activation in vivo is not invariably linked to a specific oxygen 
concentration in all cells.  Rather, the cellular oxygen response operates at different levels 
of sensitivity in different cells and tissues and presumably can adapt to local oxygen 
tensions (Wiesener, Jurgensen et al. 2003). We therefore cannot interpret the expression of 
HIF-2 in both CLM and HCC as markers of hypoxia. It may be that hypoxia accounts for the 
significant difference in HIF-2 expression when compared to open resection tissue but in the 
absence of real-time oxygen monitoring, this remains speculation.   
 
What is the role of HIF2 and what are its targets? 
 
The contrasting levels of HIF-1 and HIF-2 expression in the resected liver tumours represent 
a significant finding (Stroka, Burkhardt et al. 2001). Stoka’s study of healthy mice inspiring 
different levels of oxygen showed that HIF-1a induction in normal liver tissue in mice is 
transient, required a more severe level of hypoxia and only lasted 3 hours, while HIF-2 
expression was sustained for more than 6hrs (Stroka, Burkhardt et al. 2001). A molecular 
mechanism for this has recently been characterised (Uchida, Rossignol et al. 2004; 
Holmquist-Mengelbier, Fredlund et al. 2006; Luo, Zhong et al. 2010). This time dependent 
shift in relative expressions of HIF1:HIF2 may explain why little or no HIF-1 was evident in 
resected liver tissue and why we have demonstrated higher HIF-2 expression. In a 
retrospective study, such as this, one can only speculate on earlier expression profiles. 
Following Stoka’s model, it is plausible that HIF-1 may have been evident in the resected 
tissue. However, as both open and laparoscopic liver resections are lengthy procedures, 
lasting on average 3hr40mins and 5hours, respectively, HIF-1 would undergo degradation. 
Interestingly, we did demonstrate GLUT1 expression in the liver and genetic inactivation 
studies suggest this is predominantly dependent on endogenous HIF-1 (Sowter, Raval et al. 
2003). Therefore there are valid reasons to infer that HIF-1 was induced in the first place. 
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It is also possible that our hypoxic stimulus may not amount to ‘the severe’ pro-HIF-1 
hypoxia. However, many elements of the resection would generally be regarded as typically 
‘acute’ HIF-1 type stimuli. For example, RF ablation generates heat, a noxa of inflammation, 
necrosis and, with every application of the radiofrequency probe, increasing 
devascularisation. Furthermore, the CO2 pneumoperitoneum is known to precipitate a 
systemic acidosis in 50% of patients and this reinforces the notion that RF resection does 
induce pro-HIF-1 hypoxia.  
 
An alternative explanation is that HIF-1 may never have been upregulated during the 
procedure and we are simply resecting a HIF-2 pathology subset indicative of established 
metastases. The HIF-1 response itself may, in fact, lead to metastasis through its effect on 
E-cadherin, either as a result of hypoxia or abnormal cell signaling, causing cell shedding 
and the resultant increase in the number of circulating tumour cells. It has been observed 
that HIF-1 levels peak at the invasive stage of invasive colon carcinogenesis (Simiantonaki, 
Taxeidis et al. 2008). Thereafter, once shed, the CTCs may change either as a result of 
being in a bloodstream, (through the lungs and oxygenation) or by default, as they are no 
longer in a solid tumour mass and therefore no longer in competition for oxygen delivery 
and relative hypoxia. Consistent with these differential characteristics, Talks et al. showed 
that HIF-1 protein expression appeared to be more restricted to perinecrotic tumour regions 
than HIF-2, whereas HIF-2 was more prominent in stromal cells around the tumour (Talks, 
Turley et al. 2000; Onita, Ji et al. 2002).  
 
HIF-1 and HIF-2 both exert adaptive responses to hypoxia by activating transcription of 
overlapping, but distinct, batteries of target genes, thereby playing distinct roles in many 
developmental, physiological, and pathological processes (Hu, Sataur et al. 2007; 
Mastrogiannaki, Matak et al. 2009; Semenza 2009). One study has shown that when 
incubating PBLs from 10 healthy humans, significant differences exist between individuals in 
baseline HIF-regulated gene expression, and that there were also significant differences 
between individuals in the degree to which these genes are regulated by hypoxia (Brooks, 
Elvidge et al. 2009). In contrast to basal expression levels, there was a common pattern 
across the genes for the induction by hypoxia, such that if one gene was strongly induced 
by hypoxia in an individual then this would tend to be the case for all the other genes within 
that individual (Brooks, Elvidge et al. 2009). This finding is particularly relevant to our study 
because it means that while our choice of HIF target genes is limited, it can nevertheless be 
regarded as representative of HIF regulated transcr
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transactivation domains of HIF-1α and HIF-2α are responsible for target gene specificity. 
The theory that HIF-2 regulates a different set of genes than HIF-1 is clearly emerging. It 
must be noted that we skewed our HIF target gene profile to HIF-1 related targets and, in 
view of  our findings, including more HIF-2 target genes would have been wise. It must be 
noted however, that HIF-2 targets in the liver are not yet fully characterized, (Talks, Turley 
et al. 2000).  As a prognostic marker, high HIF-2a expression relates to an advanced stage 
and/or poor patient outcome in several tumour forms including breast, non small cell lung 
cancer and colorectal cancer (Lofstedt, Fredlund et al. 2007; Helczynska, Larsson et al. 
2008) . Raval et al. used the same VHL and VHL deficient renal cell carcinomas cell lines as 
I did  to demonstrate that HIF-1 positively regulated Bnip3 (no effect on cyclin D1, TGF-a, 
VEGF) and HIF-2 positively regulated cyclinD1, TGFA and VEGF (Raval, Lau et al. 2005). 
Another HIF-specific target gene, VE-cadherin gene, is not responsive to hypoxia however 
HIF-2 specifically activates its promoter while HIF-1 does not. Interestingly, 3 other 
endothelial cell markers (Tie-2, flk-1, eNOS) are all HIF-2 specific target genes. This 
mechanism may be involved in the in the process of vascular mimicry by tumour cells, and 
may suggest a mechanism by which CTCs are able to bind to new sites in endothelia, for 
example, in liver venules when shed as CTCs from primary colorectal cancer (Le Bras, 
Lionneton et al. 2007). Certainly, CTCs show altered response to hypoxia both in vitro and 
in vivo (Ameri, Luong et al. 2010). The importance of HIF-2 expression in colorectal liver 
metastases and hepatocellular carcinoma both clinically and in terms of therapeutic 
implications is dependent to an extent on the downstream target genes of HIF-2 in this 
setting. Given the complexity of the HIF transcriptional cascade and the large number of 
direct and indirect HIF targets identified in gene expression arrays, such an analysis is a 
formidable task (Jiang, Lu et al. 2002; Zatyka, da Silva et al. 2002; Hu, Wang et al. 2003). 
Certainly of the potential HIF targets we investigated, genetic inactivation studies suggest 
that, outwith the setting of renal cell carcinoma, GLUT1 is predominantly dependent on HIF-
1α (Sowter, Raval et al. 2003). The case of cyclin D1 is less clear. Cyclin D1 is one of the 
main G1-phase cyclins and its expression is associated with G1 to S phase transition in the 
cell cycle and is upregulated in many types of cancers (Sherr 1996). In VHL deficient RCC it 
is a HIF-2 target and its HIF-dependent expression in other organs is as yet unclear. In 
contrast to the high levels of expression of HIF-2 in the resected liver samples, cyclin D1 
demonstrated low or no levels of expression. Similarly, colorectal adenocarcinoma with 
CD10 expression are at increased risk of liver metastasis (Yao, Takata et al. 2002) and for 
this reason we included this in our IHC study in liver. We used the same in vitro well-
established methodology that has led to much of our understanding of the roles of HIF-1α 
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and 2α on target genes albeit in VHL+/- RCC cell lines to show that its expression correlates 
with both hypoxia and HIF-1 expression (Raval, Lau et al. 2005). Unfortunately, we cannot 
draw any conclusions from the IHC data, presented in Chapter 4, on HIF or hypoxia 
dependent expression of CD10 or its role in colorectal carcinogenesis. Nonetheless a HIF 
dependent control over CD10, a member of the MMP family, is plausible, as other members 
of the same family, such as MMP9, promote key processes underlying tumor cell 
propagation, from migration and invasion to angiogenesis and tumor growth (Coussens, 
Fingleton et al. 2002) and key downstream attributes of the HIF, more specifically HIF-1, 
mediated adaptive response.  
 
The role of CTCs? 
 
In Chapter 7 we prospectively analysed the effects of laparoscopic and open RFALR on 
circulating colorectal tumour cells to assess whether there is a fundamental difference in 
tumour behaviour when resected using different techniques. The pneumoperitoneum and 
laparoscopic set-up were the same as in the pilot study. We also compared RFALR to the 
effect of RFA alone, without resection.  This line of investigation was prompted by the 
observation that patients undergoing laparoscopic resection present earlier with disease 
recurrence and by the fact that CTCs are known to have prognostic significance. The 
methodology for CTC measurement has recently been validated. Although the numbers of 
patients recruited were small, 11 and 4 for open and laparoscopic resection, respectively, 
results showed that the level of CTCs was significantly lower following resection, 
independently of whether this was open or laparoscopic. Interestingly, RFA treatment of the 
tumour led to significantly higher levels of CTCs. In the context of our earlier findings, one 
can hypothesise the following: the lapRFALR has equivalent shedding of cells compared to 
open and poor oncological outcome is an unrelated phenomenon; alternatively, the poorer 
outcome in the R0 resection resulted from the probes passing through tumour tissue during 
resection, despite clear margins; or, and this is the most likely explanation, oncological 
outcome is multifactorial and the sequestration of the mobile pool of CTCs to the liver 
microcirculation is at least in part, a hypoxia driven process. 
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8.3 Conclusions  
 
This thesis, commenced in October 2005, stems from a surgical trainee’s interest in the 
applications of laparoscopic surgery to the treatment of liver cancer. The data and analysis 
from Chapters 3 to 6 were completed in October 2007. Chapter 8 and the overall critical 
analysis and discussion were completed as I returned to my surgical training. In November 
2009, one year after a consensus conference convened in Louisville, USA, an article was 
published in The Annals of Surgery entitled “The International Position on Laparoscopic Liver 
Surgery” (Buell, Cherqui et al. 2009). In summarizing its background and objectives, this 
article mirrors some of the important points raised in my introduction about the role of 
laparoscopic liver surgery in the 21st century and also about the limitations that inevitably 
befall upon a small academic pilot study in what is still recognised as a contentious area of 
clinical practice. For example, it recognizes that multiple series have reported on the safety 
and efficacy of laparoscopic liver surgery and its application to major cancer resections in 
specialist centres without any published randomised control trials comparing it to the more 
established open resection procedures. Appraising this paper and grasping its findings and 
recommendations is of paramount importance, not only in the context of clinical research in 
this field but also to any aspiring academic HPB surgical trainee.  
 
It is important to note that an organizing committee ‘selected 45 recognised experts from 
around the world with the most extensive published experience in both laparoscopic and 
open liver surgery’. The committee members’ details are not disclosed, nor the criteria 
defining “extensive publication”. This is tantamount to an admission of publication bias, 
suggesting that those who are the most prolific at publishing within the field of liver surgery 
are those most technically competent and thereby ‘experts’ in the field. Furthermore, 17 of 
the 45 experts were based at US institutions. This raises the question of whether equally 
competent liver surgeons, whose native language is not English, are underrepresented 
because they have fewer publications.  Nevertheless, there will inevitably be some 
correlation between expertise and a strong track record of publications as surgeons with a 
busy clinical practice are more likely to produce significant data. Furthermore, it should be 
noted that of the 17 experts recruited from US institutions not all are of US (or primarily 
English speaking) origins. 
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The paper identifies different liver parenchymal transection techniques and concludes that 
to date ‘no single method has been shown to be superior’. When reviewing safety and 
efficacy of the laparoscopic approach, it was recognised that publication bias and ‘failure to 
publish negative events might have contributed to an overly optimistic view of the 
procedure’. The scope of what is deemed safe in terms of liver volume is 1: left lateral 
sectionectomy, 2: anterior segmentectomies or 3: wedge resections, (ideally on solitary 
lesions less than 5cm in maximum diameter in peripheral segments 2-6). In this way, any 
comparative trial or retrospective analysis hereon would, in a similar way to our pilot, 
involve comparing non-anatomical resections for which each surgeon will have a preferred 
parenchymal resection tool. Finally, in the context of patient safety, it was acknowledged 
that where there is ‘lack of case progress’ conversion to open resection should be 
performed. However, the paper stopped short of suggesting target resection times in either 
laparoscopic or open procedures. 
 
When assessing the respective roles in CLM resection vs HCC, there are significant 
differences. For example, data support the resection of small HCCs laparoscopically in terms 
of preventing postoperative ascites, yet anatomical resections (technically challenging 
laparoscopically) are associated with less recurrence in this pathology. Furthermore, the role 
of radiofrequency ablation is advocated in small HCCs but not recommended in equivalent 
sized CLMs, due to the high recurrence rates. This may reflect the generally higher ASA for 
those with HCC or the recognised alternative end-stage treatment of liver transplantation. 
So despite evidence presented at the conference suggesting similar low resection margin 
positivity in laparoscopic and open surgery at one centre, it remains that ‘there are 
currently no trials that clearly demonstrate that laparoscopic hepatic resections have 
equivalent long-term outcomes to open hepatic resection’. Explanations for this conclusion 
may be that the negative resection margin rates of open surgery cannot be matched and 
that small metastases could be missed laparoscopically. It is of course plausible that other 
specialist centres that have not published their data have found similar results to ours in 
terms of our high resection margin positivity and earlier recurrence after laparoscopic 
resection. Furthermore, the passage of the radiofrequency probe during RFALR, as shown in 
Chapter 8, may account for increased CTC shedding from missed small metastases and the 
significantly earlier recurrence rate we identified in our R0 group.  
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The role of a Randomised Control Trial? 
 
Many minimally invasive procedures share common benefits, problems and questions. The 
Louisville conference examined the North American laparoscopic vs open primary colonic 
resection trial, which took 10 years to complete, and applied the model to hepatic resection. 
However, the primary end-point must be carefully considered. If it is patient safety, with 1-
2% mortality from liver resection, a substantial trial would be required to find any 
significant evidence. If the endpoint is oncological outcome then the different pathologies, 
HCC or CLM, would have to be identified. As both have a lower incidence compared to 
primary colonic carcinoma, any meaningful results would require over 10 years of follow-up. 
In short, the paper recommends a prospective centralized registry. This would require broad 
surgeon participation but would also allow the controlled introduction of the technique, 
minimising the learning curve effect and enabling the detection of severe negative events. 
Interestingly, conference experts argue that another trial showing that minimally invasive 
surgery has benefits on pain control and recovery time is unnecessary. While they 
acknowledge that the safety of laparoscopic liver surgery remains a valid question, their 
assertion that there is no need to ‘reproduce the (colon) trial to determine whether 
laparoscopy per se has a negative effect on oncologic outcome and tumour seeding to 
incisions’, is questionable. We have shown that laparoscopically resected tissue expresses 
different cellular markers and may thus be more sensitive or primed to different stimuli 
within the pneumoperitoneal environment compared to openly resected liver cancer.  
 
While this publication does not support the setting up of RCTs, it advocates the use of liver 
resection registries and it is clear that future clinical or cellular applied laboratory research 
in this field will be dependent on these registries and this will involve academic-clinician 
cooperation, multicentre networking and pooling of data and time. 
 
Summary of conclusions:  
1: The role of laparoscopic liver resection is still under review and our data have shown that 
it involves a longer operative time and a poorer oncological outcome after RO resection for 
colorectal liver metastases when compared to open surgery. 
2: HIF-2 and CD10 may have significant physiological roles under laparoscopic conditions in 
conferring a poorer prognosis on those patients under resection for colorectal liver 
metastases, although more research is required to further characterise these markers. 
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3: HIF-1 and HIF-2 levels are inversely related to E-Cadherin expression in a cervical 
stratified epithelial model of dysplasia-carcinoma. Further work is required before similar 
data can be compiled on this inverse relationship in colorectal carcinoma. 
4: CD10 may represent a novel hypoxia inducible target in an in vitro clear cell renal 
carcinoma model regularly used to investigate HIF-target genes. Although clinical data exist 
suggesting CD10 as a poor prognostic marker and predictor of metastatic disease in primary 
colorectal carcinoma, more in vitro and prospective clinical trials are required before its role 
in colorectal carcinoma can be characterised. 
5: Radiofrequency ablation causes significant shedding of circulating tumour cells 
systemically; that is not evident when it is used for liver resection. Hence its role in non 
resectable liver metastases remains under investigation and review in clinical practice. 
6: The future of laparoscopic liver resection lies in international collaboration and 
prospective collection of liver resection data in secure databases. A randomised control trial 
is unlikely to yield meaningful and contemporary data that will alter future practice. 
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8.4 Future Work   
 
My future work will focus on the following areas: 
 
1: HIF-1 to HIF-2 switch 
I would like to analyse tissue bank samples of excised precancerous polyps and colorectal 
carcinoma from patients with accelerated monitored disease for HIF-1, HIF-2 and other 
potential prognostic markers, including CD10 and other MMPs. I would also investigate E-
Cadherin expression in these samples. Key questions are whether there is a change in 
malignant potential when HIF-2 becomes upregulated and if so, whether this is mediated by 
MMPs, specifically CD-10. Also, whether cell shedding is a function of downregulation of E-
cadherin by HIF-1 or HIF-2 in primary colonic carcinoma. 
 
2: The pneumoperitoneum 
I would like to apply for the ethical approval to biopsy human liver under the effects of 
pneumoperitoneum at different time points and pressures under O2 probe monitoring of pO2 
of portal vein and hepatic artery. I would prospectively collect samples and snap freeze 
them in liquid nitrogen to gain a time dependent spectrum of HIF-1/2 nuclear localisation 
and upregulation. 
 
3: Differing effect of RF on normal liver (control), HCC and CLM 
I would like to set up a metabonomic database on patients undergoing radiofrequency 
ablation of HCC and CLM to investigate whether there is a different inflammatory response 
and identify the relevant inflammatory markers.  
 
4. CTCs 
I would like to isolate CTCs from primary and metastatic colorectal cancer to see whether 
they have differing responses to hypoxia. In particular, I would look at whether colorectal 
CTCsprimarily target the liver  and those that metastasise beyond or to different organs 
using different stimuli in their propagation. 
 
5. The effect of RF on liver cell biology, architecture and the process of coagulative necrosis.  
Using standardised settings, I would like to sample liver tissue at different times of 
exposure and different radial distances from the RF probe in order to assess whether there 
is time for cellular adaptation to the stimulus. I would seek to establish whether RF is a 
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secondary hypoxic stimulus, distinct from the devascularising effect of liver parenchymal 
resection.
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ABC kit avidin-biotin-peroxidase complex kit 
ADP adenosine diphosphate 
ASA American Society of Aesthesiologists 
ATP adenosine triphosphate 
bp base pairs 
CAIX Carbonic Anhydrase IX 
CALLA Common Acute Lymphoblastic Leukaemia Antigen 
CCRCC clear cell renal cell carcinoma 
CD10 Cluster of Differentiation molecule 10 
cDNA complementary DNA 
CLM colorectal liver metastasis 
CO2 carbon dioxide 
cRNA complementary RNA 
CSA catalysed signal amplification 
CT computerised tomography 
CTC circulating tumour cell 
DAB diaminobenzidine tetrahydrocholride 
DAPI 4′6-diamidino-2-phenylindole·2HCl 
DFO desferrioxamine 
dH2O deionised water 
DMSO dimethyl sulphoxide 
DNA deoxyribonucleic acid 
dsDNA double stranded DNA 
E-cad  E-cadherin 
ECL enhanced chemiluminescence 
EMT Epithelial-Mesenchymal Transition 
EORTC European Organisation for Research and Treatment of Cancer 
EPAS Endothelial PAS domain protein 1 
FCS foetal calf serum 
Fe Iron 
FIH Factor Inhibiting HIF 
G6P glucose-6-phosphate 
GAPDH glyceraldehde 3-phosphate dehydrogenase 
GFP green fluorescent protein 
GLUT-1 Glucose transporter 1 
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GLUT-2 Glucose transporter 2 
HBS HIF Binding Site 
HBV Hepatitis B Virus 
HCC hepatocellular carcinoma 
HCl hydrochloric acid 
HCV Hepatitis C Virus 
H&E hematoxylin and eosin 
HIER 
HIF-1 
HIF-2 
heat induced epitope retrieval 
Hypoxia inducible factor-1 αβ polymer 
Hypoxia inducible factor-2 αβ polymer 
HIF-1α Hypoxia inducible factor -1α 
HIF-2α Hypoxia inducible factor -2α 
HIF Hypoxia Inducible Factor 
HLF hepatic leukemia factor 
HPB hepatopancreaticobiliary 
HRE Hypoxia Response Element 
HV hepatic vein 
IGF Insulin Growth Factor 
IgG Immunoglobulin G 
IHC immunohistochemistry 
IOUS intraoperative ultrasound 
IPP intra peritoneal pressure 
KM Michaelis Constant 
LDHA Lactate Dehydrogenase A 
LOX Lysyl oxidase 
LPS lipopolysaccharide 
MCL-1 myeloid leukemia cell differentiation protein 
MCT Monocarboxylase Transporter 
Mins Minutes 
MMOG Dimethyloxalylglycine (also abbreviated to DMOG) 
MMP2 matrix metalloprteinase 2 
mRNA messenger RNA 
MR(I) magnetic resonance (imaging) 
MW molecular weight 
N number 
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N2 nitrogen 
NEP neutral endopeptidase enzyme 
NFĸB nuclear factor kappa B 
NHE-1 Sodium Hydrogen Exchanger 
NS not significant 
NSCLCs non small cell lung carcinomas 
O2 oxygen 
OLT Orth 
ORFA open radiofrequency ablation 
P53 protein 53 
PBL peripheral blood leukocyte 
PBS Phosphate buffered saline 
PBST PBS-Tween 
PCR polymerase chain reaction 
PDH pyruvate dehydrogenase 
PEI percutaneous ethanol injection 
PFA paraformaldehyde 
PHD Prolyl Hydroxylase Domain 
PHD2 Prolyl hydroxylase 2 
PHD3 Prolyl hydroxylase 3 
PI3K phosphoinositide 3-kinase 
POSSUM Physiological and Operative Severity Score for the enUmeration of Mortality 
and Morbidity 
PoV portal vein 
PV peripheral vein 
pVHL VHL protein 
qRT-PCR quantitative real-time PCR 
R0 complete resection with no microscopic residual tumour 
R1 complete resection with microscopic residual tumour 
RF radiofrequency 
RFALR radiofrequency assisted liver resection 
RNA ribonucleic acid 
RNAi RNA interference 
ROS reactive oxygen species 
RPM revolutions per minute 
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RT  retrotranscription transcriptase 
Secs seconds 
SEM standard error of the mean 
siRNA short inhibitory RNA 
TACE Transcatheter Arterial Chemoembolisation 
TBS Tris buffered saline 
TBST TBS-Tween 
TCA Tricarboxylic Acid 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TGFA Tumour Growth Factor Alpha 
TLR4 Toll-like Receptor 4 
TRS target retrieval solution 
US ultrasound 
3’UTR 3’ untranslated region  
VEGF vascular endothelial growth factor 
VHL VHL gene 
Wt Wild-type 
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